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ABSTRACT 
 
Antibodies to cyclic citrullinated peptides (CCP) are diagnostically specific for 
rheumatoid arthritis (RA) and provide valuable prognostic information. The antigens 
recognised in vivo by these antibodies are still a matter of investigation and the 
candidates include citrullinated α-enolase. This thesis describes the identification of 
an immunodominant epitope, citrullinated α-enolase peptide 1 (CEP-1) . Antibodies to 
CEP-1 showed a diagnostic specificity of 97%, and sensitivity of 38%. A quantitative 
CEP-1 ELISA was developed and tested in multiple cohorts of early and established 
RA with a sensitivity of 25-60%. The relationship of anti-CEP-1 antibodies with the 
major risk factors for RA, the HLA-DRB1 „shared epitope‟ (SE), PTPN22 and 
smoking, were examined in 1497 patients and 872 controls in a collaborative study 
involving patients from Sweden and the UK. A previously described association 
between  SE and anti-CCP antibodies was found to be strongest in the subset that was 
also positive for anti-CEP-1 antibodies. In the Swedish case-control analysis, the 
combination of SE, PTPN22 and smoking was preferentially associated with this 
subset (odds ratio 37 versus 2 for the anti-CEP-1-/anti-CCP+ subset). A novel gene 
association with this subset, Bromodomain-containing protein 2, was also detected by 
dense SNP mapping of the MHC region.  The prognostic value of anti-CEP-1 
antibodies was examined in 680 patients from two early RA cohorts. Only a weak 
predictive value for clinical outcomes was found, with no significant differences when 
comparing anti-CCP antibody positive patients with and without anti-CEP-1 
antibodies. Furthermore, no predictive value for response to anti-TNF agents was 
demonstrated in 450 patients from the British Society of Rheumatology Biologics 
Register. These findings suggest that autoimmunity to at least one epitope on 
citrullinated α-enolase is a powerful probe for the aetiology of RA (genes and 
environment), but not for the downstream results of pathogenesis such as clinical 
outcome and response to treatment. 
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1.1 Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disorder primarily 
affecting the synovial tissue of joints and leading to articular destruction and disability. 
Lifetime direct healthcare costs may be considerable
1
 and life expectancy reduced. 
The aetiopathogenesis, however, remains uncertain. The recent discovery of 
antibodies to citrullinated antigens with a high diagnostic specificity for RA has 
provided a new avenue of investigation. Understanding the genetic and environmental 
risk factors that associate with this autoimmunity may give insight into the underlying 
aetiology. This chapter first addresses the currently accepted classification criteria and 
the incidence and prevalence of this disorder, and then discusses genetic and 
environmental risk factors, autoantibodies and other important aspects of pathogenesis 
before concluding with clinical considerations. In line with the subject of this thesis, 
particular attention will be given to citrullinated autoantigens. 
 
1.2 Classification 
 
The contemporary definition of RA relies heavily on clinical criteria
2
. The currently 
used standard is the 1987 American Rheumatism Association (now American College 
of Rheumatology; ACR) revised criteria (Table 1.1)
3
. A number of problems exist 
with this classification. Firstly, the „gold-standard‟ is physician diagnosis and what is 
labelled as RA may represent the common phenotypic endpoint of differing 
underlying disorders. Secondly, modifications are required for population-based 
prevalence studies in order to include patients with inactive disease
4
. Thirdly, the 
criteria were developed through studies of patients with long-standing RA and the 
inclusion of late features, in particular erosions and nodules, mean that the criteria 
perform poorly in early disease
5
. To compound this, rheumatoid factor (RF) is less 
common in early disease, and RA often presents as a mono- or oligoarthritis 
whereas the ACR criteria require at least 3 joint areas to be involved
6
. This is an 
important limitation since the current treatment paradigm stresses the benefit of early 
intervention. In many cases treatment is indicated prior to patients actually meeting 
the criteria
7
. Nevertheless, up to now these criteria have been widely used to define  
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Figure 1.1. The hypothetical triad of genes and environment, interacting in the 
generation of specific autoantibodies, which might provide insight into the 
aetiology of RA. A long phase of pre-symptomatic autoimmunity may occur 
prior to the onset of overt disease. This time period may contain ‘windows of 
opportunity’ where early intervention may resolve the disease process8.  
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Criterion Definition 
1. Morning Stiffness Morning stiffness in and around the joints, lasting at least 1h 
before maximal improvement 
2. Arthritis in three 
or more joint areas 
At least three joint areas (out of 14 possible areas: right or left 
PIP, MCP, wrist, elbow, knee, ankle, MTP joints) 
simultaneously have had soft tissue swelling or fluid (not bony 
overgrowth alone) as observed by a physician 
3. Arthritis of hand 
joints 
At least one area swollen (as defined above) in a wrist, MCP 
or PIP joint 
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas (as defined 
in 2) on both sides of the body (bilateral involvement of PIPs, 
MCPs or MTPs without absolute symmetry is acceptable) 
5. Rheumatoid 
nodules 
Subcutaneous nodules over bony prominences or extensor 
surfaces, or in juxta-articular regions as observed by a 
physician 
6. Serum rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in 
fewer than 5% of normal controls 
7. Radiographic 
changes 
Radiographic changes typical of RA on posteroanterior hand 
and wrist radiographs, which must include erosions or 
unequivocal bony decalcification localised in, or most marked 
adjacent to, the involved joints (osteoarthritis changes alone 
do not qualify) 
For classification purposes, a patient has RA if at least four of these criteria are 
satisfied (criteria 1-4 must have been present for at least 6 weeks). Patients should not 
be designated as having classic, definite or probable RA. MCP, metacarpophalangeal; 
MTP, metatarsophalangeal; PIP, proximal interphalangeal. 
 
Table 1.1. The 1987 American Rheumatism Association (now American College 
of Rheumatology; ACR) revised criteria for RA classification. For classification 
purposes, a patient has RA if at least four of these criteria are satisfied (criteria 
1-4 must have been present for at least 6 weeks). PIP=proximal phalangeal joint. 
MCP=metacarpophalangeal joint. MTP=metatarsophalangeal joint. 
RA=rheumaotid arthritis. 
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RA in clinical and epidemiological studies. A simple solution would be to add anti-
CCP antibodies to the criteria. This increases the sensitivity in early disease but 
highlights the problem of circularity as the physician, who provides the „gold-
standard‟ for diagnosis, will often have been influenced by autoantibody status7 9. The 
difficulties presented by circularity might be addressed by determining which factors 
are associated with an independent surrogate of disease. In the new criteria currently 
being prepared by the ACR and European League Against Rheumatism (EULAR), the 
surrogate is the decision to start treatment with methotrexate
7
. 
 
1.3 Epidemiology 
1.3.1 Incidence 
 
The incidence of RA is estimated to be 0.15-0.46 and 0.24-0.88 per 1000/year for 
males and females respectively, based on electronic data systems in the USA and 
Scandinavia, and a population-based register of early inflammatory arthritis in 
Norfolk, UK
4
. Reported rates are higher in the USA when compared with Europe, and 
increase with age until the mid-70s. There is little data available from developing 
countries and studies there might be influenced by lower life-expectancy (age-
adjusted rates are often not quoted) and greater difficulty in case ascertainment. 
 
 
1.3.2 Prevalence 
 
Most populations that have been studied have a prevalence of between 0.3 and 1% 
with 2 to 4 times the number of women affected as men
4
. Higher rates are seen in 
North America and Northern Europe (0.5-1%) when compared with Southern Europe 
and developing countries (Figure 1.2)
10
. Prevalence is low in Southeast Asia and rare 
in Africa, where small studies of between 500 and 2000 adults in rural populations 
were unable to identify any cases
11
. Although there are differences between study 
methodology, medical practice and access to care, it remains likely that geographical 
variation in genetic and environmental risk factors may at least in part explain these 
observations. The milder disease and lower rates seen in southern Europe is consistent  
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Figure 1.2. World map indicating prevalence rates, where reported, of 
rheumatoid arthritis defined according to the ACR Classification criteria. Green 
indicates a prevalence of 0.1-0.39%, yellow 0.4-0.79% and red >0.8%. Data is 
derived from the review by Alamanos and colleagues
10
. 
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with a genuine geographical variation in prevalence. More suggestive is the high 
incidence and prevalence of RA in certain North American Indian and Alaskan Native 
populations, the Tlingit, Yakima and Pima Indians and the Mille Lacs Chippewa Band. 
Smaller increases are seen in the North Slope Inupiat and the Siberian Eskimos
12
. The 
highest reported prevalence is 6.8-7.1% in the Mille Lacs Chippewa Band. The age-
adjusted incidence rate among the Pima Indians is 10 times that in Rochester, 
Minnesota
12
. Higher than expected rates of nodules, erosions and RF are also seen in 
these populations, suggestive of more severe disease. This may be related to the very 
high prevalence of the HLA-DRB1 „shared epitope‟ (SE; see below) in these 
populations; *04 in the Chippewa and *1402 in the other populations. A related allele, 
*1406, has also been described in the Pima. Interestingly, a meta-analysis showed that 
in these populations, the odds ratio for RA conferred by *1402 was only 2.63, given 
the high rates of carriage in the unaffected controls
12
. This suggests the continued 
importance of other genetic and environmental factors even in these populations. The 
importance of genetic factors has been emphasised by the handful of migrant studies 
that have been performed, although one study found Pakistanis living in England to 
have a higher prevalence of RA than in Pakistan, albeit still less than the Caucasian 
population
11 13
. 
 
1.3.3 Changes over time 
 
Studies conducted in the UK, Finland, amongst the Pima Indians, and in Rochester, 
USA, have all suggested a decline in incidence over time
4
. Amongst the Pima Indians 
the age-adjusted incidence between 1965-1973 and 1983-1990 declined by 55% in 
men and 57% in women, after controlling for exogenous oestrogens and pregnancy. 
Prevalence declined by 29% in men and 40% in women. Notably this was population-
based longitudinal study rather than a retrospective case-notes review, and as a result 
the criteria used were the 1961 Rome criteria, rather than the 1987 ACR criteria
14
. 
The study from Rochester reported a reduction in annual incidence from 0.61 per 
1000 in 1955-1964, to 0.33 in 1985-1994. Rather than a linear decline however, 
marked variability from year to year with a cyclical pattern was observed
15
. No such 
trend was demonstrated in a Greek study although the overall incidence and 
prevalence were low throughout
16
. These findings suggest a change in environmental 
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risk affecting those populations with a high incidence of RA. It is not possible to 
extrapolate these findings to other populations. 
 
1.4 Genetic Risk Factors 
1.4.1 HLA-DRB1 
 
There is a strong genetic predisposition to RA with an estimated heritability of 
approximately 60% based on twin studies
17
. The strongest association is with the 
HLA class II region on chromosome 6p which contributes at least 30% to the overall 
genetic effect
18
. This was first described by Stastny in 1978 who identified a 
relationship with HLA-Dw4 [DRB1*0401] using mixed lymphocyte culture
19
. This 
was followed by a broader serologically defined HLA-DR4 association. However the 
advent of PCR demonstrated that some (*0401, *0404, *0405 and *0408) but not all 
(*0402, *0403) HLA-DRB1*04 alleles were associated with RA
20
. Whilst *0401 and 
*0404 were particularly linked to RA in Northern Europe and Western North America, 
new associations emerged as other populations were studied; *1402 in Native 
Americans and *0101 and *1001 in India and the Mediterranean for example. A 
controversial question has been whether the association is one of susceptibility or 
severity. The former might imply an abnormal response to a pathogen or other 
antigenic stimulus, whereas the latter a differing intensity in immunologic response. 
This has been complicated by a number of confounding factors: 
 Differing treatment within a cohort with more severe cases being treated more 
aggressively, of particular relevance in cross-sectional studies 
 Differing treatment between cohorts 
 The possibility of some subjects being misclassified as RA, of particular 
relevance to inception studies 
 Bias towards severe disease as most subjects recruited in rheumatology clinics 
 The heterogeneity of RA with at least one major subdivision (anti-CCP 
antibody positive versus negative) 
 Small sample sizes despite wide heterogeneity of HLA-DRB1; currently there 
are over 520 HLA-DRB alleles
21
.  
 Unmatched control groups 
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It would now appear that there is a relationship with both susceptibility and severity. 
For example, in a large white North American cohort involving 793 patients and 
additional controls, a single copy of *0401 increased susceptibility, as did 2 copies of 
other RA associated DRB1 alleles. HLA-DRB1*0401 also associated with younger 
age at disease onset and male sex
22
. An association with nodules and extra-articular 
manifestations
23 24
 as well as with increased radiographic progression
25
 supports a 
relationship with disease severity. 
 
The observation that RA-associated DRB1 *04 and *01 alleles shared a conserved 
sequence at positions 70-74 of the third hypervariable region of the DRβ1 chain led to 
the concept of a „shared epitope‟(SE) that linked different susceptibility alleles26 
(Table 1.2). Four residues (67, 70, 71 and 74) from this region of the β-chain 
contribute to the MHC class II anchoring pocket known as P4 (Figure 1.3)
27
 and are 
thought to preferentially interact with certain amino acid side chains from antigenic 
peptides and thereby influence the T cell repertoire
28
. The P4 pocket, in contrast to the 
electrostatically neutral P1, P6 and P9 pockets, preferentially binds acidic residues in 
part through hydrogen bonds with lysine- β71. The particular relevance to 
citrullination is that this converts a positively charged arginine side chain into a polar 
form that can more easily fit the P4 pocket
27
. 
 
However, there have been a number of criticisms of the SE hypothesis. Some SE 
alleles are associated with greater risk than others (*0401 greater than *0101 for 
example), as are particular combinations, and the predominant allele associations vary 
between ethnic groups
29
. The combination of *0403 and *0901 confers additive risk 
but lacks the SE, and *1406 is not usually associated despite having the SE
29
. 
Furthermore, four studies unsuccessfully tested the SE as a model to explain the role 
of HLA-DRB1 in RA susceptibility
30
. Possible explanations include incorrect 
assumptions about which residues are important as well as the possibility of protective 
epitopes. A protective effect of aspartic acid (D) at position 70 and isoleucine (I) at 
position 67
31
 have been reported, although evidence for the latter is less convincing. 
Using MASC (Marker Association Segregation Chi Square)
32
 methodology in 100 
French Caucasian trio families (one case and both parents) and 132 index cases from 
affected sib pairs, du Montcel proposed a new classification of the SE. In this model,  
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HLA-DRB1* 
Allele 
Amino Acid Position 
70 71 72 73 74 
*0101 
*0102 
*0401 
*0404 
*0405 
*0408 
*1001 
*1402 
Q 
Q 
Q 
Q 
Q 
Q 
R 
Q 
R 
R 
K 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
 
Table 1.2. The amino acid sequences at position 70-74 in the third hypervariable 
region of HLA-DRB1* SE alleles. The single letter amino acid code is shown. 
Q=glutamine, R=arginine, A=alanine, K=lysine. 
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Figure 1.3 
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Figure 1.3. Collagen type II (1168-1180) peptide in the HLA-DR4 binding site. 
(A) P1 Met (green) fits into a deep pocket. Aspartate  P4 and Lysine-β71 
interact in pocket 4. P-2, P5 and P10 are displayed as alanine.  
(B)Hydrogen bonds between Collagen II (1168-1180) and HLA-DR4. Peptide 
side chains are shown as alanine, with the exception of aspartate P4. Ten 
hydrogen bonds are made from the peptide main chain to conserved class 
II residues. Lysine- β71 makes 2 other hydrogen bonds, one to the P4 
aspartate side chain and another to the carbonyl of P5. 
Reprinted from Immunity vol. 7, 473-481, Dessen A et al, ‘X-ray crystal 
structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from 
human collagen’, 1997, with permission of Elsevier33. 
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the first to utilise both association and linkage data, the risk conferred by the RAA 
sequence at position 72 to 74 is modified by amino acids at position 70 (Q and R 
confer a higher risk than D) and 71 (where K confers the highest risk, R an 
intermediate risk and A and E a lower risk)
30
. This led to the following categories 
according to the amino acid at position 71: S1 with alanine or glutamic acid, S2 with 
lysine and S3 with arginine. S3 alleles were subdivided according to the amino acid at 
position 70: S3D with D and S3P with Q or R (Table 1.3). The du Montcel 
classification was validated in a second, independent French Caucasian trio 
population
34
 and in an international collaboration comprising 758 cases and 789 
controls from 10 different ethnic groups
35
. It has also been reported to have relevance 
to progression of structural damage, differentiating predisposing (S2) and protective 
alleles (S3D) 
36
. An independent study of a large UK Caucasian population confirmed 
an association of RA with S2 and S3P but not with S1 and S3D
37
. Notably, they were 
unable to confirm any association with non-*0401 S2 alleles. However when grouped 
together these contributed only 0.4% of total HLA-DRB1 alleles in the study (80% 
power to detect an OR of 1.5), highlighting the difficulties in studying rare alleles. A 
further difficulty arises in studying „protective‟ alleles as it can be difficult to 
distinguish a true protective effect from simply being a non-SE allele. By testing for a 
hierarchy of effect among low risk alleles, Morgan et al were unable to demonstrate a 
protective effect of S1 or S3D, finding a similar risk reduction for both „neutral‟ and 
„protective‟ alleles37. However, there was the possibility that an aspartic acid at 
position 70 in any allele might confer a reduction of risk in the presence of the SE. In 
contrast, van der Helm-van Mil and colleagues reported that the DERAA sequence in 
alleles 0103, 0402, 1102, 1103, 1301, 1302 and 1304 (comprising most of S1) was 
associated with a reduction in susceptibility and severity of RA, independent of the 
presence and absence of the SE risk alleles
38
.  
 
Interestingly, just as having a SE non-inherited maternal antigen (NIMA) predisposes 
to RA
39 40
, so a DERAA NIMA protects, with a lower odds for DERAA-negative RA 
patients of having a DERAA-positive mother compared with DERAA-positive father 
(OR 0.25) 
41
. The mechanisms whereby the DERAA sequence and the NIMA effect 
might afford protection are unexplained. Possibilities for the former could involve  
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Du Montcel classification Amino acids at positions 
70-74 
 HLA-DRB1* alleles 
S1 DERAA 
QARAA 
0103, 0402, 1102, 1103, 
1301, 1302, 1323, 15  
S2 xKRAA 0401, 1303, 1310, 1333, 
1337, 1419, 1421  
S3P QRRAA 
RRRAA 
0101, 0102, 0404, 0405, 
0408, 1001, 1402  
S3D DRRAA 1101, 1104, 12, 16  
 
Table 1.3. The du Montel classification of the HLA-DRB1 shared epitope alleles
30
 
with the genotype in the left-hand column, the amino acids encoded at positions 
70-74 in the middle column (single letter code), and the HLA-DRB1 alleles 
sharing each genotype in the right-hand column. HLA-DRB1 alleles in italics are 
additional rarer alleles identified as S2 by Morgan et al.
37
. Q=glutamine, 
R=arginine, A=alanine, K=lysine, D=aspartic acid, x=any amino acid other than 
D, Q or R. 
 
Chapter 1                Introduction 
28 
 
induction of anergy or regulatory T cells, negative selection of T cells, or T cell 
receptor antagonism
42
. Microchimerism leading to tolerance induction could explain 
the latter. 
 
Most studies of HLA-DRB1 alleles have examined associations with RA as defined 
by the ACR classification criteria. However it is increasingly realised that RA may be 
subdivided into at least two major groups, anti-CCP antibody positive and negative, 
with a differing association that is discussed in more detail below. 
 
1.4.2 PTPN22 
 
Another important genetic risk factor for RA is the R620W allele (arginine replaced 
by tryptophan at position 620) of the protein tyrosine phosphatase non-receptor 22 
(PTPN22) gene. This was first described in association with type 1 diabetes, and more 
recently with autoimmune thyroid disease and Myasthenia Gravis
43
. Other possible 
associations are with Addison‟s disease, juvenile RA, vitiligo and SLE. There appears 
to be no association with inflammatory bowel disease and multiple sclerosis. Of 
interest, there is a gradient of increasing frequency in European populations ranging 
from 2% in Italy to 15% in Finland. The allele is virtually absent in African and Asian 
populations. PTPN22 encodes a lymphoid-specific phosphatase (Lyp) that is a 
negative regulator of T and B cell signalling. The R620W allele seems to be a gain of 
function variant
44
, so increasing the threshold for TCR signalling. Theoretically this 
might increase the number of autoreactive T cells escaping negative selection in the 
thymus, or reduce activation of regulatory T cells
43
. However more recent data 
suggests that this allele may also alter B cell receptor signalling
45
. 
 
1.4.3 Other Genetic Risk Factors 
 
An increasing number of other genes have now been associated with RA, identified 
via genome-wide association studies and candidate gene approaches. The strongest 
signals remain within the MHC and fine mapping studies of this region have recently 
identified genetic associations with anti-CCP positive RA that are independent of the 
HLA-DRB1 alleles. These include DPB1, regions in the central MHC, and MHC class 
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1 chain-related gene A (MICA)
46 47
. Other non-MHC associations include the tumour 
necrosis factor receptor associated factor 1/ complement component 5 (TRAF1-C5) 
region, signal transducer and activator of transcription 4 (STAT4), the 6q23 region 
where there are both risk and protective haplotypes, the 4q27 region (which includes 
the genes for IL-2 and IL-21) and cytotoxic T-lymphocyte associated protein 4 
(CTLA4)(reviewed by Coenen and Gregersen)
48
. Several of these loci are associated 
predominantly with anti-CCP positive RA. Other candidates have been confirmed or 
have been suggested by genome-wide association studies. One potential susceptibility 
locus identified by such a study is on Chromosome 21 
49
 and Down Syndrome, with 
its well recognized association with autoimmunity, is a natural opportunity to study 
this. However, unlike organ-specific autoantibodies, anti-CCP antibodies and RA do 
not appear to be a feature of this disorder
50
. 
 
The gene encoding the citrullinating enzyme peptidylarginine deiminase 4 (PADI4) 
was first reported as a risk factor for RA in a Japanese population in 2003
51
. The 
highest risk was associated with a SNP at position 94 and this was proposed to 
increase mRNA stability which could in turn lead to increased amounts of PAD4 
enzyme and citrullination at sites of injury. The specificity of antibodies to 
citrullinated proteins for RA makes this gene an attractive candidate. Several studies 
in Asian populations have replicated the finding, but data from European cohorts has 
been inconsistent with associations only demonstrated in single studies from Germany 
and North America and in meta-analyses
52
. The possibility that the inconsistency in 
European studies may have arisen through them being underpowered to detect a 
modest effect, was recently addressed by Burr et al. They studied two UK cohorts, 
totalling almost 5600 RA subjects, in which PADI4_94 had no association with RA or 
anti-CCP antibodies and no interaction was demonstrated with the SE or with 
PTPN22
53
. The reasons for this ethnic discrepancy are unknown at present and may 
include interactions with other genes or environmental factors. One hypothesis is that 
the higher prevalence of smoking in Western females might mask the influence of 
allelic variation at this locus
48
.  
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1.5 Environmental Risk Factors 
 
At least a third of susceptibility to RA is explained by environmental factors, based on 
a comparison of concordance rates in mono- and dizygotic twins
17
. The declining 
incidence noted in several populations, as well as the higher prevalence in urban 
compared to rural populations, is also suggestive of important environmental effects
54
. 
It is increasingly appreciated that RA can be phenotypically divided into anti-CCP 
antibody positive and negative and, as with genetic associations, these populations 
may be differentially associated with environmental risk factors. Most environmental 
factors have only been studied in relation to RA as defined by the ACR classification 
criteria.  
 
1.5.1 Smoking 
 
Smoking is the best attested environmental risk factor for RA. The first evidence 
appeared in 1987, when the Oxford-Family Planning Association contraceptive study 
reported no association of first referrals to hospital for RA with oral contraceptives 
but did find an unexpected increase amongst smokers
55
. The association has since 
been confirmed by several large prospective and case-control studies (reviewed by 
Harel-Meir 
56
). In some studies the effect appears greater for men than women, 
although these did not control for dose, and is largely confined to RF-positive or anti-
CCP positive
57
 disease. The magnitude of risk is dose-dependent (both intensity and 
duration) and may persist for 10 or even 20 years after cessation
58
. Smoking may have 
effects on the progression of RA as well as susceptibility. There is an association with 
greater disease activity, rheumatoid nodules and a reduction in response to anti-TNF 
inhibitors
56 59-61
. However, in a Swiss population-based registry, radiographic joint 
damage progressed at an equivalent rate in smokers and non-smokers with, 
remarkably, a trend for reduced radiographic progression and greater improvement in 
HAQ scores in heavy smokers. Smoking has been implicated in a gene-environment 
interaction that is discussed in more detail below.  
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1.5.2 Hormonal Factors 
 
Given the higher incidence of RA in women, hormonal factors have been investigated 
in a number of studies
54
. Oral contraceptives may decrease the risk, or simply 
postpone the onset
62
. One study reported a lower prevalence of RF in women on oral 
contraceptives
63
. Onset of disease is reduced in pregnancy but increased in the post-
partum period, possibly under the influence of breastfeeding. The latter observation is 
thought to reflect the pro-inflammatory effects of prolactin, however it seems to 
pertain only to the first or second pregnancy and a higher cumulative lifetime history 
of breastfeeding is associated with a halving of risk
64 65
. There is a peak in onset of 
RA around the time of menopause but there are conflicting reports about whether 
hormone-replacement therapy reduces this risk with some studies showing no effect
64
. 
One study found that very irregular periods were associated with RA, and an early age 
at menarche with a greater risk of RF-positive RA
64
. Overall, studies of reproductive 
factors have produced conflicting results and the interrelationship between these 
factors increases the likelihood of confounding; for example, oral contraceptive use 
may be associated with pregnancy avoidance
54
. 
 
1.5.3 Occupation 
 
Occupational exposure to silica has been identified as a risk factor in 2 studies
66 67
. 
Data from the Swedish Epidemiological Investigation into Rheumatoid Arthritis 
(EIRA) study has shown that work involving rock drilling or stone crushing increases 
the risk of RA threefold
67
. The EIRA study has also suggested that mineral oil 
exposure, which can induce polyarthritis in rats, increases the risk, particularly for RF 
or anti-CCP positive disease
68
. 
 
1.5.4 Infection 
 
It is widely perceived that there are likely to be infectious triggers for RA particularly 
as a number of other inflammatory joint diseases may arise following infection, 
examples being rheumatic fever, reactive arthritis, HTLV-1 associated polyarthritis 
and self-limiting parvovirus B19 and Chikungunya virus associated arthritis. 
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Additional „soft‟ evidence includes the declining incidence over time and the 
hypothesis, based on skeletal remains, that RA may have existed in North America 
prior to its arrival in the Old World
69
. Contact with cats
70
, primarily in patients with 
DRB1*0401 and *0404
71
, and blood transfusions
72
 have been reported as more 
common in those developing  RA.  But whilst there has been a wide range of 
candidate microbes, none has had convincing evidence to support a role in RA 
(reviewed by Carty 
73
). Most studies have been cross-sectional, investigating patients 
with established disease which might itself predispose to infection, and often with 
inadequate controls. Further difficulties in uncovering an infective aetiology will 
occur if there is more than one microbe that can trigger disease, if the infection were 
to occur years before onset of clinical disease (as suggested by the presence of anti-
CCP antibodies) particularly if it does not persist, if the agent is unknown, and if it 
reflects a rare response to a common infection
73
. These complicating factors might 
explain the apparent absence of geographical and temporal clustering although this 
may occasionally occur
74 75
. An added difficulty for investigators is that synovial 
tissue may non-specifically trap microorganisms
73
. 
 
Mechanisms whereby infection might initiate or enhance autoimmunity have been 
reviewed by Munz et al
76
. Pattern-recognition receptors (PRRs), such as the Toll-like 
receptors (TLRs), are an important component of the innate immune system and are 
capable of recognising a number of pathogen-associated molecular patterns leading to 
activation of immune cells and secretion of type I interferons and chemokines. The 
microbial triggering of PRRs in the vicinity of autoreactive T cells might lead to T 
cell activation instead of anergy, via an adjuvant effect. Similarity between microbial 
antigens triggering an adaptive immune response and host proteins, could result in 
cross-reactivity („molecular mimicry‟). „Bystander activation‟ might occur in a site of 
inflammation whereby antigen-presenting cells present self-peptides derived from 
necrotic tissue to autoreactive T or B cells. This may be followed by diversification of 
the immune response to recognise other epitopes in the same autoantigen or to others 
in the vicinity („epitope spreading‟). Other mechanisms might include increased T cell 
signalling through microbial-toxin mediated lipid raft aggregation
77
 and the 
immortalisation of B cells by Epstein-Barr virus (EBV). 
 
 
Chapter 1                Introduction 
33 
 
 
1.5.4.1 Viruses 
1.5.4.1.1 Epstein-Barr Virus 
 
One of the most popular candidates has been Epstein-Barr Virus (EBV), a double-
stranded DNA herpes virus that infects 98% of the world‟s population and persists as 
a latent infection in memory B cells with occasional reactivation. It is a B cell 
stimulator with the capability of inducing autoantibodies and RF
73
. Higher antibody 
levels to EBV antigens can be detected in RA patients compared with healthy 
controls
78
 and some data are suggestive of reduced cell-mediated immunity, with 
greater numbers of B cells infected and decreased T cell responses to the lytic cycle 
antigen glycoprotein 110 (gp110), which is an important target for control of viral 
replication
79 80
. It is of interest that there is sequence similarity between gp110 and the 
SE, which provides opportunity for cross-reactivity
81
, as well as a reduction in 
immune responses to gp110 through the influence of HLA-DRB1*04 on thymic 
selection and peripheral tolerance
79
. EBV DNA has been detected in synovium, 
synovial fluid and peripheral blood mononuclear cells (PBMC) at a higher frequency 
than in controls
79 82
. Direct evidence of a link has not been provided however and 
serological evidence, due to high prevalence, is difficult to interpret
73
. Furthermore, 
RA may occur without evidence of prior EBV infection
83 84
. Deficient T cell function 
may be a result of disease activity, as it is not found in early RA but does occur in 
other diseases
79
. Similarly, raised antibody titres are seen in a number of other 
autoimmune diseases including Sjogren‟s syndrome, multiple sclerosis and systemic 
lupus erythematosus (SLE)
78
. Whether the findings in RA are indicative of EBV 
having a pathological role, or occur as an epiphenomenon due to an innate or acquired 
immune defect, is unknown. Furthermore, EBV may be present in joints simply as a 
result of B cells being latently infected, and high PBMC viral loads have also been 
reported for other viruses in RA
85
. 
 
1.5.4.1.2 Parvovirus B19 
 
Acute infection with Parvovirus B19, a single-stranded DNA virus, is associated with 
polyarthritis in 8% of children and 60% of adults, more commonly in females (59% v 
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30%)
86
. The polyarthritis is symmetric, initially involving the MCP and PIP joints, 
and often accompanied by flexor tenosynovitis. It typically resolves in 1-2 weeks, 
although a protracted course has been reported in a few cases with persistence more 
likely in the presence of HLA-DR4
87 88
. Parvovirus B19 appears to have been 
introduced to Europe from North America in the 16
th
 century, when RA was first 
thought to have occurred
89
. Further suggestion of a link is the detection of Parvovirus 
B19 in RA synovial tissue
90
. Evidence against a link is that progression to RA 
following acute infection seems rare and the virus is also detectable in synovial tissue 
from other diseases[Meyer O 6]. In addition, serological evidence of recent infection 
was found rarely in a large cohort of patients with very early inflammatory arthritis
91
. 
 
1.5.4.2 Bacteria 
 
A large number of bacteria have been proposed as candidates, including various 
mycobacteria and mycoplasma, but with little supportive evidence
73
. DNA from a 
wide variety of bacteria have been detected in synovium but this may simply reflect a 
property of inflamed synovium to act as a non-specific trap for bacterial fragments
73
. 
Recently there has been interest in a possible association with periodontitis. 
 
1.5.4.2.1 Periodontitis 
 
Chronic periodontitis describes the inflammation of tooth-supporting tissues which 
may progress to destruction of periodontal ligament and alveolar bone
92
. A number of 
studies have reported an association with RA, although most are of small size and 
with inadequate controls
92
. However, one population-based study which identified 
cases of RA according to the ACR criteria, with the exception of X-ray data which 
was unavailable, reported an association with an odds ratio of 4.1 for subjects 
fulfilling 4 out 6 ACR criteria
93
. RA patients were also observed to have a higher rate 
of tooth loss. Whether periodontitis is a risk factor for RA, or vice versa, or whether 
common factors predispose to both is not yet established. There are however some 
compelling reasons to consider oral bacteria, and in particular Porphyromonas 
gingivalis (P. gingivalis), as a candidate environmental risk factor. P. gingivalis is the 
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only known bacterium to date that has been found to express a peptidyl arginine 
deiminase (PAD) enzyme (see below) and which is capable of citrullinating fibrin
94
. 
Consequently it might have a role in breaking tolerance to citrullinated proteins. Anti-
CCP antibodies have been described in patients with periodontitis in the absence of 
RA
95
, and levels of antibodies to P. gingivalis and CCP are correlated in patients with 
RA
96
. Furthermore, three small studies in patients with both RA and periodontitis 
have demonstrated improvement in ESR and DAS28 scores following periodontal 
treatment (scaling, root planing and oral hygiene)
97-99
, although with major 
methodological limitations including small sample size and short duration, inadequate 
matching at baseline or high control group drop-out, and lack of blinding and placebo 
control. 
 
1.5.5 Other environmental risk factors 
 
A dose-dependent protective effect of alcohol has been reported in two North 
European studies
57 100
. High birthweight has been associated with later development 
of RA in two studies
101 102
. The influence of socioeconomic factors has been 
controversial
54 103
 with some recent studies showing an association with a lower 
educational attainment and with manual labour
104 105
. 
 
1.6 Pathogenesis 
1.6.1 The Synovium in RA 
 
The healthy synovium is a lining layer of synoviocytes that is generally only 2-3 cells 
thick. In RA, the synovium becomes thickened through proliferation of macrophage-
like and fibroblast-like synoviocytes and can form into organised frond-like growths 
in which a central pathological feature is chronic, cellular accumulation. Infiltrating 
CD4+ T cells, B cells and macrophages may aggregate and develop features akin to 
lymphoid tissue
106 107
 and the leading edge of inflammatory synovium, known as 
pannus, erodes underlying articular cartilage. Theories on pathogenesis have evolved 
over the years and are reviewed by Firestein
106
. Following the discovery of RF, RA 
was widely considered to be an autoimmune disease, and later models implicated 
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immune-complex mediated disease
108
. After this T cells came to prominence followed 
by cytokine networks. More recent findings have reemphasised the roles of B cells, 
autoantibodies and immune complexes, as well as of T cells. 
 
1.6.2 Autoantibodies 
 
RA is widely considered to be an autoimmune disease and a key evidence for this has 
been the presence of autoantibodies i.e. antibodies that recognise self. However the 
antigens that drive this process are still unknown. A wide variety of candidates have 
been reported and the most important will be discussed here. 
 
1.6.2.1 Rheumatoid Factor 
 
The first candidate autoantigen to be described was IgG. Rheumatoid Factor (RF) was 
first reported in 1940 by Waaler and later identified as antibody reactive with the Fc 
region of IgG
109. Most RFs bind an epitope in the Fc region between the γ2 and γ3 
domains found in IgG1, IgG2 and IgG4 but not IgG3. Of interest is that this site is 
also bound by some bacterial proteins such as staphylococcus protein A and 
streptococcus protein G
110
. This specificity is classified as Ga but a number of other 
binding sites on IgG occur including F(ab
1
)2 and neoantigens on altered IgG. The 
latter might arise following damage by nonenzymatic glyoxidation or advanced 
glycation end products
110
, or by hypoglycosylation since decreased 
galactosyltransferase activity is a feature of RA as well as some other chronic 
inflammatory and infectious diseases
109 111
. RF are found in 60-80% of RA patients
109
, 
and a number of studies have shown them to predate the clinical onset of RA
112 113
 and 
to be associated with more severe disease. The frequency of RF-producing B cells is 
10 times higher in the synovium than in the peripheral blood and there is evidence of 
somatic mutation suggesting an antigen-driven process
110
. Somatic mutation is not 
seen in all RF however and the majority of RF are of the IgM isotype (although IgG 
and IgA also occur), raising the possibility of partial T cell independence. A potential 
explanation has been provided by Leadbetter et al who have shown that production of 
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RF can be stimulated by immune complexes containing a Toll-like receptor (TLR)-9 
ligand
114
. 
 
It has been proposed that small immune complexes arising from the interaction 
between RF and IgG may be bound by FcγIIIa receptors present on macrophages 
within joints, leading to production of pro-inflammatory cytokines and inflammation. 
FcγIIIa receptors are only expressed at high level in the synovium and those sites 
where extra-articular manifestations occur in RA
115
. Furthermore, a RF response may 
become „self-perpetuating‟, since soluble IgG RF may polymerise and accumulate 
complement fragment C3d which is capable of providing a second, positive B cell 
signal via binding to complement receptor 2
116
. RF-producing B cells can also bind, 
endocytose and present foreign antigen to non-autoreactive T cells and thereby 
receive T cell help without requiring T cell responses to IgG which are usually absent. 
This became the rationale for B cell targeting therapy in RA (Section 1.14.6)
116
. RF-
IgG immune complexes are also capable of activating Natural Killer (NK) cells which 
are present in the RA synovium, resulting in the release of TNFα and IFNγ109.  
 
Criticisms of the role of RF in RA principally relate to their lack of specificity. RA 
may occur in the absence of RF, but this seems less pertinent if the ACR criteria 
might encompass different diseases with similar phenotypic endpoints. RF are seen in 
healthy individuals with a prevalence ranging from 1.3 to 4% in Caucasians, to as 
high as 30% in some Native American tribes (where of course there is also an 
increased incidence of RA)
110
. The frequency of IgM RF increases with age whereas 
IgG RF decreases. RF also arise in infectious diseases, triggered by immune 
complexes and polyclonal B cell activators, with a greater incidence in secondary 
infections when compared with primary, and in chronic infections with antigen 
persistence. Not all infections are associated with RF however, and the stochastic 
arrangement of epitopes is thought to be important
110
. In contrast to RA, RF 
accompanying infectious diseases tend to be transient (or disappear after removal of 
antigen such as following treatment of Hepatitis C), are rarely associated with arthritis 
although arthralgia may occur, and are thought to be beneficial rather than detrimental. 
The possible benefits are summarised in Table 1.4. 
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Increased clearance of immune complexes as RF increases avidity and size 
Formation of immune complexes facilitates antigen uptake and presentation by 
dendritic cells 
RF-bearing B cells are also efficient at antigen presentation so enhancing the anti-
pathogen response 
Presentation of antigen by RF-bearing B cells enhances immunological memory 
Rapid production of low-affinity RF may prevent activation of higher affinity RF B 
cells as well as additional B cells („competitive tolerance‟) 
 
Table 1.4. Proposed benefits of RF and RF-producing B cells. After Dörner
117
, 
Steiner
109
, Newkirk
110
. RF=rheumatoid factor. 
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RF also occur frequently in other rheumatological illnesses, such as primary Sjögren‟s 
syndrome and systemic lupus erythematosus (SLE), in which erosive joint disease is 
unusual. With the caveats that RF in healthy individuals and in Sjögren‟s syndrome 
usually bind IgG with lower affinity, are not somatically mutated and are polyreactive, 
the above data suggest to many that RF might simply be a marker of sustained 
immunological activity
110
. They might amplify immune responses but IgG is unlikely 
to be the principal autoantigen driving RA. 
 
1.6.2.2 Anti-Type II collagen 
 
Five out of the 14 different collagens are found in human cartilage, types II, IX, X, 
and XI are mostly restricted to cartilage whilst type VI is found elsewhere
109
. Of these, 
type II collagen (CII) is the most abundant and the presence of antibodies to this have 
been described for 30 years. Besides the specificity for cartilage, CII is an attractive 
target for other reasons (reviewed by Mewar
118
). Immunisation with CII induces a 
destructive arthritis in animal models (collagen-induced arthritis; CIA). Antibodies to 
native and denatured CII are found in 3-30% of RA sera and production occurs within 
the joint, with both antibodies and immune complexes containing CII being detected. 
A dominant B cell epitope consisting of a triple helical structure formed by 11 amino 
acids (triple helical position 494-504) was identified in 14/22 RA sera positive for 
antibodies to CII, and this same epitope is immunogenic in a rat model
119
. T cell 
responses have been observed in 50% of antibody-positive patients. In contrast to RF, 
anti-CII antibodies are not detected before the onset of clinical synovitis
120
 and seem 
to peak at the time of diagnosis and decline thereafter. Mullazehi et al described very 
high levels of anti-CII in 3% of a cohort of early inflammatory arthritis and these 
patients were noted to have a high acute phase response and PBMC that, when 
stimulated ex vivo by anti-CII-containing immune complexes, produced high levels of 
TNFα, IL-1β and IL-8121. No difference in long-term outcome was demonstrated in 
these patients however, and most studies do not find that anti-CII antibodies associate 
with particular disease subsets
109
. In a cohort of patients presenting with synovitis of ≤ 
3 months, anti-CII antibodies were found in 5% but no difference in prevalence was 
found between patients developing RA and those with other diagnoses, several of 
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which resolved
122
. They therefore demonstrate little predictive value and may simply 
occur in association with high levels of joint inflammation. Low levels of anti-CII 
antibodies occur in a variety of disorders and in healthy individuals. Unlike in CIA, 
oral tolerance with CII in RA has been disappointing
123
. Consequently, CII does not 
appear to be a significant target antigen in the majority of RA patients. 
 
1.6.2.3 Anti-Glucose-6-phosphate isomerase 
 
An animal model of arthritis was a chance finding following the crossing of a mouse 
with a transgenic T cell receptor recognising bovine pancreas ribonuclease in the 
context of murine MHC molecule I-A
k
, with the autoimmune prone NOD mouse
124
. 
The resulting mice, labelled K/BxN, recognised a different antigen in the context of 
the new MHC I-A
g7   
and developed an aggressive arthritis starting at 3-4 weeks of age 
bearing a number of similarities with RA. The arthritis was chronic, progressive and 
symmetrical, with a greater involvement of distal joints, and resulted in destruction of 
cartilage and bone. The associated synovitis and pannus formation was Il-1 
dependent
124
. A number of differences to RA were also observed such as the 
involvement of distal interphalangeal joints and spine, the greater ratio of myeloid 
cells in the synovium in comparison with T cells and plasma cells, the presence of 
IgG antibody deposits coating organs, the lesser dependence upon TNFα and the 
absence of RF
124-127
. The inciting antigen was later identified as glucose-6-phosphate 
isomerise (GPI)
127
. This is an essential enzyme in both glycolysis and 
gluconeogenesis, catalysing the interchange of glucose-6-phosphate and fructose-6-
phosphate, and consequently is ubiquitously expressed. The enzyme is multifunctional 
and has cytokine and growth factor activities
128
. Immunisation of non-transgenic mice 
with GPI in adjuvant also results in a high incidence of symmetrical peripheral 
arthritis but which differs from the transgenic model in a number of respects including 
its transient nature and requirement for T cells and TNF throughout (reviewed by 
Kamradt  and Schubert
129
). An initial human study reported a high diagnostic 
sensitivity and specificity of antibodies to rabbit GPI in RA with 44/69 (69%) of 
subjects positive
130
. The authors also provided evidence of affinity maturation of the 
antibody response. These results have not been confirmed by other studies using 
either rabbit or recombinant human GPI as substrate
131-135
. Jouen et al found 
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antibodies in 45% of RA subjects using rabbit GPI as substrate but with a similar 
prevalence in other autoimmune diseases and no association with radiographic 
progression
136
. A possible explanation for the discrepant results is provided by van 
Gaalen et al who found anti-human GPI antibodies in 4% of controls and 5% of 
uncomplicated RA, but in 18% of RA patients with nodules, 45% with rheumatoid 
vasculitis and 92% with Felty‟s syndrome135. Notably, 47 of the 69 patients in the 
original study had Felty‟s syndrome. Other proposed explanations include the impure 
and variable nature of the rabbit preparation
131 134
, although the original samples were 
later retested against recombinant GPI with similar findings
134
.  
 
Although antibodies to GPI appear to bear little relevance to human disease the 
animal model does provide valuable insights into how autoimmunity to a ubiquitous 
antigen can result in a joint-specific disease. Although T cells are required for disease 
to commence they are not involved in the effector phase which is antibody 
dependent
124
. The joint specificity appears to lie not in some peculiarity of intra-
articular GPI expression but in the binding of GPI to cartilage
137
. Cartilage is a non-
cellular surface and consequently does not have the cell surface inhibitors of 
alternative complement pathway activation (decay accelerating factor and membrane 
cofactor protein). Instead it relies on the soluble proteins Factors H and I and on the 
inhibitory effect of sialic acid. Factor H, however, has limited access to complement 
component C3b once the latter has bound to Ig and is stabilised by properdin. The 
deposits of GPI on cartilage increase following the onset of arthritis and extend along 
the inflamed synovium and pannus. This is thought to represent additional binding of 
circulating immune complexes to the GPI-antibody already bound to cartilage in a 
„positive feedback‟ fashion137. This provides a model of how an extra-articular 
molecule, readily able to diffuse into the joint since the articular vasculature lacks a 
basal membrane, can trigger an inflammatory arthritis in the absence of other systemic 
disease. In the case of GPI, binding to cartilage is thought to occur via a high affinity 
interaction with glycosaminoglycans and it is possible that a differing distribution of 
particular glycosaminoglycans might explain the joint distribution in this model
138
.  
 
1.6.2.4. Other autoantigens 
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A wide variety of other, non-citrullinated, autoantigens have been described in RA 
and a selection of these that show greater specificity for RA, or have been more 
recently described, are shown in Table 1.5. 
 
1.6.2.5 Antibodies to citrullinated protein antigens 
 
In 1964 Nienhuis and Mandema described an immunofluorescent pattern of labelling 
in human superficial buccal epithelial cells that was specific for RA sera and called 
the antiperinuclear factor (APF)
154
. This was found to have a variable diagnostic 
sensitivity (48-87%) but a high specificity (73-100%)
155
. Antikeratin antibodies, 
which bind to the keratinised stratum corneum of rat oesophagus, were first described 
in 1979
156
. Again there was a variable sensitivity (33-80%) but high specificity (87-
100%)
155
. These assays never became widely used because of their reliance upon 
immunofluorescence and the difficult nature of the substrates, for example only 5% of 
buccal mucosal cell donor samples were suitable. Both APF and AKA were later 
demonstrated to recognise the same target, filaggrin, and the term antifilaggrin 
autoantibodies was proposed
155
. At the same time it was also recognised that filaggrin 
was not expressed in synovium, and that cross reactivity with an as yet unidentified 
autoantigen was likely. Profilaggrin is heavily phosphorylated and stored in granules 
in epithelial cells. During terminal differentiation filaggrin is released by proteolytic 
cleavage, dephosphorylated and approximately 20% of arginine residues are 
converted to citrulline. A key discovery was that antifilaggrin antibodies were in fact 
citrulline-specific
157 158
. Using a cyclised synthetic peptide sequence from filaggrin, 
with a citrulline substituted for an arginine residue, an ELISA termed the anti-CCP[1] 
test was developed which had a diagnostic sensitivity of 68% and a specificity of 
98%
159
. Given that the diagnostic sensitivity of the anti-CCP1 assay was not superior 
to RF and that filaggrin is not found in the joint, a second assay was developed by 
screening large libraries of citrulline-containing peptides
160
. The peptides selected for 
the CCP2 assay are a commercial secret but are thought to be non-physiological. This 
assay has an improved diagnostic sensitivity of approximately 80% (68% in a meta-
analysis compared to 53% for CCP1
161
) but with a preserved specificity of  95%
160
. 
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Antibody Method Antigenic 
source 
Sensitivity Specificity 
 
Ref 
Healthy 
controls 
Disease 
controls 
Anti-RA33 
(hnRNP-
A2) 
Blotting HeLa cell 
nuclear 
extract 
35 100 90 
(96*) 
 
 
139 
140
 
Anti-
eEF1A-1 
ELISA rec. 
eEF1A-1 
23 (FS-) 
66 (FS+) 
100 91 
141
 
Anti-α-
enolase 
Blotting Placenta 25  97 
142
 
Anti-BiP Blotting HeLa 
extract 
63 99 93 
143
 
Anti-
Calpastatin 
Blotting rec. h. 
calpastatin  
46 
57 
100 
- 
95 
71 
144 
145
 
rec. h. C-
terminal 
fragment 
11 92 - 
146
 
Anti-MBL ELISA h. serum 
MBL 
60.7 98 - 
147
 
Anti-CAIII ELISA rec. h. 
CAIII 
17 100 67 
148
 
Anti-
RAGE 
ELISA rec. h. 
RAGE 
26 (IgM) 95 - 
149
 
18 (IgG) 91 - 
Anti-
Ferritin 
ELISA Eq. spleen 
ferritin 
16-19 97 98 
150
 
Anti-
PADI4 
Immunoprecipitation 
 
rec. h. 
PADI4 
36-42 
 
100 
 
99 
 
151
 
ELISA rec. h. 
PADI4 
22-25 95 85 
152
 
Anti-
BRAF 
Blotting rec. h. 
BRAF 
47 100 100 
153
 
 
 
 
 
 
 
 
Table 1.5 
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Table 1.5. A selection of autoantibodies in RA, other than those described in the 
text, which show greater specificity for RA. The detection method used, the 
source of the antigen, and the sensitivity and specificity against healthy and 
disease controls (mostly non-RA rheumatological diseases) are also shown. In 
contrast to the other autoantigens, anti-RAGE may be protective. hnRNP-
A2=A2 protein of heterogeneous nuclear ribonucleoprotein; eEF1A-1= 
eukaryotic elongation factor 1A-1; BiP=binding protein; MBL= mannose 
binding lectin; CAIII=carbonic anhydrase III; RAGE=receptor for advanced 
glycation end products; PADI4= peptidylarginine deiminase 4; BRAF= v raf 
murine sarcoma viral oncogene homologue B1 catalytic domain. 
Rec.=recombinant; h.=human; eq.=equine. FS=Felty’s syndrome. *If SLE and 
MCTD excluded. 
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This assay has proved to be a useful diagnostic and prognostic tool. For example, anti-
CCP antibodies predict the development of rheumatoid arthritis in patients with early 
undifferentiated arthritis
162-164
, and in established RA they predict a more severe 
disease course
165
 and development of erosions
166 167
. The finding that ACPA occur 
years before clinical symptoms further suggests they may be pathologically 
important
112 113
. However the artificially created CCP2 antigen is not found in the 
rheumatoid joint where local production of antibodies to citrullinated proteins has 
been demonstrated to occur
168 169
. Therefore the CCP2 assay provides little insight 
into aetiopathogenesis and identification of the true citrullinated target antigen(s) 
remains of importance for understanding RA pathology. 
 
1.7 Citrullination (deimination) 
 
Citrulline is an amino acid for which there is no tRNA, meaning that it is only 
incorporated into proteins as a post-translational modification (reviewed by 
Vossenaar
170
) . This occurs via a family of enzymes known as peptidylarginine 
deiminase (PAD) which catalyse the deimination of arginine residues into citrulline. 
PAD enzymes are unable to deiminate free L-arginine. This requires nitric oxide 
synthase and arginine deiminase, in eukaryotic and prokaryotic cells respectively. The 
conversion of arginine into citrulline results in a loss of positive charge which impacts 
upon the formation of intramolecular ionic and H-bonds with a resultant partial 
unfolding of protein (Figure 1.4). This is thought to render the protein more 
susceptible to proteolytic cleavage. There may also be a loss of intermolecular bonds, 
such as is seen with the disintegration of vimentin filaments upon citrullination of the 
head domains
171
, or the creation of new bonds as occurs with keratin aggregation by 
filaggrin. The role of citrulline in normal physiology is incompletely understood but 
certain proteins in the stratum corneum of the skin and in the CNS are constitutively 
deiminated
170
. A role in regulation of DNA transcription is suggested by the ability to 
inhibit arginine methylation on histones
172
 and the citrullination-dependent formation 
of highly decondensed chromatin structures in neutrophils
173
. Citrullination of 
intracellular proteins appears to be a feature of apoptosis and also of inflamed 
tissues
170 174
. There are 5 PAD enzymes in humans (PAD 1-4 and 5) of which PAD2  
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Figure 1.4. The conversion of an arginine residue to a citrulline residue is 
catalysed by the enzyme peptidylarginine deiminase (PAD). It involves a 
positively charged guanidino group changing into a neutral ureido group in the 
presence of water with ammonia and hydrogen ions as byproducts. The red 
dotted line represents hydrogen bonds (with protein backbone or with polar 
amino acid side chains) or ionic interactions (with negatively charged amino acid 
side chains). The loss of such bonds upon citrullination can result in partial 
unfolding of the protein. Figure from Wegner et al
175
. 
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and 4 are of particular interest in the study of RA. PAD2 has widespread tissue 
expression and PAD4 is mainly expressed in white blood cells. Thus expression of 
both can be found in the RA joint
176 177
. PAD2 can be detected in synovium from both 
inflammatory synovitis and osteoarthritis, whereas PAD4 is observed only in 
inflammatory conditions
178
. Opposite results were reported from synovial fluid, with 
PAD2 but not PAD4 limited to inflammatory joint disease
176
. Activity of PAD 
enzymes is calcium-dependent and the concentration required for the activation of 
PAD2 is more than 100 times that normally present in the cytoplasm. Consequently 
PAD activation is often associated with terminal cell differentiation, such as the 
deimination of keratin and filaggrin by PAD1 and of trichohyalin by PAD3 in the 
skin
170
, and with apoptosis. Macrophages treated with calcium ionophores to increase 
intracellular calcium concentration become apoptotic and show selective citrullination 
of vimentin
177
. During differentiation of monocytes into macrophages, there is 
enhanced translation of PAD2 mRNA and a reduction of PAD4 expression, although 
protein levels remain unchanged
177
. Long term activated macrophages are prone to 
apoptotic cell death with concurrent PAD activation and leakage out of dying cells. 
Macrophage-like cells make up a large percentage of the lining cells in RA synovium, 
where large amounts of citrullinated proteins are found
177
. 
 
1.8 Physiological citrullinated autoantigens: the candidates 
1.8.1 Fibrin/fibrinogen 
 
Serre and co-workers solubilised the intra- and extracellular proteins present in RA 
synovial samples and immunoblotted them with purified anti-filaggrin antibodies. 
Whilst they found a number of citrullinated proteins, only 2 were recognised by the 
anti-filaggrin antibodies. These were identified as the α and β chains of fibrin179. All 
the anti-filaggrin antibody positive samples recognised purified plasma fibrinogen 
citrullinated in vitro, as did a number of RA samples that were antifilaggrin antibody 
negative. The Serre group went on to demonstrate the presence of citrulline in 
synovial deposits of fibrin which are a feature of RA
179
. Filaggrin derived peptides 
recognised by antibodies to citrullinated proteins were able to inhibit binding to 
citrullinated human fibrinogen. Such cross-reactivity presumably relies on structural 
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homology since there is little sequence similarity between the filaggrin peptides and 
fibrinogen
180
. When testing citrulline-containing fibrin peptides, 18 were found to 
react with RA sera with variation in the pattern of reactivity between individual sera 
suggesting that the „fine specificity‟ of the anti-citrullinated protein response differed 
between patients
180
. Some of the anti-citrullinated peptide epitopes were located at 
plasmin cleavage sites raising the hypothesis that antibody binding might inhibit 
clearance of fibrin, which is of interest since fibrin deposits may enhance synovial 
inflammation
181
.  
 
A number of other lines of evidence are supportive of fibrin(ogen) being an 
autoantigen. The majority of RA sera positive for anti-CCP2 antibodies are also 
capable of reacting with citrullinated fibrinogen
182
. Both fibrin and fibrinogen have 
been demonstrated to be citrullinated in the RA joint
183 184
. Immune complexes 
formed from human anti-citrullinated protein antibodies and immobilised citrullinated 
fibrinogen, induced TNFα secretion from macrophages via FcγRIIa receptors185. 
Immune complexes containing citrullinated fibrinogen were detected in the peripheral 
blood of half of RA patients with anti-CCP antibodies in a recent study, and were also 
isolated from synovial pannus where co-localisation with C3 was also demonstrated
186
.  
Whilst immunisation of mice with citrullinated fibrinogen generally does not induce 
arthritis
187 188
, in one collagen-induced arthritis model, antibodies to citrullinated 
fibrinogen were detected and tolerisation with a citrulline-containing filaggrin peptide 
ameliorated disease. Conversely, co-administration of a murine monoclonal antibody 
specific for citrullinated fibrinogen exacerbated arthritis when disease was induced 
with a suboptimal dose of anti-collagen II antibodies
189
. Further evidence for a 
pathogenic role of immunity towards citrullinated fibrinogen comes from a mouse 
model transgenic for human HLA-DRB1 *0401. Immunisation with citrullinated, but 
not uncitrullinated, human fibrinogen resulted in arthritis in 35% of mice that was 
associated with a mild synovial hyperplasia leading to ankylosis. Interestingly, these 
mice also developed antibodies to a wide array of other citrullinated proteins, but 
whether these arose through cross-reactivity or epitope-spreading, and whether they 
contributed to pathogenesis, is undetermined
190
.  
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1.8.2 Vimentin 
 
Anti-Sa antibodies were first described in RA sera in 1994, and detected with 
immunoblots utilising human spleen and placenta extracts as substrate
191
. They had a 
diagnostic sensitivity of 43% and specificity of 99%
191
 and appeared to associate with 
more severe disease
192
. The antigen was later identified as citrullinated vimentin
193
. 
Vimentin is a major intermediate filament with roles in cell adhesion, migration and 
signalling
194
. As mentioned, vimentin is a substrate for citrullination during calcium 
ionophore induced apoptosis in macrophages
177
. Hill et al demonstrated that switching 
an arginine to a citrulline in a vimentin peptide that was predicted to bind to HLA-
DRB1*0401, dramatically increased such binding
195
. Furthermore, in the above 
mentioned model of arthritis induced by immunising HLA-DRB1 *0401 transgenic 
mice with citrullinated human fibrinogen, few differences were seen in the repertoire 
of anti-citrullinated fibrinogen protein or peptide antibodies between the transgenic 
mice and the control mice whereas significant differences were seen with antibodies 
to citrullinated vimentin peptides
190 196
. Induction of arthritis by immunisation with 
citrullinated vimentin has not been reported. Bang et al described citrullination of 
vimentin in synovial fluid but also discovered a mutated form with a glycine to 
arginine substitution, thought to have occurred as a result of oxidative stress. When 
recombinant mutated vimentin was citrullinated in vitro and studied by ELISA, it had 
a greater diagnostic sensitivity than CCP2 for detecting antibodies in a large cohort of 
patients with RA
197
. Some relationship of titres with disease activity was also reported. 
Diagnostic specificity when compared with healthy controls was comparable to that of 
CCP2, although 17.5% of SLE patients were also weakly positive
197
. A systematic 
review of 14 studies concluded that the anti-mutated citrullinated vimentin(MCV) 
assay could be used as an alternative to CCP2
198
, although agreement between the two 
assays was not perfect and the diagnostic specificity was a little less with the MCV 
test. The lower specificity was recently confirmed in a large early arthritis cohort, 
where anti-MCV antibodies were found in 62% of RA patients but also in 17% of 
those with non-RA inflammatory arthritis
199
. Whether the reactivity in non-RA 
patients is citrulline-dependent, specific for inflammatory arthritis or predictive of 
erosions is unknown. Using a single linear citrullinated vimentin peptide however, 
Verpoort et al only found 26% and 35% of samples to be positive in 2 early arthritis 
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cohorts, compared to 57% and 61% for anti-CCP2 antibodies and 43 and 51% for a 
citrullinated fibrinogen peptide in the same cohorts
200
. 
The high diagnostic sensitivity of the MCV assay, like that for citrullinated fibrinogen, 
makes vimentin an attractive candidate. Further proof for pathogenicity is required 
however, to be sure that MCV is not simply another surrogate like CCP2. 
 
1.8.3 Collagen type II 
 
Noting that the immunodominant collagen II epitope (359-369) possessed an arginine-
containing motif, also found in other CII epitopes, Burkhardt et al created a citrulline-
containing triple-helical peptide of this region and found IgG antibody reactivity by 
ELISA in 40.4% of RA sera compared to 19.7% with the arginine-containing peptide. 
Being an early arthritis cohort with disease duration less than 12 months, this 
compares well with the CCP assay since only 50% of patients were positive
201
. 
Antibodies to native collagen are most prevalent close to onset of clinical disease 
(section 1.6.2.2), and it might be that the diagnostic sensitivity of anti-citrullinated 
collagen peptide antibodies decreases, relative to anti-CCP antibodies, as disease 
duration increases. In a more established RA cohort, antibodies to the same citrulline-
containing peptide were found in a comparable number of samples (41%), whereas 
anti-CCP antibodies were detected in 72%
182
. An attractive aspect of collagen is that 
T cell responses to a galactosylated epitope (260-271) are detectable in RA, 
suggesting the hypothesis that there is a linked T and B cell response since only B 
cells need recognise a citrullinated epitope
201
. In a CIA rat model, Lundberg et al 
demonstrated that in vitro citrullination increased the arthritogenicity of collagen with 
earlier onset of disease and a higher incidence
202
. More recently, monoclonal 
antibodies to citrullinated collagen were used to show its presence in RA synovial 
fluid, and were also capable of inducing arthritis in mice, particularly when combined 
with antibodies to native collagen II
203
. Crystal structure analysis of a monoclonal Fab 
fragment bound to the citrulline-containing immunodominant epitope, showed that the 
peptide had adopted a β-hairpin conformation, suggesting that the introduction of 
citrulline resulted in a change in tertiary structure
203
. 
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1.8.4 Epstein Barr Nuclear Antigen 1 (EBNA-1) 
 
Starting with the observation that citrulline residues in antigens recognised by 
antibodies to citrullinated proteins are often flanked by a neutral glycine, serine or 
threonine, and that EBV has been implicated in the pathogenesis of RA, Pratesi at al. 
examined the 6-fold glycine-arginine repeat sequence in the N-terminal region of 
EBNA-1
204
. Using 4 identical EBNA-1 peptides (aa35-58), each with 6 arginines 
substituted with citrulline (Viral citrullinated peptide, VCP) and branching radially 
from a lysine-containing backbone
205
, they detected reactivity with 50% of RA sera 
by ELISA. Affinity-purified anti-VCP antibodies immunoprecipitated citrullinated 
EBNA-1 derived from calcium ionophore treated immunoblastoid cell lines, and were 
capable also of binding CCP2 and deiminated fibrinogen, cross-inhibited by pre-
incubation with VCP
204
. EBNA-1 is expressed in the nuclei of infected cells and 
initiates replication by cross linking the EBV DNA episome to mitotic chromosomes. 
The glycine-alanine repeat sequence comprises one third of the molecule and is the 
dominant epitope in the immune response to EBNA-1
204
. IgA and IgM anti-VCP 
antibodies also occur but no isotype associates with severity or clinical phenotype, 
although only cross-sectional cohorts have been reported
206 207
. The high citrulline 
content of VCP suggests that, like CCP2, it may be a useful substrate for detecting 
antibodies to citrullinated proteins but not for providing aetiological insight. 
 
1.8.5 α-enolase 
 
Antibodies against bacterial α-enolases are common208 and, given the high degree of 
homology with human α-enolase, might provide opportunity for cross-reactivity and 
thus breaking tolerance. This may be one explanation why antibodies to α-enolase 
have been noted to occur in a variety of autoimmune disorders. These include anti-
neutrophil cytoplasmic antibody (ANCA) positive vasculitis
209
, systemic lupus 
erythematosus (SLE) particularly in the presence of renal disease
209 210
, mixed 
cryoglobulinaemia with renal involvement
210
, systemic sclerosis
210
, Behçet‟s 
disease
211, Hashimoto‟s encephalopathy212, cancer-associated retinopathy213 and 
autoimmune liver diseases
214 215. Antibodies to α-enolase have also been described in 
RA. Saulot et al found that 25% of early RA sera reacted with α-enolase present in a 
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placental preparation and that the presence of antibodies was associated with 
radiographic severity and progression. Interestingly, there was a much lower 
reactivity with recombinant α-enolase suggesting a requirement for post-translational 
modification or appropriate folding
142
. It is possible that their placental enolase may 
have been partially citrullinated, which is feasible since PAD2 is expressed in the  
placenta and placental citrullinated vimentin has been reported
193
. 
 
Previously our group suggested that if a dominant autoantigen exists, it is likely to be 
expressed in myeloid cells which are the principal cell type in the rheumatoid joint. 
Lysates of promyelocytic HL-60 cells, differentiated into monocytic or granulocytic 
phenotypes, were citrullinated in vitro and probed with a screening panel of RA sera. 
An immunoreactive 47 kDa band was isolated from the cytoplasm and identified by 
tandem mass spectrometry as α-enolase, which is abundantly expressed in the 
rheumatoid joint. Antibodies against a non-recombinant, purified α-enolase 
preparation deiminated in vitro were detected in 46% of RA sera studied compared 
with 15% of healthy controls. All the healthy control sera that tested positive, and 
13% of RA samples, also reacted with non-citrullinated α-enolase. It was 
hypothesised that the binding seen with control samples might represent reactivity 
with non-citrulline containing epitopes and that the testing of citrulline containing 
peptides might increase the specificity of the assay
216
. 
 
Glycolysis is the principal pathway of glucose metabolism, as well as the main route 
for the metabolism of fructose, galactose, and other carbohydrates derived from the 
diet. It occurs in the cytosol of all cells and may operate both in the presence and 
absence of oxygen
217
. Alpha-enolase is a metalloenzyme which functions principally 
to catalyse the dehydration of 2-phospho-D-glycerate to phosphoenolpyruvate in the 
glycolytic pathway (Figure 1.5), and hydration in the reverse direction during 
gluconeogenesis (reviewed by Panchioli
218
). Divalent metal ions are required and 
magnesium appears to be the principal cofactor. Fluoride is an effective inhibitor and 
its addition to blood samples allows accurate measurement of glucose levels which 
would otherwise decline as a result of glycolysis
217
. Alpha-enolase forms dimers with 
2 identical subunits facing each other in an anti-parallel arrangement. Three 
isoenzymes occur in vertebrates: α- enolase is expressed in a variety of tissues, 
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Figure 1.5. The glycolytic pathway in which one mole of glucose is converted into 
two moles of pyruvate, NADH and ATP. Glycolysis may be divided into a 
priming step (depicted in green), in which glucose is converted into fructose-1,6-
bisphosphate and 2 moles of ATP are consumed, and a energy-yielding step 
(depicted in orange) which produces pyruvate, 4 moles of ATP and 2 moles of 
NADH. Under aerobic conditions, pyruvate is further oxidised by mitochondrial 
enzymes into carbon dioxide and water. Under anaerobic conditions, pyruvate is 
converted into lactate. ADP, adenosine diphosphate; ATP, adenosine 
triphosphate; NAD+, nicotinamide adenine dinucleotide. 
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 whereas β-enolase is found predominantly in muscle tissue and γ-enolase in neuron 
and neuroendocrine tissue. α-enolase is highly conserved (40-90% identity between 
species
218
) and the amino acids that take part in catalytic activity are identical (His159, 
Glu168, Glu211, Lys345, His373 and Lys396). The additional conservation of amino 
acids on both sides of the catalytic residues suggests that the basic tertiary structure of 
all α-enolase molecules is the same. α-enolase is not a „housekeeping‟ gene and is 
almost undetectable in resting cells
218
. Its expression is upregulated by hypoxia
219
 and 
pro-inflammatory stimuli
220
. In addition to its presence in the cytoplasm, α-enolase is 
also found on the cell surface where, in neutrophils, B and T cells and monocytes, it is 
upregulated by phorbolmyristateacetate (PMA) and lipopolysaccharide (LPS)
220
. 
Aside from glycolysis, α-enolase has a number of other roles which include 
plasminogen binding, transcriptional repression and stimulation of immunoglobulin 
production. Plasminogen is a component of the fibrinolytic system, which has an 
important role in maintaining vascular patency. Binding of plasminogen to cell 
surfaces leads to it being more rapidly activated, and subsequently protected from 
inhibition by α2-antiplasmin
221
. This may enhance cell migration by facilitating 
degradation of barrier matrix proteins. α-enolase has been identified as one of a class 
of surface molecules that utilise C-terminal lysyl residues to bind plasminogen
222
. 
Other classes of plasminogen binding protein exist
221
 and  α-enolase has been 
estimated to contribute 10% of the plasminogen binding sites present on a cell line
222
. 
In infection with Streptococcus pyogenes, the plasminogen binding activity of 
surface-bound α-enolase is thought to play an important role in pathogenesis220.  
 
C-myc is a DNA-binding protooncogene that has an important role in regulating cell 
growth and development. A negative regulator of c-myc expression, Myc promoter-
binding protein-1 (MBP-1), binds to the P2 promoter and interacts with histone 
deacetylase which may account for its transcriptional repressor activity
128
. MBP-1 
shares sequence homology with α-enolase and is thought to be an alternative 
translation initiation product of α-enolase RNA218. As a reduction in α-enolase 
expression has been associated with decreased survival in lung cancer, it has been 
hypothesised that one explanation for this may be an increase in c-myc expression
128
. 
Interestingly, α-enolase expression itself may be increased by c-myc so there is the  
possibility of a negative feedback loop
128
. 
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Investigation of factors that influence immunoglobulin production in vitro, led to the 
discovery of several immunoglobulin production stimulating factors (IPSFs). IPSF-IIb 
was first identified in a human lymphoma cell line and identified as enolase; further 
study suggested that addition of rabbit, but not yeast, α-enolase increased IgM 
production from human cell lines and peripheral blood lymphocytes
223
. This effect 
was not dependent on the glycolytic function of α-enolase. Lymphocyte mRNA 
studies in New Zealand Black (NZB) mice found α-enolase to be differentially up-
regulated in splenic B cells when compared with T cells and B and T cells from 
BALB/c mice
224
. NZB mice spontaneously develop autoimmune disease in 
conjunction with polyclonal B cell hyperactivity. The α-enolase gene is located close 
to the previously identified region on chromosome 4 associated with this B cell 
hyperactivity. Soluble α-enolase stimulates IgM production in cultures of naive 
BALB/c B cells and may act by increasing transcription, especially in pre-activated 
cells. It also appears to be an accessory stimulus for expression of the activation and 
co-stimulatory molecules, CD69 and B7.2
224
.  
 
The presence of anti-α-enolase antibodies in a wide spectrum of differing 
inflammatory diseases raises the question of whether they are pathologically 
important. Some experimental evidence suggests that they might be. Fontan et al 
found that monoclonal antibodies raised against streptococcal enolase both cross 
reacted with human α-enolase and also inhibited the phagocytosis of streptococci by 
binding to α-enolase expressed on the surface of neutrophils220. Such cross reactivity 
was hypothesised to be the mechanism of tissue damage in acute rheumatic fever, 
which occurs in 2-3% of untreated streptococcal pharyngitis, and higher titres of 
antibodies to streptococcal α-enolase were seen in acute rheumatic fever when 
compared with healthy controls and individuals with uncomplicated pharyngitis. 
Antibodies to enolase, as well as to other glycolytic enzymes, namely neuronal-
specific enolase, pyruvate kinase and aldolase, occur in post-streptococcal 
neuropsychiatric illness. Commercial antibodies to enolase induce neuronal apoptosis 
in vitro and this is a proposed pathogenic mechanism of action
225
.  Antibodies to α-
enolase in cancer-associated retinopathy have been demonstrated to cause retinal cell 
apoptosis
226
. 
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1.8.6 Other candidate citrullinated autoantigens 
 
Screening studies have identified a number of other possible citrullinated autoantigens. 
In the study by Kinloch et al which identified citrullinated α-enolase, other 
citrullinated proteins were noted to react specifically with RA sera, including 
elongation factor 1α (EF1 α) and adenyl cyclase-associated protein 1 (CAP1)216. In 
another study which employed HL-60 cell lysates, but without an in vitro deimination 
step, Goëb et al identified a number of proteins recognised by RA sera. Mass 
spectrometry suggested the presence of citrulline residues in a number of these, 
namely aldolase, phosphoglycerate kinase 1, calreticulin, heat shock protein 60 
(HSP60) and far upstream element binding proteins 1 and 2 (FUSE-BP 1 and 2)
227
. 
Reactivity with a FUSE-BP peptide was of some interest since this did not correlate 
with antibodies to CCP. Okazaki and colleagues screened in vitro citrullinated 
proteins from a chondrocyte cDNA library and reported that a citrullinated fragment 
of eukaryotic translation initiation factor 4G1 (eIF4G1) was recognised by 50% of RA 
sera with high diagnostic specificity
228
. The same group also identified citrullinated 
collagen type I as a candidate, using a RA synoviocyte cDNA library, and reported 
that 32% of RA sera were reactive with high diagnostic specificity
229
. Lysate from the 
synovium of a patient with RA was used to screen RA sera for autoantibodies by 
Matsuo et al
230
. They found 990 protein spots of which 51 were citrullinated, as 
determined by anti-modified citrulline antibody reactivity. Thirty of the citrullinated 
proteins were also bound by RA sera and 13 of these were identified. Alongside 
fibrinogen, these were asporin, cathepsin D, β-actin, F-actin capping protein α-1 
subunit (CapZα-1), albumin, histamine receptor, protein disulfide-isomerase (PDI) 
ER60 precursor, and mitochondrial aldehyde dehydrogenase (ALDH2). They 
investigated CapZα-1 further and found antibodies to both the citrullinated and 
uncitrullinated protein in RA sera, although a greater number reacted with the 
citrullinated form. Further studies are needed to validate these provisional candidates 
as true citrullinated autoantigens in RA. 
 
 
 
Chapter 1                Introduction 
57 
 
1.9 Evidence for pathogenicity of antibodies to citrullinated proteins 
in RA 
1.9.1 General 
 
A fundamental question is whether antibodies to citrullinated proteins are pathogenic 
in human disease or merely a „bystander‟ phenomenon. Indirect evidence cited in 
favour of pathogenicity includes their specificity, their association with severe and 
erosive disease, and their appearance years before the onset of clinical disease. 
Induction of arthritis in human and animal models by transfer of human sera has been 
difficult to demonstrate
231-233
. Recently, a transient arthritis has been reported to occur 
in mice deficient in the low affinity inhibitory receptor FcγRIIB following 
intraperitoneal injection of plasma IgG from patients with RA. Pathogenic antibodies 
were not further defined however and only 3 of the 4 RA samples were positive for 
anti-CCP
233
. Further suggestive evidence has been provided by studies of the 
interaction between genetic and environmental risk factors for RA. 
 
1.9.2 Association of antibodies to citrullinated proteins with the HLA-DRB1 
shared epitope 
 
It is now clear that the shared epitope is a risk factor for anti-CCP positive but not 
anti-CCP negative RA, and this has contributed to the concept that antibodies to 
citrullinated proteins define a pathogenetically distinct subset of patients amongst 
those defined as having RA according to the ACR criteria
234 235
. It appears that not all 
antibodies to citrullinated proteins associate with the shared epitope. Verpoort et al 
showed an association with antibodies to a citrulline-containing vimentin peptide but 
not to one from fibrinogen
200
. This conflicts with the findings of 2 studies using 
citrullinated fibrinogen protein in which an association was demonstrated, although in 
one of the studies this was only with HLA-DRB1*0404 which might reflect the 
statistical methodology employed
182 236
. There are a number of possible explanations 
for the discrepancy. It is possible that a non-immunodominant peptide of fibrinogen 
may have been inadvertently selected, or that antibodies to citrullinated fibrinogen 
arise through epitope spreading and are not the first-occurring antibodies to 
Chapter 1                Introduction 
58 
 
citrullinated proteins. Alternatively, there might be an association with non-
citrullinated epitopes and the shared epitope. In the study by Auger et al, citrullination 
did not enhance the binding of any peptide derived from the α or β chains of 
fibrinogen to HLA-DR or their recognition by T cells
236
. The presence of antibodies 
to citrullinated proteins does not automatically imply that T cells need recognise a 
citrullinated epitope in the antigen. Conversely, citrullinated but not native fibrinogen 
induces arthritis in HLA-DR4 transgenic mice
190
.  
 
It is of interest that the association of the HLA-DRB1 shared epitope with antibodies 
to citrullinated proteins is confined to the *04 alleles, and is not seen with *01
182
.  
This might explain the difference in clinical severity between carriers of DR4 and 
DR1. One study examining the association of the du Montcel genotypes with 
antibodies to citrullinated proteins found that HLA-DRB1 alleles encoding the 
sequences DERAA/QARAA and DRRAA (S1 and S3D) reduced the risk of 
antibodies to CCP2 or citrullinated fibrinogen. In contrast, alleles encoding 
KRAA/QRRAA or RRRAA (S2 and S3P) increased the risk
237
. 
 
1.9.3 Interaction of genetic and environmental risk factors in the generation of 
antibodies to citrullinated proteins 
 
The first indication that genes and environment may interact in the aetiology of RA 
came with a small study of mono- and dizygotic twins who were discordant for RA as 
well as for smoking
238
. The smoking twin in 12 of the 13 monozygotic pairs studied 
was also the one with RA. The interaction of the shared epitope and smoking in the 
generation of anti-CCP antibodies was investigated by Klareskog and colleagues
239
.  
In a Swedish case-control study, the Epidemiological Investigation of Rheumatoid 
Arthritis (EIRA), they reported an odds ratio of 21 (CI 11.0-40.2) for anti-CCP 
positive RA in smokers having 2 copies of the shared epitope, versus 5.4 (2.7-10.8) 
for non-smokers with 2 copies. The odds ratios for anti-CCP negative RA were 0.8 
and 0.7 for smokers and non-smokers respectively, who had 2 copies of the shared 
epitope. The authors also described the presence of citrullinated proteins in 
bronchoalvealoar lavage cells from healthy smokers but not from non-smokers, and 
hypothesised that smoking enhanced deimination of autoantigens in the lung. This 
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could result in the activation of adaptive immunity through presentation by the shared 
epitope. The interaction of smoking and the shared epitope as risk factors in anti-CCP 
positive RA has been confirmed in other North European studies, albeit weaker
240 241
, 
but not in one comprising North American cohorts
242
. Although there were no 
population controls in the North American cohorts, a case-only analysis of the EIRA 
data came to the same conclusions
242
. The cause for such a discrepancy is unclear, but 
if the effect of smoking occurs via induction of citrullination in the lung, and other 
atmospheric pollutants are capable of similar effects, then the impact of smoking will 
be greater where background pollution levels are less. Differences in the method of 
obtaining the smoking history or the number of cigarettes smoked may also have been 
important. This is suggested by a recent report from the North American Nurses‟ 
Health Study which did find a strong interaction between smoking and the shared 
epitope in RF positive RA, when stratifying according to pack-years of smoking, 
emphasising the importance of a detailed smoking history
243
. The prevalence of 
glutathione S-transferase M1 (GSTM1) polymorphisms in the respective populations 
do not appear to have been examined. GSTM1 is involved in the detoxification of 
carcinogens in tobacco smoke and homozygosity for a null allele is common in 
Caucasian populations. Mattey et al reported a gene-environment interaction between 
smoking and GSTM1-null in relation to severity of disease in RA and association 
with RF
244
.  
 
Interestingly, Van der Helm-van Mil and colleagues reported that a gene-environment 
interaction only existed in their cohort between smoking and DR1 and DR10, but not 
DR4. They hypothesised that DR1 and DR10, which are associated with a lower 
susceptibility risk for RA than DR4, might bind citrullinated peptides with a lower 
binding affinity and the effect of smoking in increasing the availability of citrullinated 
proteins might increase the chance of immune activation in this context
245
. On the 
other hand, recent results from EIRA suggested a large amount of biological 
interaction existed between smoking and the DR4 SE
246
. These results were derived 
from a larger number of RA subjects with matched population controls and assessed 
with an additive rather than a less sensitive multiplicative model
247
. 
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1.10 T cells in RA 
 
T cells are one of the commonest infiltrating cell types in the RA synovium, making 
up approximately 30%
248
, and the discovery of the HLA associations led many to 
believe that RA is primarily a T cell mediated disease. HLA molecules function to 
present peptide to T cells and, in the context of appropriate co-stimulation, this leads 
to their activation and thus the initiation of adaptive immunity. Several animal models 
of inflammatory arthritis, such as collagen-induced arthritis (CIA) and adjuvant-
induced arthritis (AIA), are T cell dependent
248
. However, whilst a number of antigens 
have been identified that cause ex vivo proliferation of T cells derived from RA 
patients, specific peptides binding to HLA-DR molecules in vivo have not been 
identified
106
. A number of other findings have also questioned whether RA is 
primarily a T-cell driven disease. For example, the presence and significance of 
oligoclonal T cell expansion within the RA joint, which might indicate an antigen 
driven process, has been controversial and much variation exists between subjects
249
. 
Many infiltrating T cells bear a memory phenotype (CD4+CD45RO) with only a few 
showing evidence of local activation, consistent with a polyclonal origin of the T cell 
infiltrate
248
. Intra-articular levels of T cell cytokines such as IL-2 and IFNγ are usually 
low. Furthermore, alternative hypotheses have been presented to explain the 
association of HLA molecules with RA without invoking presentation of arthritogenic 
peptides
106
. 
 
Renewed interest in the role of T cells has been stimulated by two animal models of 
spontaneous arthritis. In the first, the previously discussed K/BxN model, T cells are 
essential for induction of arthritis, although not for its continuance
124
. The second is 
the SKG mouse, first described in 2003, which has a point mutation in the gene 
encoding ZAP-70. ZAP-70 is a tyrosine kinase that is implicated in T cell receptor 
signal transduction. The point mutation results in alterations in thymic selection such 
that autoreactive T cell clones are positively selected. At around 2 months of age an 
arthritis develops, initially in the small joints of the paws and later involving the 
wrists and ankles, that is characterised by synovitis and pannus formation, neutrophil 
infiltration, joint destruction and the presence of RF and anti-collagen II antibodies. 
Disease can be transferred by T cells but not serum. In addition, the mice also develop 
interstitial pneumonitis, subcutaneous nodules and vasculitis
250
. It is possible that an 
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analogous system in humans might result in RA. As thymic T cell production 
decreases with age, the T cell repertoire is maintained by homeostatic proliferation of 
naïve T cells. Recognition of self-peptide in the context of MHC is necessary not only 
for naïve T cell survival but also for their homeostatic proliferation. A consequence of 
this is that T cells with a higher affinity for self-peptide/MHC will replicate faster to 
fill the gap, resulting in gradual contraction of the repertoire and preferential survival 
of T cells with more autoreactive potential. A number of lines of evidence suggest that 
subjects with RA have a reduction in thymic T cell production occurring early in age, 
and that their peripheral T cells have replicated more than healthy subjects of the 
same age. Such premature immune senescence may also be associated with a change 
in the functional capability of T cells (reviewed by Goronzy and Weyand
251
). Whilst 
the cause for this is unknown, it is of interest that healthy donors who are HLA DR4 
positive also have evidence of telomere erosion in both myeloid and lymphoid 
lineages, suggesting an increased history of replication
252
.  
 
Additionally, several single nucleotide polymorphisms that have been linked to RA 
are associated with genes which have roles in T cell function
253
. For instance the RA 
associated PTPN22 allele R620W is thought to result in decreased T cell signalling 
which might result in a failure to delete autoreactive T cells in the thymus or else a 
reduction in regulatory T cell production. 
  
Whatever role T cells might have in the initiation for RA, it is clear that they may 
contribute to the pathogenesis through activating or interacting with B cells, 
macrophages, fibroblast-like synoviocytes, chondrocytes and osteoclasts that are 
variously implicated in inflammation and joint destruction
254
. The high diagnostic 
specificity of IgG ACPA for RA has rekindled the search for pathogenic T cell 
epitopes on citrullinated proteins, since CD4+ T cell help is presumably required for 
isotype switching from IgM to occur. Whilst a number of anti-T cell therapies in RA, 
such as cyclosporine, anti-CD4 and anti-CD52 antibodies, have been disappointing
255
, 
the co-stimulation blocker abatacept has recently been demonstrated to be of benefit. 
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1.11 Cytokines in RA 
 
Cytokines play important roles in many aspects of RA pathogenesis including the 
initiation of autoimmunity, persistence of synovitis and the destruction of cartilage 
and bone (reviewed by McInnes
255
). It is important to note that most human studies 
have investigated established disease and the cytokine profile in early RA may differ. 
For example, Raza et al found elevated levels of IL-4 and IL-13 in synovial fluid from 
early RA, whereas IL-4 was absent and levels of IL-13 were low in established 
disease
256
. The role of the most prominent cytokines, TNF, IL-1, IL-6 and IL-17, are 
discussed below. The actions of other important cytokines are summarised in Table 
1.6.  
 
1.11.1 Tumour Necrosis Factor (TNF) 
 
Previous work at the Kennedy Institute of Rheumatology identified a pivotal role for 
TNFα in the pathophysiology of rheumatoid arthritis (RA)257. TNFα production can 
be stimulated by any noxious stimuli and in vivo is the most rapidly produced pro-
inflammatory cytokine
257
 . The major source is cells of the monocyte/macrophage 
lineage but other cell types have been implicated. TNFα appears to play a 
fundamental role in the cytokine response to injury and induces expression of other 
pro-inflammatory cytokines such as IL-1 and IL-6 as well as multiple chemokines and 
adhesion molecules, resulting in immune trafficking to the site. TNF promotes 
activation of leukocytes, endothelial cells and synovial fibroblasts and promotes 
survival of the latter
255
. Addition of anti-TNFα antibody to cultures of dissociated 
synovial membranes inhibited production of cytokines with overlapping or synergistic 
functions, such as IL-1, IL-6, IL-8 and GM-CSF, suggesting that TNFα was a key 
regulator of other proinflammatory cytokines
258
. Immunohistochemistry demonstrated 
upregulated TNFα and TNF receptor in inflamed rheumatoid synovium and the 
destructive pannus-cartilage junction
257
. A role in bone erosion was suggested by 
TNF-mediated upregulation of VEGF and therefore angiogenesis, as well as 
osteoclast differentiation
259
 with concurrent osteoblast inhibition
260
.  Furthermore, in  
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Cytokine Articular cell 
expression 
Potential functions in the pathogenesis of rheumatoid arthritis 
IL-  
or IL-1β 
Monocytes, B cells, 
synovial 
fibroblasts, 
chondrocytes 
Synovial fibroblast cytokine, chemokine, MMP, iNOS and PG 
release; monocyte cytokine, ROI and PG release; osteoclast 
activation; GAG synthesis, iNOS, MMP and aggrecanase; 
endothelial-cell adhesion molecule expression 
IL-18 Monocytes, PMNs, 
DCs, platelets, 
endothelial cells 
T-cell differentiation (TH1 cells with IL-12; TH2 cells with IL-4); 
NK-cell activation, cytokine release and cytotoxicity; 
chondrocyte GAG synthesis, iNOS expression; monocyte 
cytokine release and adhesion molecule expression; PMN 
activation, cytokine release and migration; pro-angiogenic for 
endothelial cells 
TNF Monocytes, T cells, 
B cells, NK cells, 
PMNs, mast cells, 
synovial 
fibroblasts, 
osteoblasts 
Monocyte activation, cytokine and PG release; PMN priming, 
apoptosis and oxidative burst; T-cell apoptosis, clonal regulation 
and TCR dysfunction; endothelial-cell adhesion molecule 
expression, cytokine release; synovial fibroblast proliferation and 
collagen synthesis, MMP and cytokine release; adipocyte FFA 
release; endocrine effects 
 
LTβ 
T cells, monocytes, 
synovial fibroblasts 
Peripheral lymphoid organ development; otherwise similar 
bioactivities to TNF 
RANKL Stromal cells, 
osteoblasts, T cells 
Stimulates bone resorption via osteoclast maturation and 
activation; modulates T-cell–DC interactions 
BAFF Monocytes, T cells, 
DCs 
B-cell proliferation, antibody secretion, isotype switching and 
survival; T-cell co-stimulation 
APRIL Monocytes, T cells B-cell proliferation 
IL-17A TH17 cells, 
synovial 
fibroblasts 
Synovial fibroblast cytokine and MMP release; 
osteoclastogenesis; haematopoiesis; chondrocyte GAG synthesis; 
leukocyte cytokine production 
IL-12 Macrophages, DCs TH1-cell proliferation and maturation; T-cell and NK-cell 
cytotoxicity; B-cell activation 
IL-23 Macrophages, DCs TH17-cell proliferation 
IL-7 Synovial 
fibroblasts, 
monocytes? 
T-cell expansion and survival; macrophage activation; 
haematopoietic regulation; thymic regulation; NK-cell maturation 
IL-15 Monocytes, 
synovial 
fibroblasts, mast 
cells, B cells, 
PMNs, DCs 
T-cell chemokinesis, activation and memory maintenance; B-cell 
differentiation and isotype switching; NK-cell activation and 
cytotoxicity; synovial fibroblast activation; macrophage 
activation/suppression (dose dependent); PMN activation, adhesion 
molecule expression and oxidative burst 
IL-10 Monocytes, T cells, 
B cells, DCs, 
epithelial cells 
Macrophage cytokine release, iNOS and soluble receptor 
expression, ROI; T-cell cytokine release, MHC expression, 
anergy induction, TReg-cell maturation and effector function(?); 
DC activation and cytokine release; synovial fibroblast MMP 
and collagen release; B-cell isotype switching 
IL-6 Monocytes, 
synovial 
fibroblasts, B cells, 
T cells 
B-cell proliferation and antibody production; haematopoiesis and 
thrombopoiesis; T-cell proliferation, differentiation and 
cytotoxicity; hepatic acute-phase response; neuroendocrine 
effects 
Oncostatin 
M 
Monocytes, 
activated T cells 
Megakaryocyte differentiation; synovial fibroblast TIMP and 
cytokine release, acute-phase reactants, protease inhibitors; 
monocyte TNF release, IL-1 effector function; neuroendocrine 
effects and corticosteroid release; osteoblast modulation(?) 
TGFβ Synovial 
fibroblasts, 
monocytes, T cells, 
platelets 
Wound repair, matrix maintenance and fibrosis; TH17- and TReg-
cell proliferation; NK-cell proliferation and effector function; 
initial activation then suppression of inflammatory responses; 
early phase leukocyte chemoattractant, gelatinase and integrin 
Chapter 1                Introduction 
64 
 
expression; early macrophage activation then 
suppression;  iNOS expression 
BMP 
family 
(BMP2– 
BMP15) 
Epithelial cells, 
synovial 
fibroblasts, 
mesenchymal 
embryonic tissues 
Regulate crucial chemotaxis, mitosis and differentiation processes 
during chondrogenesis and osteogenesis; tissue morphogenesis 
PDGF Platelets, 
macrophages, 
endothelial cells, 
synovial fibroblasts 
Paracrine and/or autocrine growth factor for various lineages; 
wound healing 
FGF 
family 
Synovial 
fibroblasts, 
monocytes 
Growth and differentiation of mesenchymal, epithelial and 
neuroectodermal cells 
VEGF Monocytes, 
endothelial cells, 
synovial fibroblasts 
Angiogenesis 
IL-32 Epithelial cells, 
monocytes(?), 
synovial 
fibroblasts(?) 
Macrophage cytokine, PG and MMP release 
MIF Macrophages, 
activated 
T cells, synovial 
fibroblasts 
Macrophage phagocytosis, cytokine and NO release; T-cell 
activation, DTH; fibroblast proliferation, COX expression, PLA2 
expression and intrinsic oxidoreductase activity („cytozyme‟) 
Type I 
IFNs 
Widespread Antiviral response; broad immunomodulatory effects; MHC 
expression; macrophage activation; lymphocyte activation, 
differentiation, survival (antiproliferative) and cytoskeletal 
alterations 
 
 
Table 1.6. A selection of the most important cytokines implicated in the 
pathogenesis of rheumatoid arthritis, together with their cellular origin and 
proposed functions. This table is adapted from McInnes
255
. APRIL, a 
proliferation-inducing ligand; BAFF, B-cell activating factor; BMP, bone 
morphogenetic protein; COX, cyclooxygenase; DTH, delayed-type 
hypersensitivity; DC, dendritic cell; FFA, free fatty acid; FGF, fibroblast growth 
factor; GAG, glycosaminoglycans; IFN, interferon; IL, interleukin; iNOS, 
inducible nitric-oxide synthase; LT, lymphotoxin; MIF, macrophage migration-
inhibitory factor; MMP, matrix metalloproteinase; NK, natural killer; PDGF, 
platelet-derived growth factor; PG, prostaglandin; PLA2, phospholipase A2; 
PMN, polymorphonuclear leukocyte; RANKL, receptor activator of nuclear 
factor-κB (RANK) ligand; ROI, reactive oxygen intermediate; TCR, T-cell 
receptor; TGFβ, transforming growth factor-β; TH, T helper; TIMP, tissue 
inhibitor of MMPs; TNF, tumour-necrosis factor; TReg, regulatory T; VEGF, 
vascular endothelial growth factor. 
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murine collagen-induced arthritis, blocking TNFα led to a marked reduction in 
inflammation and joint destruction, even when administered after the onset of 
arthritis
261
. Conversely, over expression of TNFα in a transgenic mouse model led to 
an erosive inflammatory arthritis which occured spontaneously
262
. The efficacy of 
anti-TNF agents (section 1.14.5) confirms the important role of this cytokine in RA. 
Such treatment not only removes the pro-inflammatory stimulus but allows the 
generation of regulatory T cells that suppress effector T cell function via IL-10 and 
TGFβ263. In addition to its role in the joint, TNF has a number of systemic effects in 
RA such as cachexia, depressed mood and altered cognitive function. 
 
1.11.2 IL-1 
 
IL-1α and β, as well as the natural antagonist IL-1ra, are found in large amounts in 
RA synovium, particularly in pannus, and are mostly produced by macrophages 
(reviewed by Dayer 
264
). IL-1 is very effective in inducing cytokine production from 
mononuclear cells, prostaglandins and matrix metalloproteinases (MMPs) from 
synovial fibroblasts, and chondrocyte catabolism and cytokine production. It is more 
potent than TNF in inducing MMPs and inhibiting chondrocyte proliferation and 
production of cartilage matrix proteins, and is also effective in activating osteoclasts, 
together leading to joint destruction. Inhibiting IL-1 ameliorates joint inflammation 
and destruction in CIA
265 266
. Furthermore, when mice transgenic for human TNF, 
which spontaneously develop arthritis, are crossed with IL-1 deficient mice, cartilage 
damage and to a lesser extent bone erosion is inhibited
267
. Mice deficient in IL-1ra 
spontaneously develop arthritis through an increase in IL-1 signalling which triggers 
downstream IL-17 mediated effects
268
. A role for IL-1 in the pathogenesis of human 
RA is confirmed by the use of anakinra, which is a recombinant non-glycosylated 
version of human IL-1ra. Inflammation and bone erosions are decreased but 
disappointingly the effects are much less than that seen with TNF inhibitors
269
. 
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1.11.3 IL-6 
 
IL-6 is a pleiotropic cytokine produced by a wide variety of cells including T and B 
cells, monocytes, fibroblasts and endothelial cells
270
. It induces the proliferation and 
differentiation of T cells and the differentiation of B cells into antibody-secreting 
plasma cells. IL-6 induces the liver to produce acute-phase proteins such as CRP, as 
well as hepcidin which reduces the availability of iron by inhibiting both intestinal 
absorption and iron recycling by macrophages
271
. IL-6 also induces leukocytosis and 
fever, increases VEGF production
272
 and promotes osteoclast differentiation
273
. A 
point-mutation of the signal-transducing component of the IL-6 receptor (IL-6R) gene 
is associated with arthritis in a mouse model, thought to occur through excess 
signalling
274
. IL-6 deficiency renders mice less susceptible to CIA and prevents the 
onset of arthritis in the SKG mouse
275-277
. Importantly, this may operate through 
inhibition of TH17 cell differentiation, which appears to require both IL-6 and TGFβ. 
TGFβ in the absence of IL-6 induces T cells to differentiate into regulatory cells278. 
Inhibition of IL-6 with a monoclonal antibody to IL-6R ameliorates arthritis in murine 
and monkey models
279 280
. In humans, IL-6 is markedly increased in the serum and 
synovium of patients with RA and levels correlate to some extent with clinical 
measures of disease activity
281 282
. Antibody to IL-6R has been found effective in 
phase III clinical trials and has now entered clinical practice. 
 
1.11.4 IL-17A 
 
Research over the last few years has suggested an important role for IL-17 produced 
by TH17 cells. Differentiation into TH17 cells requires IL-6, TGFβ and IL-23, and 
mice with IL-6 and IL-23p19 knocked out are resistant to collagen-induced arthritis
275 
283
. In mouse models, reducing IL-17 improves disease activity and bone erosion
284
, 
and generation of TH17 cells is thought to be important in the SKG mouse
285
. In 
human RA synovium, IL-17 expression has been demonstrated in perivascular T cells 
and is present in synovial fluid
286
. IL-17 is capable of driving the differentiation and 
activation, either alone or in synergy with other key cytokines, of neutrophils, 
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synovial fibroblasts and dendritic cells (reviewed by McInnes
255
). Il-17 also promotes 
the formation of osteoclasts
287
. The role that TH17 cells may play in human disease, as 
opposed to mouse models, is less clear
288
 but IL-17 appears a promising target for 
intervention. 
 
1.12 Synovial Fibroblasts 
 
Synovial fibroblasts, along with synovial macrophages, are a predominant cellular 
component of the pannus that erodes joint structures in RA (reviewed by Muller-
Ladner
289
). The normal function of synovial fibroblasts is to provide nutrition for 
articular structures and lubricating molecules to facilitate function. They are no longer 
considered passive players in a pathology orchestrated by immune cells. Indeed, in a 
severe combined immunodeficiency (SCID) mouse model, RA synovial fibroblasts 
showed proliferative and erosive behaviour in the absence of immune cells
290
. 
Synovial fibroblasts bear toll-like receptors (TLR) 2, 3 and 4 and thus may become 
activated as part of innate immunity. The binding of bacterial peptidoglycan to TLR2, 
for example, results in release of VEGF, IL-8 and other chemokines
291
. TLR3 can 
bind endogenous RNA released from necrotic cells. Consequently it is conceivable 
that activation of synovial fibroblasts may be a first step in initiation of RA, leading to 
recruitment of immune cells. The potential exists for amplification of this response 
since cell-cell contact with T cells leads to further chemokine release. Aside from 
recruitment of immune cells, RA synovial fibroblasts contribute to the inflammatory 
state by producing proinflammatory cytokines themselves, and are a major synovial 
source of cyclooxygenase 2 (COX-2), which is upregulated in inflammation, and thus 
prostaglandins
289
. RA synovial fibroblasts promote angiogenesis by producing not 
only VEGF, but other proangiogenic mediators also. In addition, they make a major 
contribution to joint destruction by being a source of the matrix-degrading enzymes, 
MMPs and cathepsins, and also by producing RANKL
292
. RANKL plays a key role in 
the activation of osteoclasts. 
 
Factors that transform synovial fibroblasts to the proliferative, activated state seen in 
RA are thought to include fibroblast growth factor (FGF), which is also produced by 
synovial fibroblasts in an autocrine loop, transforming growth factor beta (TGFβ), 
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platelet derived growth factor (PDGF) and proinflammatory cytokines
289
. Cytokine 
independent pathways are also required and these include the up-regulation of early 
response genes and proto-oncogenes
293
, with down-regulation of tumour suppressor 
genes
294
, and the expression of anti-apoptotic molecules. Epigenetic modifications 
may also be important. For example, expression of endogenous retroviral L1 elements 
occurs following DNA demethylation
295
, and can induce the galectin 3 system which 
promotes angiogenesis and inhibits apoptosis
296
. Galectin 3 levels are elevated in the 
sera and synovial fluid of RA patients and correlate with CRP levels
297
. Such 
epigenetic and cytokine independent pathways may explain why established RA 
cannot be cured by anti-TNF therapy. 
 
1.13 Measurement of Disease Activity and Outcome 
 
This section is focussed on clinical measures of disease activity, the Health 
Assessment Questionnaire (HAQ) and X-rays, as these are employed in the cohort 
studies described in this thesis. Other imaging modalities, in particular ultrasound and 
magnetic resonance imaging (MRI), are increasingly being used in clinical practice 
and research studies but are not discussed here. The capability to effectively measure 
levels of disease activity, as well as to distinguish patients with ongoing synovitis 
from those in remission, is crucial for the effective management of patients in the 
clinic. It is also vital for evaluating prognostic factors in cohort studies and the 
efficient evaluation of therapies in clinical trials. Disease activity, joint damage and 
functional impairment are inter-related in the natural history of RA
298
. With time, 
active disease usually leads to joint damage, and both active disease and irreversible 
joint damage contribute to functional impairment.  
 
1.13.1 ACR responses and DAS28 
 
Joint counts are widely used in rheumatology research and practice. A swollen joint 
count attempts to quantify the amount of inflamed synovial tissue, and a tender joint 
count the degree of pain. A number of different joint counts have been used and are 
reviewed by Sokka and Pincus
299
. The joints included in the commonest standard joint 
counts are summarised in Table 1.7. The Ritchie Index consists of 52 joints assessed  
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Joint 66/68 RI 44 36 28 42 
Temporomandibular + +
2
     
Sternoclavicular + +
2
 +    
Acromioclavicular + +
2
 +    
Shoulder + + +  + + 
Elbow + + + + + + 
Wrist + + + + + + 
Metacarpophalangeal  +     
1
st
  +  +  + + 
2
nd
 +  + + + + 
3
rd
  +  + + + + 
4
th
  +  + + + + 
5
th
 +  + + + + 
Proximal interphalangeal + +     
1st   + + + + 
2
nd
 +  + + + + 
3
rd
  +  + + + + 
4
th
  +  + + + + 
5
th
  +  + + + + 
Distal interphalangeal       
2
nd
 +      
3
rd
 +      
4
th
 +      
5
th
 +      
Hip +
1
 +    + 
Knee + + + + + + 
Ankle + + + +  + 
Talocalcaneal  +     
Tarsus + +     
Metatarsophalangeal  +     
1
st
 +  + +  + 
2
nd
 +  + +  + 
3
rd
  +  + +  + 
4
th
  +  + +  + 
5
th
  +  + +  + 
Proximal interphalangeal (toe)       
1
st
  +      
2
nd
 +      
3
rd
 +      
4
th
 +      
5
th
 +      
 
Table 1.7. The joints included in standard joint counts. RI, Ritchie Index. 
1
 
Assessed for tenderness but not swelling. 
2
 Right and left joints assessed together. 
After Sokka and Pincus
299
. 
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only for tenderness according to the grading: 0 = non-tender, 1 = tender, 2 = tender 
with wincing, and 3 = tender with wincing and withdrawal. The total score ranges 
from 0 to 78. The ACR introduced a 66/68 joint count that assesses tenderness and 
swelling as either present or absent. The ACR later proposed an 80 joint count with 
assessment for swelling, tenderness, pain on motion, limited motion, and deformity. A 
close relationship, however, was found between tenderness and pain on motion, as 
well as with limited motion and deformity
299
. The Thompson Index was designed to 
have the best correlation with a laboratory measure of inflammation, C-reactive 
protein (CRP), and counted the simultaneous presence of swelling and tenderness in 
38 joints which were weighted according to surface area
300
, with a total score of 0-534. 
This never became widely used, most probably because a weighted index is harder to 
use in clinical practice. 
   
The Disease Activity Score (DAS) in its original format incorporated the Ritchie 
Index, a 44 swollen joint count, ESR and an optional general health assessment on a 
visual analogue scale. It was developed on the basis of decisions made by 
rheumatologists in a large prospective study
301
. High disease activity was defined as a 
decision to start a DMARD, or to stop one due to lack of efficacy. Low disease 
activity was defined as stopping a DMARD due to remission, or not changing or not 
starting a DMARD for at least one year. Regression analysis was used to determine 
which variables could best discriminate between high and low disease activity. The 
DAS showed greater discrimination when compared other indices or single variables. 
DAS values, and fluctuations in scores, were found to correlate well with joint 
damage over time
302 303. As measuring a patient‟s DAS score can be time-consuming, 
the same but expanded patient cohort was used to develop the DAS28.  This is based 
on a 28 joint count for both tenderness and swelling, alongside the ESR and visual 
analogue scale. The DAS28 has a continuous scale ranging from 0 to 9.4 and usually 
follows a Gaussian distribution in RA cohorts
301
. Because significant change in a 
relative measure does not by itself indicate the number of patients that respond to 
treatment, the EULAR response criteria were developed. These categorise patients as 
good, moderate and non-responders, according to endpoint DAS or DAS28 and 
improvement in DAS or DAS28 scores. EULAR response categories are as effective 
as those proposed by the ACR in differentiating active from placebo treatment
301
. The 
advantage of using a continuous score, such as the DAS-28, is that there is no loss of 
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power due to categorisation, and there is greater precision in comparing similar 
treatments. Nevertheless cut-offs, providing a measure of success or failure, are more 
interpretable and it is low or absent joint inflammation, rather then change in 
inflammation, that has the best prognosis in regards to joint damage
301
. In the 
TICORA (Tight Control for Rheumatoid Arthritis) study intensive treatment with 
DMARDs and intra-articular steroids was used, with the aim of maintaining a DAS 
≤2.4, and this strategy was compared with „usual‟ clinical care. The intervention 
group were more likely to be in remission, and had greater reduction in disability and 
less progression of joint damage at the end of the study
304
. 
Problems with joint counts include inter- and intra-observer variability and 
incomplete objectivity; in at least one clinical trial, joint tenderness and swelling 
improved more in the placebo group than patient questionnaires and standard 
laboratory measures such as the CRP
299
. In addition, not all synovitis is detectable 
clinically
305
. 
 
1.13.2 Health Assessment Questionnaire (HAQ) 
 
The HAQ is a patient self-report questionnaire that was first published in 1980
306
. It 
incorporates a scale of 20 activities of daily living (ADLs) in eight categories that 
assess functional disability, with four patient response options: “without any 
difficulty”=0, “with some difficulty”=1, with much difficulty”=2 and “unable to 
do”=3. Categories address dressing, arising, eating, walking, bathing, reaching, 
gripping and performing errands. The score for each category is the highest score 
among the 2 or 3 ADLs in each category, with scores of 0 or 1 being increased to 2 if 
the patient uses aids or devices for that category. The total HAQ score is the mean 
score derived from all eight categories which each have a score of 0-3. Patient 
questionnaires are significant predictors of many long-term outcomes in patients with 
RA, including functional status, work disability, costs, joint replacement surgery and 
death
307
. HAQ scores reflect disease activity and joint damage, with the former being 
the predominant influence in early RA. Many long-term studies have shown an 
association between joint damage and HAQ scores over time
308
. However disability in 
RA is also influenced by gender, age, co-morbidities, muscle strength and social and 
psychological factors. Perhaps as a result of this, not all studies have demonstrated 
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such a relationship
309
. Other confounding factors include the advent of effective 
treatment modalities, the non-linear progression of HAQ scores with an initial 
improvement following diagnosis, and the greater contribution of large joint damage 
to disability whereas it is the smaller joints which are normally assessed in X-ray 
scoring methods
308
. 
 
1.13.3 Biomarkers 
 
The heterogeneity of disease characteristics, severity and outcomes amongst patients 
fulfilling the ACR classification criteria for RA has driven interest in the use of 
biomarkers to subgroup patients and provide prognostic information. A biomarker can 
be a gene or product of gene expression, an autoantibody, cytokine, acute phase 
reactant or tissue abnormality that constitutes an indicator, or a surrogate, with 
diagnostic or prognostic value, that is measurable and can be validated objectively
298
. 
As of yet, the only markers of value in routine use are anti-CCP antibodies and the 
acute phase reactants ESR and CRP. Anti-CCP antibodies are associated with a more 
severe outcome in terms of disease activity, disability and erosions. High levels of 
ESR and CRP associate with disease activity and predict erosive change
300 302 310
, but 
are imperfect markers. However no other biomarker has yet demonstrated 
superiority
298
. 
 
1.13.4 X-rays 
 
X-ray scoring systems have for some time been considered the gold-standard for 
evaluating the progression and severity of RA (reviewed by Ory
311
 and Boini
312
). 
They have a number of advantages which include being inexpensive, easy to generate, 
widely available and accepted. They provide a permanent record that can be 
randomised and blinded for the study of progression in clinical trials. Results are 
reproducible and single point damage and progression can be identified with 
reasonable precision. A clear relationship has been demonstrated between 
inflammatory disease activity and X-ray scores of structural damage
313
. These also 
correlate with disability, particularly in more advanced and established disease
308
. The 
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disadvantages include the need for consistent radiographical technique and 
positioning, and the presence of „floor‟ and „ceiling‟ effects311.  The „floor‟ effect 
reflects insensitivity for detecting damage in early disease, and the „ceiling‟ effect 
refers to the inability to measure ongoing structural damage once the maximum score 
in a joint has been reached. Including X-rays of the feet improves sensitivity in early 
disease, as radiographically detectable erosions often appear first in the 
metatarsophalangeal joints
314
. The scoring systems in current use reflect 2 broad 
approaches. Global scores assign a single grade to each joint assessed, whereas 
detailed scores assess 2 or more variables with a grading system for each. Currently, 
the most commonly used example of the former is the Scott modification of the 
Larsen score, and for the latter a modification of the Sharp score. These methods are 
compared in Table 1.8.  
 
Although there are differences between methods, results are highly correlated
311
. 
Nevertheless, modified Larsen scores appear less sensitive to change than modified 
Sharp scores. This is borne out by one study in which the Sharp/van der Heijde score 
was found to have a smallest detectable difference (SDD) that was close to the 
minimal clinically important difference (MCID i.e. the amount of progression that 
would make a rheumatologist change treatment), whereas the Larsen/Scott method 
had a SDD that was significantly greater than the MCID as determined by an 
international panel of experts
315
. Modifications of the Larsen score, which are used in 
2 of the cohorts described in this thesis, grade joints on a 0-5 scale where 0 is normal, 
1 represents early or non-specific findings of RA (periarticular osteoporosis/joint 
swelling if these are major features, or if there are suggested erosions/cysts of <1mm 
at 2 sites in the joint), 2 is for definite early abnormalities (≥1 erosion of >1mm with a 
break in the cortical margin), 3 describes medium destructive abnormalities 
(significantly sized erosions on both sides of the joint but with preservation of some 
joint surface), 4 describes severe abnormalities with subluxation, and 5 is a mutilating 
abnormality where the original articular surfaces have disappeared
311
. A series of 
standard radiographs is used to guide scoring. 
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 Modified Sharp Genant/Sharp Modified Larsen 
Type of scoring 
method 
Detailed Detailed Global 
Joints evaluated Hands, wrists, feet Hands, wrists, 
sometimes feet 
Hands, wrists, 
sometimes feet 
Scoring Each joint given a 
score for erosions 
(0–5; 0–10 for feet 
in some variations) 
and joint space 
narrowing (0–4) 
Each joint given a 
score for erosions 
(0–3+, with half 
grades) and joint 
space narrowing 
(0–4, with half 
grades) 
Each joint given a 
single score (0–5) 
to reflect the 
extent of both 
erosions and joint 
space narrowing. 
Uses comparison 
with reference 
films 
Strengths/weaknesses More sensitive, 
more tedious to 
use 
Sensitive, but 
studies that omit 
feet may 
underestimate 
damage in early 
RA 
Easier to learn and 
use, less sensitive 
 
Table 1.8. Comparison of 3 commonly used methods for scoring X-rays in RA 
comprising 2 modifications of the Sharp score and a modified Larsen score. A 
global score assigns one grade for each joint assessed, whereas a detailed score 
assigns grades for 2 or more variables, usually erosions and joint space 
narrowing. After Ory
311
. 
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A number of problems arise if one wishes to compare radiographic data between trials. 
Firstly, not only are there several different scoring systems but several of them also 
have a number of variants, with small differences in the joints examined and the 
scoring range. Secondly, results may be influenced by the method of comparing 
radiographs within a trial. Images can be assessed in single order (randomised to 
patient and sequence) which is an effective way of validating a scoring system but 
which may lack sensitivity if there are differences in the quality and positioning of the 
X-ray. Alternatives are paired order (films from individual patients grouped without 
knowledge of the sequence) and lastly, chronological order which risks introducing 
bias if change is expected. A number of studies have suggested that paired order is 
preferable
312
 but chronological order may be more sensitive to change, especially with 
longer follow-up
316
. Thirdly, the experience and training of the readers affects the 
reliability of scoring. Fourthly, results may be influenced by baseline damage and 
disease activity. This is a particular issue since rates of radiographic progression are 
higher in early disease. In one observational cohort the rate of progression in the first 
2 years after enrolment (mean disease duration 11 months) was 3 times that seen in 
the later years of the study
317
. Furthermore, early disease may be more responsive to 
treatment. An additional potential problem with scoring systems is that they do not 
take into account healing phenomena
312
 which may be associated with remission
318
. 
However repair, as determined by a panel of experts, is associated with a reduction in 
Sharp/van der Heijde scores
319
. 
 
1.14 Treatment 
 
The ability of antibodies to citrullinated α-enolase peptide to predict response to 
treatment with anti-TNF inhibitors is investigated in this thesis. A discussion of 
treatment is also relevant given its potential to influence studies of clinical outcomes. 
Current treatment paradigms stress the need to treat rheumatoid synovitis early, both 
to prevent the development of erosions, which can occur in the first few months of 
disease, and also to capitalise on a possible „window of opportunity‟ for modifying 
disease phenotype or even inducing remission. Disease modifying anti-rheumatic 
drugs (DMARDs) have been demonstrated to retard the development of erosions and 
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can be broadly divided into non-biological and biological. Non-biological drugs 
currently in use include methotrexate, sulfasalazine, hydroxychloroquine and 
leflunomide. Biological agents include anti-TNF inhibitors, rituximab, tocilizumab 
and abatacept. 
 
1.14.1 Methotrexate 
 
Methotrexate is a folate antagonist and has been in used in rheumatoid arthritis for 
nearly 30 years, but was initially used late in the disease course and in a small 
proportion of patients. Its success in improving disease activity
320
 and the consequent 
inhibition of radiographic progression
321
, have made it the first-line drug worldwide 
and the „anchor‟ drug of combination therapy322. Response to methotrexate has been 
associated with survival benefit
323
 and one study demonstrated a 60% reduction in 
overall mortality and a 70% reduction in cardiovascular mortality after adjusting for 
disease severity
324
. The reduction in cardiovascular mortality likely reflects a 
reduction in inflammation but an atheroprotective effect may also operate through 
enhancement of reverse cholesterol transport
325
. Proposed mechanisms of action in 
RA have been reviewed by Wessels et al and include reduction of cell proliferation, 
increased T cell apoptosis, enhancement of adenosine release which has anti-
inflammatory properties, and alteration of cytokine production, humoral responses 
and bone formation
326
.  
 
1.14.2 Sulfasalazine 
 
Sulfasalazine, developed in the 1940s, was an attempt to combine the anti-
inflammatory properties of salicylic acid with the anti-microbial sulfapyridine by 
linking them with an azo bond. The negative findings of a small trial, employing 
lower doses than used today, together with the introduction of cortisone led to its 
disappearance from use until further studies in the late 1970s and early 1980s 
suggested benefit
327
. It is now accepted that sulfasalazine improves clinical indices 
and inflammatory markers
328
, as well as retarding development of erosions
329
 and 
improving physical function
330
. Its mechanism of action is unclear. The azo bond is 
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cleaved in the large intestine following which the salicylic acid is mostly excreted 
faecally whereas the sulfapyridine is absorbed. A comparison with other 
sulphonamides, which are ineffective
331
, suggests that the antimicrobial properties are 
not the main mechanism of action. An in vitro study found that sulfasalazine inhibited 
nuclear factor Kappa B (NF-κB), a pivotal molecule in the induction of inflammatory 
cytokines, but this function was not shared by the salicylic acid and sulfapyridine 
components
332
. Sulfasalazine is also capable of inhibiting macrophage expression of 
TNF through induction of apoptosis
333
, and like methotrexate may promote local 
adenosine release
334
. Sulfasalazine may block the cellular uptake of both methotrexate 
and reduced folate via the reduced folate carrier
335
, explaining both the apparent lack 
of synergy between these agents
336 337
 and the elevated homocysteine levels, 
indicative of folate deficiency, seen with the combination
336
. Sulfasalazine remains 
widely used in the management of RA. 
 
1.14.3 Hydroxychloroquine 
 
Hydroxychloroquine is an antimalarial that has been demonstrated in randomised 
controlled trials to have a modest beneficial effect in RA
338
. It is a popular choice as 
add-on therapy due to its good side effect profile when compared with other 
DMARDs. The combination of methotrexate, sulfasalazine and hydroxychloroquine is 
superior to methotrexate alone
339
 and this combination is only marginally superior to 
methotrexate and hydroxychloroquine
337
. The possibility of a synergistic effect with 
methotrexate is suggested by its ability to inhibit conversion of methotrexate to its less 
active metabolite, 7-hydroxy-methotrexate
322
. Hydroxychloroquine is a lipophilic 
molecule that accumulates in intracellular lysosomes where, being a weak base, it 
impairs acidification. Consequently, it has long been assumed that its mode of action 
in RA is due to impaired antigen presentation
340
. Other proposed mechanisms include 
inhibition of IL-1, IL-6 and TNF production, and sensitising RA synovial fibroblasts 
to apoptosis
341
. More recently, it has been demonstrated to be an inhibitor of intra-
cellular toll-like receptors (TLRs)
340 341
. TLRs are an important component of the 
innate immune system differentiating microbial macromolecules from those of the 
host. However human DNA and RNA in immune complexes can also stimulate TLR 
9 and 7 respectively, and it is possible that immune complexes containing TLR 
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ligands may stimulate RF production
114
. Furthermore, RNA from necrotic cells may 
activate synovial fibroblasts via TLR3
342
. Consequently hydroxychloroquine may act 
through TLR inhibition. Hydroxychloroquine remains widely used, although only as 
monotherapy in very mild disease.  
 
1.14.4 Leflunomide 
 
The active metabolite of leflunomide, teriflunomide, is an inhibitor of the 
mitochondrial enzyme dihydro-orotate dehydrogenase (DHODH)
343
. This catalyses 
the formation of ribonucleotide uridine monophosphate pyrimidine (rUMP), which is 
the fourth committed step in the de novo biosynthesis of pyrimidines. Rapidly 
proliferating lymphocytes require unusually high levels of pyrimidines to progress 
from the G1 to the S phase of the cell cycle, and the reduction in de novo biosynthesis 
results in cell cycle arrest and inhibition of clonal expansion. Other cell types are less 
susceptible as they can utilise a salvage pyrimidine pathway
344
. Other proposed 
mechanisms include inhibition of tyrosine kinases
345
 and NF-κB activation346, 
reduction of adhesion molecule expression and transendothelial migration of 
peripheral blood monocytes
347
 associated with a reduction in synovial macrophages
348
, 
and an alteration of cytokine profiles with a reduction in IL-2 and increase in TGFβ1 
expression
349
. A North American study demonstrated no difference in clinical and 
radiological outcomes over 1 year between leflunomide and methotrexate, both of 
which were better than placebo
350
. However a European study reported better clinical 
outcomes at 1 year, and radiological outcomes at 2 years, in patients treated with 
methotrexate
351
. Both studies have been criticised for using a lower dose of 
methotrexate (not exceeding 15mg/week) than that used in clinical practice. The 
combination of leflunomide and methotrexate is attractive as the agents are perceived 
to have different but complimentary mechanisms of action. The benefits of adding 
leflunomide in patients with an inadequate response to methotrexate have been 
confirmed in a randomised placebo-controlled trial
352
. Careful monitoring of liver 
function tests is required. 
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1.14.5 Anti-TNF therapy 
 
Experimental evidence indicating a key role for TNF in perpetuation of rheumatoid 
synovitis led to trials with TNF inhibitors in RA, initially with infliximab
353
, and later 
with etanercept
354
 and adalimumab
355. Infliximab is a chimeric IgG1κ monoclonal 
antibody with a human constant and murine variable region. It is administered by 
intravenous infusion and binds free and cell bound TNFα. Etanercept is a soluble p75 
TNF receptor dimeric fusion protein linked with the Fc portion of human IgG1. It 
binds soluble TNFα as well as the related TNFβ. Unlike infliximab it does not appear 
to bind membrane-bound TNFα, except in some experimental systems where it does 
so with much lower affinity
356
. It is administered by subcutaneous injection. 
Adalimumab is a fully human IgG1κ monoclonal antibody administered by 
subcutaneous injection. Clinical results with these agents are impressive with a major 
reduction in the signs and symptoms of disease and retardation or even halting of 
progressive joint destruction. The mechanisms of action are thought to include 
downregulation of the pro-inflammatory cytokine cascade, a reduction in leucocyte 
trafficking into joints, and suppression of VEGF with a subsequent reduction in 
synovial angiogenesis
257
. Despite differences between these agents in both mechanism 
of action, such as reverse signalling through the binding of membrane-bound TNF, 
and pharmacokinetics, their efficacy in RA appears broadly similar. This is supported 
by observational registry data
60
 although no head-to-head trials have been performed. 
Despite their success approximately only one third of patients have a good response, 
another third have a moderate response and a third are classed as non-responders. 
Two new anti-TNF agents, golimumab and certolizumab, have been developed and 
the latter has recently been approved for the treatment of RA by the National Institute 
of Clinical Excellence. Golimumab is a fully human IgG1 monoclonal antibody and 
certolizumab is a Fab
1
 fragment of an IgG1 monoclonal antibody which consequently 
lacks Fc region associated functions. The hinge region of certolizumab is modified 
and linked to 2 crosslinked chains of polyethylene glycol which enhances solubility 
and half-life
357
. 
 
Given the high costs of biological therapy and potential toxicities, the increasing 
treatment options, and the desire to avoid delay in suppressing synovitis, there is 
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increasing interest in the possibility of predicting response. Understanding non-
response may also lead to new therapeutic strategies. As the relationship between 
antibodies to citrullinated enolase peptide and response to TNF inhibitors is addressed 
in this thesis, the search for genetic, clinical and serological predictors will be 
discussed here.  
 
It is unknown whether alleles affecting response will have large or small effect sizes 
but it is becoming clear that the majority of genetic factors affecting susceptibility in 
RA have odds ratios less than 1.5
358
. Demonstration of such small effects requires 
hundreds or even thousands of samples and few studies looking at response are 
sufficiently powered. Criswell et al studied 301 patients on either low dose or 
standard dose etanercept participating in a randomised controlled-trial. The ACR50 at 
12 months was used to determine response or non-response. Having 2 copies of the 
HLA-DRB1 shared epitope was associated with response to standard dose etanercept 
(OR 4.3; CI 1.8-10.3), as was an extended haplotype of a specific shared epitope 
allele (*0101 or *0404) and 6 single-nucleotide polymorphisms in the LTA-TNF 
region (OR 4.9; CI 1.5-16.1 and OR 2.5; CI 0.8-7.3 for *0101 and *0404 
respectively)
359
. However, an observational study of 930 patients including 198 on 
infliximab using ACR20 at 30 weeks to define response, found no influence of shared 
epitope alleles, although patients on infliximab were more likely to be shared epitope 
carriers
360
. Similarly, no association was seen in a Swedish observational study 
including 123 patients on etanercept
361
, and in a larger British Society of 
Rheumatology Biologics Register (BSRBR) study of more than 500 patients, which 
also found no association with PTPN22*620W
362
. No other genetic variant examined 
in these or other, mostly smaller studies, has shown a consistent effect on response
358
. 
The first genome-wide study has shown multiple SNP markers around loci on 
chromosomes 7, 9 and 20 that associate with response
363
. However the study only 
included 89 clinically diverse patients and larger studies are awaited. 
 
Clinical predictors were studied in almost 3000 patients, on either etanercept or 
infliximab, enrolled in the BSRBR prospective observational study
60
. Lower response 
rates, as determined by EULAR improvement criteria at 6 months, were seen with 
higher HAQ scores, which reflect both reversible and irreversible disability, and with 
current smoking in the infliximab group. A higher response occurred with concurrent 
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use of non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate, although 
the latter only reached statistical significance with etanercept. A higher number of 
previously failed DMARDs and female sex were independently associated with a 
lower rate of remission. However the limitations are clear: in the absence of positive 
predictors a good response occurred in 8% of infliximab and 10% of etanercept 
treated patients, and a moderate response in 60% and 55% respectively. A study of 
1565 patients enrolled in a Swedish register found a good response to be associated 
with a lower HAQ at baseline and concomitant methotrexate as well as with other 
DMARDs
364
. Higher disease activity at baseline was a positive predictor of ACR50 
and ACR70 responses, but a higher DAS-28 score was inversely associated with 
EULAR remission, highlighting how the choice of outcome measure can influence 
results. No effect of gender was detected.  
 
The relationships of RF and anti-CCP antibody status to response have been examined 
in a number of studies. 521 samples (not baseline) were collected from patients 
enrolled in the BSRBR
362
. Patients with RF or anti-CCP antibodies demonstrated less 
improvement in DAS-28 at 6 months using linear regression analyses, but no 
statistically significant effect was seen using logistic regression with EULAR 
response criteria as the outcome measure. Notably, a model comprising clinical and 
serological predictors only accounted for a small proportion of the variance in drug 
response (R
2
=17%). Other studies investigating baseline serological predictors were 
smaller and have yielded conflicting results
365-367
. Bobbio-Pallavicini et al found 
higher titres of IgA RF at baseline in the non-responder group
365
, whereas no effect of 
either RF or anti-CCP was seen by Lequerré et al
366
. A greater influence of RF 
compared with anti-CCP might be consistent with RF being a more dynamic marker 
of disease activity
368
. 
 
Recently, Hueber et al studied 93 patients from 3 independent cohorts (from the USA, 
Sweden and Japan) to develop a biomarker „signature‟ that was predictive of response 
to etanercept. Twenty-four parameters (13 antigens and 11 cytokines) from a panel of 
more than 540 peptides and proteins, representing 25 candidate autoantigens and 12 
cytokines, best segregated between responders (≥ACR50) and non-responders 
(≤ACR20). Positive predictive value in the 3 cohorts ranged between 58 and 72%, and 
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negative predictive value between 63 and 78%. However the training was performed 
on the whole dataset and so independent validation is required. Pre-treatment blood 
cytokine levels by themselves were unable to predict response and were undetectable 
in a number of samples
369
. In line with this, pre-treatment levels of TNF or the soluble 
TNF receptors (p55 and p75) do not predict response
370
, and whilst synovial TNF 
levels as measured by immunohistochemistry are higher in responders on a cohort 
level, they are unable to predict response in an individual
367
. However, reduction of 
plasma TNF bioactivity following infliximab, as assessed by the ability to induce IL-6 
production from RA synoviocytes in vitro, has been shown to associate with response 
in a small cohort (n=20). Poor responders demonstrated little bioactivity before or 
after infusion
370
. This needs to be replicated in a larger cohort, ideally with a more 
accessible measure of TNF bioactivity, particularly as there is face validity to the idea 
that variation in anti-TNF response may relate to TNF. 
 
A number of complicating issues surround prediction of response to anti-TNF agents. 
The populations studied are often heterogeneous in RA phenotype, co-morbidities and 
concomitant medications. The incorporation of subjective elements in the assessment 
of disease activity introduces noise as other factors and placebo responses may 
influence scores. The definition of response itself, and the timing of its measurement, 
will also influence results, particularly as some established patients may take longer to 
reach their maximum improvement whilst others may have secondary failure. 
Consequently it is unlikely that any variable will come close to 100% predictive 
power. 
 
1.14.6 Therapies targeting B cells 
 
There is a two way interaction between B and T cells in the generation of immune 
responses. B cells provide signals to T cells through antigen presentation, and T cells 
provide „help‟ to B cells through provision of cytokines and cell-surface ligands. This 
provides the potential for a positive feedback loop. The theory that RA is a primarily 
B cell driven disease led to B-cell targeting therapies
116
. Rituximab is a chimeric IgG1 
B-cell depleting antibody that targets CD20, a marker expressed during B cell 
development from the pre-B-cell through to the pre-plasma-cell stage. However, 
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germinal-centre and marginal-zone B cells may be resistant to killing through local 
protective mechanisms. A course of rituximab, given with corticosteroid, in the 
context of an unchanged dose of methotrexate, produces clinical benefit that is 
comparable to anti-TNF
371
. Treatment with rituximab has good efficacy even in those 
patients who have failed treatment with anti-TNF
372
. The usual regime is now to give 
two intravenous infusions of 1g 2 weeks apart. Repeat courses are usually given no 
more frequently than 6 monthly, as clinically indicated. Patients treated with a second 
or third course have similar clinical responses to the first treatment
107
. The longest 
follow-up so far reported is 7 years
373
. Circulating B cell numbers decline to less than 
2% of pre-treatment levels and the period of B cell depletion often lasts for 7-8 
months. In approximately half of cases, clinical benefit lasts for longer than the period 
of B cell depletion
116
. Despite effective peripheral B cell depletion, approximately one 
third of patients do not gain an appreciable clinical response
107
. Antibodies to RF and 
anti-CCP significantly decrease in those responding to rituximab and not in non-
responders, although in the study by Cambridge et al the lack of significance in the 
latter group may reflect the small sample sizes
374
. Relapse is usually preceded by an 
increase in one or more isotypes of RF
374
. The decline in autoantibodies is greater 
than that of total immunoglobulins. The selective decline in autoantibodies may 
indicate that there is constant generation of short-lived plasma cells from CD20-
positive precursors, or that their location outside of secondary lymphoid organs 
renders them more susceptible to depletion. Alternatively, there may be a proportion 
of autoreactive antibody-secreting cells that are not fully differentiated to the CD20 
negative plasma cell stage
375
. Expansion of non-autoreactive clones into the space 
vacated by such selective deletion could explain the increase in anti-pneumococcal 
capsular polysaccharide (PCP) antibody levels that is frequently seen after treatment 
with rituximab
375
. This might be promoted by the marked post-rituximab rise in B 
Lymphocyte Stimulator (BLyS) that is anti-parallel to the decline in autoantibodies 
and may offset the beneficial effects of treatment
375
. Because clinical improvement 
and relapse follow antibody levels more closely than B cell numbers, it could be 
argued that the main role of B cells is not simply to act as accessory cells in the 
activation of T cells
374
.  
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1.14.7 Anti-IL-6R 
 
Tocilizumab is a humanised antibody to the IL-6 receptor (IL-6R) that is capable of 
blocking both membrane-bound and soluble IL-6R. Complexes of the soluble receptor 
and IL-6 are also capable of binding to the signal-transducing molecule gp130 and 
activating cells. Phase II and III clinical studies have shown that tocilizumab has 
comparable efficacy to anti-TNF in reducing disease activity, improving physical 
function and quality of life, suppressing VEGF production and retarding development 
of erosions (reviewed by Mima
278
). It has efficacy as monotherapy and in combination 
with methotrexate. Similar to rituximab and abatacept, it also shows efficacy in 
patients who have failed anti-TNF inhibitors
376
. Uniquely, it is statistically superior to 
methotrexate in reducing disease activity in patients who are methotrexate-naive
377
. 
Efficacy is sustained over at least 5 years in the majority of patients. Infections are 
increased, as is the case with anti-TNF agents, but there appears to be no increased 
risk of TB which can be explained by IL-6 having no role in granuloma formation
270
. 
 
1.14.8 Abatacept 
 
Abatacept is a soluble fusion protein consisting of the extracellular domain of human 
cytotoxic T lymphocyte-associated antigen 4 (CTLA4) linked to a modified Fc 
portion of IgG1. T cell activation requires binding of the T cell receptor to a 
peptide/MHC complex but, in order to avoid anergy, costimulation is also needed. 
One important costimulatory signal is provided by the interaction of T cell CD28 with 
CD80 (B7-1) or CD86 (B7-2) on antigen presenting cells. CTLA4 is a naturally 
occurring homologue of CD28 which inhibits this interaction by competitively 
binding to CD80 and CD86. Blocking this costimulatory pathway ameliorates CIA
378
 
and inhibits immune responses by decreasing T cell proliferation in response to 
antigen presentation by dendritic cells, and by reducing subsequent cytokine and 
antibody production
379
. An interesting additional mechanism of action is that CTLA4 
binds osteoclast precursor cells and prevents their differentiation, which may 
contribute to the reduction in radiological progression seen following treatment with 
abatacept
380
. Abatacept has demonstrated clinical efficacy in patients who have failed 
methotrexate, both as monotherapy and in combination with methotrexate
381-383
, and 
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in those who have previously failed anti-TNF agents
384
. Abatacept has a slower onset 
of action when compared with anti-TNF agents, but in a randomised controlled trial 
comparing abatacept, infliximab and placebo in methotrexate inadequate responders, 
abatacept had a better safety profile, with fewer serious adverse events and infections 
when compared with infliximab, and also demonstrated better clinical outcomes at 1 
year
385
.  
 
1.15 Windows of opportunity 
 
Use of the medications discussed above can result in suppression of disease activity 
that fulfils clinical criteria for remission. Clinical experience, however, shows that in 
the majority of patients discontinuation of medications will lead to recurrence of 
disease activity. In most patients, biological therapy has been started years after the 
onset of RA, and it has been proposed that a „window of opportunity‟ may exist in 
early disease, where effective treatment may modify the disease course and even 
resolve it
8
. In studies of DMARD treatment, disease duration is the strongest predictor 
of response, with the greatest improvement seen when treatment is begun within one 
year of onset
386
. A better functional outcome is also observed when treatment is begun 
within the first 2 years
387
. It has been debated whether this represents an alteration of 
the disease process itself, or the benefits accrued from an earlier de-bulking of 
inflammatory synovitis. The latter remains possible, particularly as radiological 
damage occurs early, with 90% of patients demonstrating damage on X-ray by 2 years, 
and MRI and ultrasound imaging showing that this can commence within weeks of 
the clinical onset of disease
8
. But an increasing number of studies provide some 
evidence for a modification of the disease process itself with early treatment. 
Möttönen et al reported that a delay to therapy of greater than 4 months was the only 
significant predictor of remission rates at 2 years in patients treated with sulfasalazine 
(with half switching to methotrexate during the course of the study) plus or minus low 
dose prednisolone
388
. The same study also reported the benefit of early aggressive 
treatment (a combination of methotrexate, sulfasalazine and hydroxychloroquine plus 
or minus low-dose prednisolone) on long-term outcomes. At 2 years, greater clinical 
remission rates and less radiographic damage were seen in the combination group 
when compared with the single DMARD group. After 2 years treatment was 
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unrestricted in both groups with the continued aim of reaching remission. Despite this, 
there was greater work capacity at 5 years
389
 and remission rates at 11 years in the 
group which had originally been assigned to combination therapy
390
. This suggests 
that early treatment with combination therapy may have modified the course of later 
disease. This is further supported by the COBRA study in which a combination of 
sulfasalazine 2g/day, methotrexate 7.5mg/week (discontinued at week 40), and a 
tapering course of prednisolone starting at 60mg/day (discontinued at week 28), were 
compared with sulfasalazine alone in early RA (median duration 4 months). Once the 
prednisolone was stopped the 2 groups had similar levels of disease activity, and yet 
an improvement in radiographic outcome with the combination group was still noted 
at 80 weeks
391
. Treatment was unrestricted after 1 year, but the radiographic benefit 
was still observed at 4-5 years
392
.  
 
The value of early treatment with biological therapy was first studied by Quinn et al 
who compared a small group of poor prognosis patients treated with infliximab or 
placebo in combination with methotrexate. One year after withdrawal of infliximab, 
no patient who had a good response to the combination had a flare of disease activity 
requiring additional DMARD treatment
393
. Early use of infliximab and methotrexate 
was also examined in the BeSt study which reported that 56% of patients were able to 
discontinue infliximab in the first year as a result of a sustained DAS28 score ≤2.4, 
and that these patients maintained a good response through the second year
394
. The 
group initially treated with infliximab and methotrexate also had better functional and 
radiographic outcomes at 3 years, and more had discontinued infliximab due to 
sustained DAS28 scores in the remission range, when compared with patients who 
had started this combination after failing treatment with at least 3 traditional 
DMARDs
395
. This is despite the latter group having a median disease duration of only 
14 months before commencing infliximab. 
 
All this data suggests that initiation of effective treatment very early after the onset of 
clinical disease may alter the later disease course and might even be capable of 
inducing drug-free remission, so supporting the „window of opportunity‟ concept. 
What is not known, however, is whether there is a further window of opportunity 
before the onset of the symptoms and signs of RA, in which treatment of 
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asymptomatic anti-CCP antibody positive individuals may prevent the clinical 
manifestations of disease. 
 
1.16 Aim 
 
To identify a peptide from α-enolase that, when citrullinated, may be used in a simple, 
reproducible assay (CEP-1) with the following objectives: 
 To establish the diagnostic sensitivity of an anti-CEP-1 antibody ELISA in 
different RA cohorts, including both early and late disease (Chapter 2) 
 To examine the associations of anti-CEP-1 antibodies with the HLA-DRB1 
shared epitope, PTPN22 and smoking, which preferentially segregate with 
anti-CCP antibody positive disease (Chapter 3) 
 To investigate whether anti-CEP-1 antibodies are predictive of clinical, 
functional and radiological outcomes, or response to anti-TNF agents, using 
well-characterised, longitudinal RA cohorts (Chapter 4). 
  
Chapter 2                   Identification of CEP-1 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: IDENTIFICATION OF CEP-1 AS THE 
IMMUNODOMINANT EPITOPE OF CITRULLINATED ALPHA-
ENOLASE AND THE FREQUENCY OF ANTI-CEP-1 
ANTIBODIES IN DIFFERENT COHORTS OF RA SERA
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2.1. Introduction 
 
Alpha-enolase is a multifunctional glycolytic enzyme that catalyses the conversion of 
2-phosphoglycerate to phosphoenolpyruvate. Whilst expression is required for steady-
state glucose metabolism, its role in anaerobic glycolysis means it is upregulated by 
hypoxia
219
 and pro-inflammatory stimuli
220
.  Both hypoxia and inflammation are 
features of the rheumatoid joint where elevated levels of α-enolase have been 
detected
176. Antibodies to α-enolase have been reported during infections and in a 
range of autoimmune diseases
208
, including RA
142
. Such propensity to develop 
antibodies to α-enolase and the high inter-species sequence homology of the 
antigen
396
 provide potential for molecular mimicry between infectious organisms and 
host proteins leading to a breakdown of immunological tolerance. Antibodies reacting 
only with citrullinated α-enolase appear specific for RA, with antibody positivity in 
healthy controls thought to result from reactivity with uncitrullinated epitopes
216
. 
Importantly, in contrast to the artificial peptides in the CCP2 assay, citrullinated α-
enolase is a real protein which has been detected in RA synovial fluid
176
.  
 
In this Chapter, I describe the development of a peptide-based ELISA using 
citrullinated epitopes of α-enolase The identification of a peptide termed citrullinated 
enolase peptide-1 (CEP-1), containing an immunodominant epitope, allowed rapid 
screening of large numbers of serum samples with a single peptide to examine 
diagnostic sensitivity and specificity in collaborative studies in over 2000 patients.  
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2.2. A disease-specific antibody response to citrullinated α-enolase 
peptides was detected in patients with RA  
2.2.1. Methods 
2.2.1.1. Peptides 
 
Eleven peptides corresponding to 15 to 23-mer stretches of α-enolase (SwissProt 
accession number P06733; Figure 2.1) were designed by A. Kinloch and synthesised 
at Cambridge Research Biochemicals (Cleveland, UK). Cysteine residues were added 
at the amino- and carboxy-termini to facilitate cyclisation of the peptide through 
disulphide bonds, and citrulline was substituted for arginine residues. The peptides 
covered seven of the nine citrulline residues previously identified by mass 
spectrometry of in vitro citrullinated α-enolase216, together with eight other sites of 
potential citrullination, so that altogether 15 of the 17 arginine residues were covered. 
Amide (NH2) groups were also added to the carboxy-terminus of each peptide to 
allow for greater stabilisation of the peptides. Additional arginine-containing control 
peptides were synthesised that corresponded to the immunodominant, citrulline-
containing peptide. 
 
2.2.1.2 ELISAs 
 
96-well plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with α-enolase 
peptides at 10 µg/ml (diluted in a 50 mM carbonate buffer, pH 9.6), or with carbonate 
buffer alone, and incubated over night at 4C. Wells were washed with PBS-Tween 
(0.05%) and blocked with 2% BSA (diluted in PBS) for 3 hours at room temperature. 
Sera were diluted 1:50 in RIA-buffer (10 mM Tris, 1% BSA, 350 mM NaCl, 1% 
Triton-X, 0.5% Na-deoxycholate, 0.1% SDS) supplemented with 10% FCS, added in 
duplicates and incubated for 1.5 hour at room temperature. Plates were washed as 
described above and incubated with peroxidase-conjugated mouse anti-human IgG 
(Hybridoma Reagent Laboratory, Baltimore, USA) (diluted 1:1000 in RIA-buffer, 
10% FCS) for 1 hour at room temperature. After a final wash (PBS-Tween, 0.05%), 
bound antibodies were detected with TMB substrate (KPL, Maryland, USA). The  
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1     MSILKIHAXE IFDSXGNPTV EVDLFTSKGL FXAAVPSGAS TGIYEALELX DNDKTXYMGK 
61   GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT ENKSKFGANA ILGVSLAVCK 
121 AGAVEKGVPL YXHIADLAGN SEVILPVPAF NVINGGSHAG NKLAMQEFMI LPVGAANFXE 
181 AMXIGAEVYH NLKNVIKEKY GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV 
241 VIGMDVAASE FFXSGKYDLD FKSPDDPSXY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD 
301 WGAWQKFTAS AGIQVVGDDL TVTNPKXIAK AVNEKSCNCL LLKVNQIGSV TESLQACKLA 
361 QANGWGVMVS HXSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL LXIEEELGSK 
421 AKFAGXNFXN PLAK 
 
 
Figure 2.1. Amino acid sequence of human α-enolase (SwissProt accession 
number P06733). The locations of peptides studied are shown in bold. Sites 
where the synthesised peptides contained a citrulline residue in place of an 
arginine are marked with an X and are highlighted in red. Amino acid residues 
are shown in their single letter code and their position in the molecule by the 
numbers on the left  
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reaction was stopped by the addition of 1M H2SO4 and absorbance measured at 450 
nm in a Multiscan Ascent microplate reader (Thermo Labsystems). A control serum 
was included on all plates to correct for plate-to-plate variation. Background OD450 
(wells coated with carbonate buffer alone) was subtracted from peptide OD450 for 
each serum tested. OD values above 0.1 were taken as positive. The majority of this 
work was undertaken by Dr Karin Lundberg. 
 
2.2.1.3. Sera 
 
Sera were obtained from a cohort of 102 patients with RA who attended the outpatient 
Rheumatology clinic at Charing Cross Hospital. All patients fulfilled the ACR 
classification criteria for RA and samples were collected with informed consent and 
anonymised according to the ethical approval granted for this study. Ethical approval 
was granted by the Riverside Research Ethics Committee and the Hammersmith NHS 
Trust Research Ethics Committee. All patients had established disease and were on 
treatment, and therefore represented a typical clinical population with relatively well-
controlled disease. However, no specific clinical data was available for these samples, 
and sera from healthy and disease controls were not age and sex-matched. The 92 
healthy control samples were kindly donated (and subsequently anonymised) by 
healthy volunteers working at the Kennedy Institute of Rheumatology, London. The 
110 disease controls consisted of patients with other rheumatological illnesses, 
including systemic lupus erythematosus (n = 32), Sjögren‟s syndrome (n = 31), 
Behçet‟s syndrome (n = 18) and psoriatic arthritis (n = 5). Anonymised serum 
samples from the Behçet‟s syndrome patients were kindly donated by Professor 
Dorian Haskard. The remaining disease controls, all on treatment, attended the 
outpatient rheumatology clinic at Charing Cross Hospital. Consequently, this aspect 
of the study was not controlled for age, ethnicity, disease duration and the effect of 
treatment. 
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2.2.2. Results 
 
Overall, 64% of RA patients and 15% of controls had IgG antibodies to one or more 
citrullinated enolase peptides (Table 2.1). Whereas the majority of RA sera reacted 
with multiple peptides, control sera, where positive, reacted predominantly with just 1 
peptide and with significantly lower IgG antibody levels (Figure 2.2). 
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Peptide Percentage of Sera Positive 
Name Sequence Location RA 
(n = 102) 
Disease controls 
(n = 110) 
Healthy controls 
(n = 92) 
1A  
(CEP-1) 
CKIHA-X-EIFDS-X-GNPTVEC 4-21 37 3 2 
1B CKIHA-R-EIFDS-X-GNPTVEC 4-21 40 nd nd 
1C CKIHA-X-EIFDS-R-GNPTVEC 4-21 20 nd nd 
1D CKIHA-R-EIFDS-R-GNPTVEC 4-21 5 2 3 
2 CVDLFTSKGLF-X-AAVPSGC 22-38 10 0 2 
3 CYEALEL-X-DNDKT-X-YMGKGVSKC 44-64 15 2 0 
4 CEKGVPLY-X-HIADLAGNSEC 125-142 16 2 2 
5 CNF-X-EAM-X-IGAEVYHNLKNC 177-194 11 4 3 
6 CF-X-SGKYDLDFKSPDDPS-X-YC 252-270 12 5 0 
7 CANGWGVMVSH-X-SGETEDTC 362-379 4 2 2 
8 CAKYNQLL-X-IEEELGSKAC 405-421 7 4 0 
9 CKFAG-X-NF-X-NPLAKC 422-434 15 1 1 
10 CIQVVGDDLTVTNPK-X-IAKAC 313-331 6 nd 1 
11 CNPK-X-IAKAVNEKSCNCLLC 324-341 18 nd 0 
 
                 Table 2.1. 
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Table 2.1. Sequences of the 14 cyclic peptides used when mapping the anti-
citrullinated α-enolase antibody response (column 2). Amino acid residues are 
shown using their single letter code and the location of the peptide in human α-
enolase is shown in column 3 (SwissProt accession number P06733). The 
percentage of RA patients (n = 102), disease controls (n = 110) and healthy 
controls (n = 92) with antibodies to the different peptides are shown in columns 3, 
4 and 5. A sample was deemed to be positive if the optical density (OD) at 450nM, 
minus the background OD, was ≥ 0.1. This corresponded to the 98th percentile of 
OD values, minus background, of the 92 healthy controls. Background was 
measured using wells coated with coating buffer alone. Peptides 1B, 1C and 1D 
substituted arginine residues in place of one or both of the citrulline residues in 
peptide 1A, in order to determine which of the two citrulline residues was most 
important for recognition by RA sera. Peptide 1A was used for subsequent 
studies and has been termed citrullinated enolase peptide 1 (CEP-1). X = 
citrulline. nd = not done (too little serum left for analysis). 
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        Figure 2.2. 
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Figure 2.2. Antibodies to citrullinated α-enolase peptides in RA patients (A; 
n=102), disease controls (B; n=110) and healthy controls (C; n=92). IgG 
reactivity is measured by optical density (OD) at 450nm following subtraction of 
the background density of wells coated with coating buffer alone. Each dot 
represents the IgG antibody reactivity of a single serum sample with the peptide 
sequence that is marked on the x axis. The majority of sera for each peptide are 
not shown as they were valued at zero and thus lie on the x axis. Grey bars mark 
mean OD values for reactivity to each peptide. RA sera have stronger reactivity 
with citrullinated α-enolase peptides than samples from the two control groups. 
Peptide 1 refers to peptide 1A (CEP-1) in Table 2.1 in which the sensitivities for 
each of the peptides is shown. nd = not done (too little serum left for analysis). 
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2.3. Identification of an immunodominant B cell epitope within 
citrullinated α-enolase 
 
The peptide sequence recognised by the greatest number of RA sera (37%) was 
Peptide 1 (1A in Table 2.1) followed by Peptide 11 (18%). The OD450 cut-off for 
positivity was set at the 98
th
 percentile of values for the 92 healthy controls and so at 
this OD450, 2% of healthy controls and 3% of disease controls were positive. The 
same cut-off was used for the other peptides. Peptide 1, which contains two citrulline 
residues, was considered to be the immunodominant epitope.  
To examine whether the binding of RA sera to Peptide 1 required the presence of 
citrulline, and if so whether one or both residues was required, a further three peptides 
(1B, 1C and 1D; table 2.1) were generated where one or both of the citrulline residues 
were replaced by arginine. The presence of IgG antibodies recognising Peptide 1D, 
which contains no citrulline residues, was detected in only 5% of RA sera, confirming 
that the presence of citrulline is a requirement. The number of sera binding to Peptide 
1B (40%), as well as the mean OD450 (Figure 2.3) was similar to that observed with 
Peptide 1A and greater than that with Peptide 1C (20%). This suggests that the second 
citrulline residue (at position 15) is relatively more important than the first (at position 
9) for recognition by RA sera. Peptide1A, containing both citrullinated residues, was 
chosen for further study and from hereon is referred to as citrullinated -enolase 
peptide-1 (CEP-1). 
Anti-CCP antibodies (Immunosan RA, Euro-Diagnostica, Arnhem, Netherlands) in 
the same serum samples, gave a diagnostic sensitivity of 71% with a specificity of 
98%. Seven (23%) of the anti-CCP negative RA patients were positive in the anti-
CEP-1 ELISA. Therefore combining the results of the anti-CCP with anti-CEP-1 
ELISAs in this cohort increases the overall sensitivity to 78% for antibodies to 
citrullinated peptides.  
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Figure 2.3. IgG antibody reactivity of RA sera with Peptide 1A, which contains 
two citrullines, compared with peptides where one or both of the citrulline 
residues are replaced by arginine (see Table 2.1 for sequences). Data was 
generated by Dr Karin Lundberg using the 102 RA sera. Each dot represents the 
binding of one serum to the peptide indicated on the x axis. IgG antibody 
reactivity is measured by optical density (OD) at 450nm following subtraction of 
the background density of wells coated with coating buffer alone. Grey bars 
indicate mean OD450 values. The low number of sera binding the arginine-
containing Peptide 1D, confirms that Peptide 1 antibody binding is dependent on 
citrulline. It is the second citrulline residue (Peptide 1B), rather than the first 
(Peptide 1C), that is associated with the high IgG antibody levels for this B cell 
epitope. *** P < 0.0001. ** P < 0.01. 
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2.4. The diagnostic sensitivity and specificity of the anti-CEP-1 
ELISA confirmed in an independent cohort of patients with RA  
 
We next sought to determine if antibodies to CEP-1 could be detected in an 
independent cohort. Baseline sera from 81 patients enrolled in a clinical trial of 
minocycline organised by the Rheumatoid Arthritis Investigational Network (RAIN; 
coordinating centre at the Omaha Veterans Medical Affairs Centre, University of 
Nebraska, USA) were kindly provided by Dr Ted Mikuls, along with sera from 82 
age- and sex-matched healthy controls. All samples were obtained with informed 
consent and covered by ethical approval from the local Institutional Review Board. 
ELISAs were performed in the same manner as described in section 2.2.1.2 with the 
exception that 2% BSA was added to the coating buffer used in the control wells. The 
98
th
 percentile of the control sera was used as cut-off (OD450 of 0.2). Half of these 
ELISAs were undertaken by Dr Karin Lundberg. The sensitivity in this RA cohort 
was increased to 62%, with a specificity of 98% (Figure 2.4). The RA subjects in this 
cohort had early, active RA and were not yet on DMARD therapy. Disease controls 
were not examined in this part of the study. 
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Figure 2.4. In the RAIN cohort, 62% of patients (n = 81) had anti-CEP-1 
antibodies compared to 2% of healthy controls (n = 82). Data was generated by 
ELISA and presented as the optical density at 450nm (OD450) following the 
subtraction of background binding (OD450 of wells coated in 2% BSA). The 
dotted line indicates the cut-off value for positive samples, based on the 98
th
 
percentile of controls (OD450 ≥0.2). Each dot represents the value for a single 
serum sample and the grey lines indicate the mean OD450 for each cohort. 
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2.5 Sensitivity of a quantitative anti-CEP1 ELISA in early and 
established RA 
2.5.1 Methods 
2.5.1.1 ELISA 
 
Further modifications were made for subsequent cohort studies. A standard curve with 
serial dilutions of pooled positive serum, kindly provided by Dr Johan Ronnelid, was 
used to measure antibody levels in arbitrary units (AU). A positive and negative 
control was used on each plate. After incubating the plates overnight they were 
washed in PBS and blocked with 2% BSA for 1 hour at room temperature. Serum was 
diluted 1:100 and incubated for 2 hours. After washing in PBS-Tween, plates were 
incubated with ALP-conjugated goat anti-human IgG (Jackson Laboratories, West 
Grove, USA) diluted 1:10 000 for 1 hour. After a final wash, ALP substrate (Sigma) 
was added and the plates incubated in the dark for 30 minutes before reading at 
405nm. The 95
th
 centile of 137 healthy controls was used as the cut-off for positivity. 
A different cut-off, based on 100 healthy controls, was used by H. Mahdi and O. Snir 
(Karolinska Institute, Stockholm, Sweden) who provided the data for the Swedish 
cohorts. 
 
2.5.1.2 Sera 
 
The Norfolk Arthritis Register (NOAR) is a primary care-based inception cohort of 
patients with inflammatory arthritis that was commenced in 1989[symmons d s94]. 
Patients with swelling in 2 or more joints that lasted 4 weeks or longer are referred by 
their GP and assessed by a trained metrologist. Evaluations include joint counts, the 
Health Assessment Questionnaire (HAQ) for measuring disability, and radiographs of 
the hands and feet. An advantage of this cohort is that it does not rely on the ACR 
classification criteria for RA which do not perform well in early disease
5
. Indeed, the 
ACR criteria applied at the baseline NOAR visit were of little value in predicting 
persistence of arthritis, development of radiographic erosions or of moderate 
disability (HAQ ≥1)397. Furthermore, as erosions are one of the ACR criteria, the 
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NOAR cohort has an advantage in evaluating erosions as an outcome measure and 
consequently whether baseline anti-CEP-1 titres have prognostic value. 583 recent 
baseline samples were available for analysis, of which 398 had fulfilled ACR 
classification criteria for RA by 3 years. Median age at disease onset for the whole 
NOAR cohort was 57, with an inter-quartile range (IQR) of 47-68, and 66% were 
female. For the group which fulfilled ACR classification by 3 years the median age 
was 58 (IQR 49-68) and 70% were female. All samples were collected with informed 
consent and approval of the local Research Ethics Committee. Samples were kindly 
donated by Dr Anne Barton and Professor Deborah Symmons. 
 
A further 320 samples were obtained from proband participants in the National 
Repository (NR). This is a database of RA affected sib-pairs
398
. Median age at disease 
onset was 42 (IQR 33-52) and 75% were female. Samples were again collected with 
informed consent and Ethical Committee Approval and were kindly donated by Dr 
Anne Barton and Professor Deborah Symmons. 
 
Serum samples from 517 patients with RA were made available from participants in 
the British Society of Rheumatology Biologics Register (BSRBR), which enrols 
patients commencing a biologic agent and follows them prospectively with 
information collected every 6 months, as previously described
362
. The following 
inclusion criteria applied for the subjects whose samples were used in this study: 
1. Currently actively participating in the BSRBR long-term safety study 
2. Physician-confirmed diagnosis of RA 
3. Currently or have been treated with an anti-TNF biologic agent 
4. European Caucasian descent 
5. Reached 6 months of follow-up 
Eligible patients from 20 collaborating centres (Biologics in Rheumatoid Arthritis 
Genetics and Genomics Study Syndicate; BRAGGSS) were invited to take part in the 
study and additional blood samples were taken from consenting patients when they 
required a blood test as part of routine care. Clinical and demographic data was 
extracted from the BSRBR database. The primary outcome measure was change in 
DAS-28 between baseline and 6 months and associations with the magnitude of 
change were tested by linear regression. EULAR improvement criteria were a 
secondary outcome and associations were tested with ordinal logistic regression. 
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Informed consent and Ethical approval exists for data collection on the BSRBR 
database and additional ethical approval was obtained for the collection of these 
serum samples. BRAGGSS samples were provided by Dr Anne Barton. 
 
The Epidemiological Investigation of RA (EIRA) is a Swedish population-based case-
control study. Newly diagnosed patients aged between 18 and 70 were enrolled 
between May 1996 and December 2003 from a geographically defined region in 
Sweden. Controls, matched for age, gender and residential area, were randomly 
selected from the national population register. Samples from 1030 RA patients and 
872 healthy controls were tested for anti-CEP-1 antibodies by H. Mahdi. 
 
2.5.2. Results 
 
Out of 579 patients from the NOAR cohort for whom we had baseline samples, 21% 
were positive for anti-CEP-1. By 3 years, 398 of these had fulfilled ACR 
classification criteria for RA and out of these 24% were positive (Table 2.2). The 
lower prevalence of anti-CEP1 antibodies in those subjects going on to fulfil ACR 
classification criteria, in comparison with the other cohorts, is in keeping with the 
lower prevalence of anti-CCP antibodies (50%) and reflects this being a primary-care 
based cohort and possibly biased towards milder disease. 
In the NR cohort, 42% were positive for anti-CEP-1 versus 88% for anti-CCP. Similar 
results were obtained in the BRAGGSS cohort. Results from the EIRA cohort 
together with published results from a second Swedish cohort
182
, obtained using the 
same ELISA and standard curve, but with a different cut-off based on 100 Swedish 
controls, are also presented in Table 2.2. Most anti-CEP-1 positive patients were also 
anti-CCP positive (98% in NR, 86% in NOAR and 88% in EIRA; DIASTAT, Axis-
Shield, Dundee, UK for NR and NOAR; Immunoscan RA, Eurodiagnostica, Malmö, 
Sweden for EIRA). 
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Cohort Description Number of RA 
subjects 
Anti-CCP 
positive (%) 
Anti-CEP-1 
positive (%) 
NOAR Early RA – 
primary care 
based 
398 50 24 
NR Established 
RA with 
family history 
289 88 42 
BRAGGSS Established 
RA requiring 
anti-TNF 
517 82 39 
KS (Sweden) Established 
RA 
291 72 41 
EIRA 
(Sweden) 
Early RA 1030 60 43 
 
Table 2.2. Prevalence of anti-CEP-1 antibodies compared to anti-CCP in 
different cohorts of patients fulfilling the ACR classification criteria for RA. 
NOAR, Norfolk Arthritis Register. NR, National Repository. BRAGGSS, 
Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate. 
EIRA, Epidemiological Investigation of RA. KS, published results of a cohort of 
Swedish patients who attended the Rheumatology Clinic at the Karolinska 
Universtiy Hospital, Stockholm, Sweden
182
. The principal inclusion criteria for 
the KS cohort was the clinical need to withdraw synovial fluid from a knee 
effusion. CCP, cyclic citrullinated peptide. CEP-1, citrullinated enolase peptide 1. 
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2.6 Summary and Discussion 
 
Citrullinated α-enolase was previously identified as a candidate autoantigen in RA216. 
In this study we used ELISAs based on synthetic peptide sequences from α-enolase in 
which arginine residues were replaced by citrulline. We demonstrated that 64% of RA 
sera reacted with one or more citrullinated α-enolase peptides, in comparison to 15% 
of control sera. Compared to the controls, RA sera reacted with a higher level of IgG 
antibody binding and to a greater number of different peptides. One of these peptides, 
CEP-1, reacted with 37% of RA sera but only 2% of controls and we concluded that 
this was the immunodominant peptide. The start and end of this peptide sequence 
were chosen in order to centre the citrulline residues and it is possible that a more 
formal epitope-mapping experiment with overlapping peptides might have resulted in 
a slightly different sequence with greater sensitivity.  The necessity for citrulline was 
also demonstrated and it appears that it is the second citrulline residue at position 15, 
rather than the first at position 9, that is important for antibody binding. The amino 
acids flanking citrulline residues are of importance, since, for example, RA serum 
does not react with deiminated bovine serum albumin
157
. It is noteworthy that the 
citrulline residue at position 15 of  α-enolase is flanked by the amino acids serine and 
glycine, as the Ser-Cit-Gly sequence occurs in some major epitopes of citrullinated 
filaggrin
157 158
. Further experiments performed by Karin Lundberg demonstrated that 
affinity-purified human anti-CEP-1 antibody reacted with recombinant in vitro 
citrullinated α-enolase demonstrating antigen specificity399.  
 
The occurrence of some patients that are anti-CEP-1 antibody positive but anti-CCP 
antibody negative suggests that reactivity with CEP-1 is not simply due to cross-
reactivity. This has been confirmed in experiments done by Karin Lundberg in which 
pre-incubation of sera positive for both anti-CEP-1 and anti-CCP antibodies with CCP, 
only partially inhibited binding to CEP-1 (percentage inhibition ranged from 0-
53%)
399
. The independence of anti-CEP-1 binding from other candidate citrullinated 
autoantigens has been examined by Snir et al. who reported little cross-reactivity with 
antibodies recognising citrullinated fibrinogen or citrullinated triple helical peptides 
of type-II collagen
182
.  
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We were able to confirm notable diagnostic sensitivity, whilst retaining specificity, in 
an independent hospital-based cohort of early, active and untreated RA. Following 
this a quantitative ELISA was developed which used a standard curve of pooled 
positive sera and cut-offs based on healthy control sera. Using this ELISA, a 
sensitivity of 24 to 43% was demonstrated in five different cohorts of over 2000 
patients with RA all of whom fulfilled the ACR classification criteria. In general, the 
percentage of subjects that are anti-CEP-1 antibody positive is approximately half that 
of anti-CCP. The variation in anti-CEP-1 antibody prevalence from 24% in NOAR to 
62% in the RAIN cohort (using the non-quantitative ELISA) deserves some comment. 
Unlike hospital cohorts, primary care based cohorts such as NOAR are not biased 
towards severe disease. This is reflected in lower familial risk and weaker HLA 
associations
400
. Environmental risk factors may also differ between the populations 
and, although we do not have smoking data available for the RAIN cohort, 
recruitment was in the 1990s when smoking may have been more prevalent. 
Furthermore, one of the inclusion criteria for the RAIN cohort was the presence of RF. 
This variation in anti-CEP-1 antibody prevalence encourages the investigation of 
genetic and environmental risk factor associations. 
 
 In all cohorts examined, the diagnostic sensitivity of the anti-CEP-1 ELISA was less 
than the anti-CCP assay, suggesting that anti-CEP-1 does not compete with anti-CCP 
as a screening test for RA as a whole. It is possible that further refinements to the 
CEP-1 ELISA, such as alteration of coating conditions and peptide configuration or 
addition of other citrullinated α-enolase peptides, may further increase diagnostic 
sensitivity for RA sera whilst retaining specificity. With this in mind, it is of interest 
that a recent study using a shortened CEP-1 sequence (amino acids 4-20 of human α-
enolase) and a linear peptide conformation, reported a much lower sensitivity of 
13.9% in a small cohort with RA (n=72) from a North American native population
401
. 
A model of α-enolase highlighting the position of CEP-1 (Figure 2.5), generated 
subsequent to our experiments, shows this epitope to be non-linear and so we were 
fortunate to have tested a cyclic peptide conformation since only a proportion of the 
linear peptides would take on a conformation similar to the original antigenic site 
resulting in „conformational dilution‟159. However, it is increasingly evident that RA, 
as defined by the ACR classification criteria, encompasses patients with widely 
different outcomes and responses to treatment and may reflect different disease 
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processes. It is therefore possible that an assay with a lower diagnostic sensitivity for 
RA than anti-CCP may still be of value by identifying a subset with characteristic 
clinical features or outcomes. It has been demonstrated that the anti-CCP assay may 
usefully subdivide groups of RA patients such that the average anti-CCP antibody 
negative patient has a more benign disease course
402 403
. However, even within the 
anti-CCP antibody positive subgroup, not all erode at the same rate
404
. Given that 
these patients may have non-cross-reactive antibodies recognising one or more „true‟ 
citrullinated autoantigens, added value might be obtained by further subdividing the 
anti-CCP positive subgroup into, for example, anti-CEP-1 positive and negative.  
 
The presence of anti-CEP-1 antibodies in patients with RA, even with a high 
specificity, does not prove pathogenicity. They could equally have arisen as a 
„bystander‟ phenomenon or be cross-reactive with another, as yet unidentified, 
citrullinated autoantigen. Further cohort studies could help refine our understanding 
by exploring associations with known genetic and environmental risk factors (i.e. do 
they arise in a certain subset of patients?) and by examining whether they are 
predictive of outcome. 
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Figure 2.5. Ribbon diagram of α-enolase based on the x-ray crystal structure 
with resolution 2.2Å reported by Kang et al
405
, created by Natalia Wegner using 
DeepView software (spdbv.vital-it.ch). Magnesium and sulphate ions are not 
depicted. The two CEP-1 epitopes in this homodimer are shown in red and 
demonstrate these to be non-linear. CEP-1, citrullinated α-enolase peptide-1. 
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CHAPTER 3: RELATIONSHIP BETWEEN ANTI-CEP-1 
ANTIBODIES AND THE MAJOR GENETIC AND 
ENVIRONMENTAL RISK FACTORS FOR RA 
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3.1 Introduction 
 
Rheumatoid arthritis, defined according to the ACR classification criteria, is a 
phenotypically heterogeneous disease. Patients differ in the pattern of joint 
involvement, severity of symptoms, degree of erosive change, response to treatment 
and long-term outcome amongst other variables. In recent years there has been 
interest in subdividing patients, particularly into anti-CCP positive and negative. If 
antibodies to CEP-1 are of aetiopathological significance but only detected in 40% of 
patients, one might anticipate that this subpopulation would be associated with 
particular genetic or environmental risk factors. Genetic factors account for two-thirds 
of the risk for RA
17
; 30% of which is attributable to the HLA class II region
18
. 
Predisposing HLA alleles are thought to share a conserved sequence at positions 70-
74 of the third hypervariable region of the DRβ1 chain referred to as the „shared 
epitope‟(SE; discussed in detail in chapter 1). The second major genetic risk factor to 
have been conclusively associated with RA is the R620W allele of the protein 
tyrosine phosphatase PTPN22. Environmental factors account for one-third of risk, 
the most recognised of which being smoking. We examined the relationship between 
these risk factors and antibodies to CEP-1. 
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3.2 Anti-CEP-1 antibodies are associated with the shared epitope in 
both early and established RA 
3.2.1 Methods 
 
Sera from the NOAR and NR cohorts (section 2.5.1.2) were tested using the 
quantitative anti-CEP-1 antibody ELISA (section 2.5.1.1). HLA typing was 
undertaken at Manchester University using a semi-automated dot-blot hybridisation 
method (INNO-LiPA, Murex Diagnostics, Dartford, UK) according to the 
manufacturer‟s instructions. The following HLA DRB1 alleles were classed as having 
the SE: *0101, *0102, *0401, *0404, *0405, *0408, *1001 and *1402. Statistical 
analyses were undertaken by Dr Darren Plant, Manchester University. 
 
3.2.2 Results 
 
HLA typing was available for the 279 patients in the NR cohort and for 283 of the 
patients in the NOAR cohort that were analysed for anti-CEP-1 antibodies, 218 of 
whom fulfilled ACR classification criteria for RA by 3 years of follow-up. As 
expected, there was greater carriage of the SE in the NR cohort when compared with 
NOAR (Table 3.1).  
The relationship between the SE and anti-CEP-1 antibodies was examined in the 
NOAR patients who went on to fulfil ACR criteria using logistic regression analysis 
(Table 3.2). The odds ratio for 1 and 2 copies were 2.13 and 4.12 respectively 
(difference between 1 and 2 copies not significant). Furthermore, those with 1 or 2 
copies of the SE had significantly higher titres of anti-CEP-1 antibody compared to 
those with none (p=0.0299 and 0.0013 respectively; Table 3.3 and Figure 3.1). The 
higher titre seen with 2 copies compared to 1 was not statistically significant 
(p=0.1783). Similar data was obtained in the NR cohort. We next investigated 
whether the association with anti-CEP-1 antibodies was similar for both HLA DR4 
and DR1 SE, as the latter appears to associate with milder disease
29
. Only odds ratios 
for DR4 were significant, with the 95% CI for 1 and 2 copies of DR1 both crossing 
one (Table 3.2). DR1/DR4 heterozygotes were excluded from this analysis.
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Cohort No copy of SE 
(%) 
1 Copy of SE 
(%) 
2 Copies of SE 
(%) 
Any SE 
(%) 
NOAR 77 (35.3) 97 (44.5) 44 (20.2) 141 (64.7) 
NR 38 (13.6) 121 (43.4) 120 (43.0) 241 (86.4) 
 
Table 3.1. Prevalence of the HLA DRB1 ‘shared epitope’ (SE) in the NOAR 
(n=218) and NR (n=279) cohorts. Only data for the 218 NOAR patients who 
fulfilled classification criteria for RA by 3 years are included. Figures represent 
the number of subjects with percentage of cohort in brackets. NOAR = Norfolk 
Arthritis Register; NR = National Repository. 
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Predictor. Obs. Odds ratio (95% CI) 
HLA-SE    
0 copy 205 Referent 
1 copy  2.13 (0.96, 4.69) 
2 copy  4.12 (1.67, 10.18) 
   
HLA-DR4 SE    
0  copy 142 Referent 
1  copy  2.91 (1.20, 7.07) 
2  copy  6.17 (2.04, 18.67) 
   
HLA-DR1 SE    
0  copy 116 Referent 
1  copy  1.77 (0.65, 4.86) 
2  copy  3.08 (0.17, 57.22) 
   
Smoking habits   
Never 303 Referent 
Ever  1.03 (0.59, 1.81) 
 
Table 3.2. Association of the HLA-DRB1 ‘shared epitope’ (SE) with antibodies to 
CEP-1. Odds ratios are derived from logistic regression using the number of 
copies of SE to predict the presence of anti-CEP-1 antibodies in NOAR patients 
fulfilling the American College of Rheumatology classification criteria for RA. 
Obs = number of observations; CI = confidence interval; DR4 SE = HLA-DRB1 
*04 alleles bearing the SE (*0401, *0404, *0405, *0408); DR1 SE = HLA-DRB1 
*01 alleles bearing the SE (*0101, *0102). NOAR = Norfolk Arthritis Register.
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Cohort  Copy 
Number 
Mean 
Levels (AU) 
Frequency p-value 
Early RA All SE 0 341 77 - 
1 1026 97 0.0299 
2 
 
1398 44 0.0013 
DR1 SE 0 341 77 - 
1 780 43 0.1773 
2 
 
691 3 0.2009 
DR4 SE 0 341 77 - 
1 1258 52 0.0259 
2 1636 21 0.0004 
 
Established 
RA 
All SE 0 528 38 - 
1 1466 121 0.0230 
2 1780 120 0.0006 
 
DR1 SE 0 528 38  
1 612 27 0.2887 
2 -  - 
 
DR4 SE 0 528 38  
1 1764 90 0.0226 
2 1857 78 0.0021 
 
 
Table 3.3. Relationship between anti-CEP-1 antibody levels and copies of the 
‘shared epitope’ (SE) in early (NOAR subjects fulfilling American College of 
Rheumatology classification criteria by 3 years) and established (NR) RA. DR4 
SE = HLA-DRB1 *04 alleles bearing the SE (*0401, *0404, *0405, *0408); DR1 
SE = HLA-DRB1 *01 alleles bearing the SE (*0101, *0102). NOAR = Norfolk 
Arthritis Register; NR = National Repository. AU = arbitrary units. 
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Figure 3.1. Anti-CEP-1 antibody levels (Log10 AU) in relation to the number of 
copies of the HLA-DRB1 ‘Shared Epitope’ (SE). Results from the cohort of 
NOAR subjects fulfilling the American College of Rheumatology Classification 
criteria for RA by 3 years are shown in A, and from the NR cohort in B. Number 
of copies of the SE are marked on the x-axis. Bars represent means. AU = 
arbitrary units.
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3.3 Association of anti-CCP antibodies with HLA-DRB1 SE occurs 
preferentially in the anti-CEP-1 positive group.  
3.3.1 Methods 
 
In addition to sera from the NOAR and NR cohorts, results were available for the 
EIRA cohort (section 2.5.1.2) with ELISAs performed by Hiba Mahdi and statistical 
analyses by Dr Henrik Källberg, Karolinska Institutet, Sweden. In the EIRA cohort 
the following alleles are classified as SE: DRB1*01 (except *0103), DRB4*04 (with 
the exception of some *0402 and *0403 alleles from limited subtyping experiments) 
and DRB1*10. 
 
3.3.2 Results 
 
An association between anti-CCP antibodies and the SE has been well established, 
and the disease risk conferred by these alleles is restricted to the subset of patients 
positive for anti-CCP. However, this does not identify the specific immune response 
underlying this association as CCP is not itself an autoantigen, and it is probable that 
the anti-CCP2 assay detects antibodies to more than one true citrullinated autoantigen. 
We therefore subdivided the anti-CCP positive group into anti-CEP-1 positive and 
negative. Using multinomial logistic regression, with the anti-CCP antibody negative 
patients as referent and the SE as predictor of antibody group, the relative risk ratio 
(RRR) of 1 and 2 copies of the SE for being both anti-CEP-1 and anti-CCP positive in 
the NOAR cohort (restricted to those fulfilling ACR classification criteria) were 4.2 
(p=0.002) and 10.8 (p<0.0001). The RRR was lower in the anti-CCP positive but anti-
CEP-1 negative group (3.2 and 5.4 for 1 and 2 copies of the SE; p=0.003 and 
p=0.001). In the NR cohort the RRR were 3.3 (p=0.062) and 8.6 (p=0.003) for the 
anti-CEP1 positive group and 1.4 (p=0.54) and 2.9 (p=0.10) for the anti-CEP1 
negative group, again showing a stronger association of the SE with the subgroup 
positive for both anti-CCP and anti-CEP1 antibodies.  
Restricting the analysis to HLA-DRB1 *04, the NR cohort showed a significant 
association of having 1 or 2 copies of the SE with the double positives (RRR 5.0; 
p=0.01), but not with the anti-CCP positive but anti-CEP-1 negative group (RRR 2.0; 
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p=0.2). No relationship was found with *01 (RRR of 1.1 and 0.8) whereas this was 
significant in the NOAR cohort but with little difference between the antibody groups. 
Table 3.4 presents data from a case-only analysis of the EIRA cohort, alongside data 
from the NOAR and NR cohorts, and results are shown to be comparable. For these 
analyses OR are derived form logistic regression using the anti-CCP-/anti-CEP-1- 
group as referent. The size of the EIRA cohort allowed HLA-DRB1 *0401 and *0404 
to be analysed separately, demonstrating an OR of 11.4 for any copy of *0401 in the 
double positives compared to 3.2 for the anti-CCP positive but anti-CEP-1 negative 
group. 
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  EIRA (n=836) NR (n=277) NOAR (n=203) 
CEP-1/ 
CCP 
Genotype 1 2 any 1 2 any 1 2 any 
-/- DRB1*SE ref ref ref ref ref ref ref ref ref 
-/+ DRB1*SE 2.1  
(1.3 – 3.4) 
3.6  
(1.8 – 7.1) 
2.4  
(1.5 – 3.8) 
3.3 
(1.5 – 7.0) 
5.0 
(1.8 – 13.7) 
3.7 
(1.8 – 7.5) 
1.7 
(0.6 – 5.4) 
2.9 
(0.8 – 10.4) 
2.1 
(0.7 – 6.1) 
+/+ DRB1*SE 5.4  
(3.3 – 8.9) 
15.6 
(7.9 – 30.9) 
7.0  
(4.4 – 11.1) 
4.3 
(1.7 – 10.6) 
10.0 
(3.4 – 29.6) 
5.6 
(2.4 – 13.1) 
4.0 
(1.1 – 14.3) 
8.6 
(2.1 – 34.6) 
5.6 
(1.7 – 
18.6) 
-/- DRB1*01 ref ref ref ref ref ref ref ref ref 
-/+ DRB1*01 1.9 
(1.0 – 3.6) 
4.1 
(0.6 – 28.9) 
2.2 
(1.1 – 4.2) 
5.2 
(2.1 – 13.1) 
3.6 
(0.2 – 60.8) 
5.1 
(2.1 – 12.6) 
1.5 
(0.3 – 6.8 ) 
………. 1.5 
(0.3 – 6.8) 
+/+ DRB1*01 4.6 
(2.2 – 9.4) 
………. 4.2 
(2.1  - 8.5) 
3.8 
(1.2 – 12.2) 
6.3 
(0.4 – 110.3) 
4.0 
(1.3 – 12.3) 
1.3 
(0.2 – 7.4) 
………. 1.3 
(0.2 – 7.4) 
-/- DRB1*04 ref ref ref ref ref ref ref ref ref 
-/+ DRB1*04 2.3  
(1.4 – 3.8)) 
4.5 
(1.9  - 10.3) 
2.6  
(1.6 – 4.2) 
2.3 
(0.9 – 5.8) 
5.4 
(1.3 – 21.7) 
2.8 
(1.2 – 6.6) 
1.8 
(0.5 – 6.0) 
3.5 
(0.8 – 15.3) 
2.3 
(0.8 – 7.2) 
+/+ DRB1*04 7.6  
(4.6 – 12.6) 
15.4  
(7.0 – 33.7) 
8.8 
(5.4 – 14.3) 
5.0 
(1.8 – 13.5) 
15.6 
(3.9 – 62.0) 
6.8 
(2.7 – 17.2) 
5.1 
(1.3 – 20.0) 
8.5 
(1.7 – 41.5) 
6.3 
(1.8 – 
22.1) 
-/- DRB1*0401 ref ref ref ………. ………. ………. ………. ………. ………. 
-/+ DRB1*0401 3.1  
(1.7 – 5.5) 
3.6 
(1.1 – 11.2) 
3.2  
(1.8 – 5.5) 
………. ………. ………. ………. ………. ………. 
+/+ DRB1*0401 11.4  
(6.5 – 20.2) 
11.0  
(3.8 – 31.6) 
11.4  
(6.5 – 19.7) 
………. ………. ………. ………. ………. ………. 
-/- DRB1*0404 ref ref ref ………. ………. ………. ………. ………. ………. 
-/+ DRB1*0404 3.6  
(1.7 – 7.8) 
………. 3.7  
(1.7 – 8.0) 
………. ………. ………. ………. ………. ………. 
+/+ DRB1*0404 8.4  
(4.1 – 17.5) 
………. 8.8 
(4.3 – 18.1) 
………. ………. ………. ………. ………. ………. 
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Table 3.4. Case only analysis of the association with the HLA-DRB1 ‘shared epitope’ of the anti-CEP-1 positive and negative subsets of 
anti-CCP antibody positive RA, compared with those RA patients negative for both anti-CCP and anti-CEP-1. The associations with the 
HLA-DRB1 ‘shared epitope’ are then broken down into DR1 and DR4 and the results for two individual DR4 alleles, *0401 and *0404, 
are also shown. Results are displayed as odds ratios derived from logistic regression, with 95% confidence intervals in brackets. The 
numbers in row two refer to copies of the shared epitope, with ‘any’ indicating having either 1 or 2 copies. A dotted line represents 
where the sample size was insufficient for analysis. SE=HLA-DRB1 ‘shared epitope.’ Ref.=reference group. EIRA=Epidemiological 
Investigation into Rheumatoid Arthritis cohort. NR=National Repository cohort. NOAR=Norfolk Arthritis Register.
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3.4 Relationship between du Montcel HLA-DRB1 genotypes and 
anti-CEP-1 antibodies.   
3.4.1 Methods 
 
Sera from the NOAR and NR cohorts (section 2.5.1.2) were studied with statistical 
analysis by Dr Darren Plant, University of Manchester. Alleles were classified into du 
Montcel genotypes according to Table 3.5. 
 
3.4.2 Results 
 
RA patients classified according to the du Montcel classification of the SE (see 
Introduction section 1.3.1) as S1 or S3D have been reported to have a lower risk for 
antibodies to CCP2 and citrullinated fibrinogen, whereas S2 or S3P increased the 
risk
237
. We applied this classification to all patients with early inflammatory 
polyarthritis in the NOAR cohort, dividing them into 5 groups: carriers of S1, S2, S3P, 
S3D and X alleles. Following previous studies that used the du Montcel classification, 
we compared carrier frequencies using a dominant effect model. Pearson Chi-squared 
test with 3 degrees of freedom was used and no departures from Hardy-Weinberg 
equilibrium were detected. Results for anti-CCP2 and anti-CEP-1 are shown in Table 
3.6. Similar to Gourraud et al., we found that carriage of S2 or S3P increased the risk 
for anti-CCP2 antibodies (OR 3.45 and 3.93; p<0.001) whereas S1 was protective 
(OR 0.51; p=0.044). No effect, however, was seen with S3D. Different results were 
obtained for anti-CEP-1 antibodies. Only S2 was positively associated (OR 2.31; 
p=0.012) and no effect was seen with S1 or S3P. There was a trend towards a 
protective effect with S3D, although this did not reach statistical significance (OR 
0.18; p=0.102). Results were less significant in the NR cohort due to the very high 
prevalence of SE (data not shown). 
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Du Montcel 
classification 
Amino acids at positions 
70-74 
 HLA-DRB1* alleles 
S1 DERAA 
QARAA 
0103, 0402, 1102, 1103, 
1301, 1302, 1323, 15  
S2 xKRAA 0401, 1303 
S3P QRRAA 
RRRAA 
0101, 0102, 0404, 0405, 
0408, 1001, 1402  
S3D DRRAA 1101, 1104, 12, 16  
 
Table 3.5. The du Montcel classification divides all HLA-DRB1 alleles into 5 
genotypes (S1, S2, S3P, S3D and X) according to the amino acid sequence at 
position 70 to 74. In this model the risk attributed to the RAA sequence at 
position 72 to 74 is modified by amino acids at position 70 (Q and R confer a 
higher risk than D) and 71 (where K confers the highest risk, R an intermediate 
risk and A and E a lower risk)
30
. Alleles were classified according to the above 
table for this study, with all non-listed alleles denoted as X. Amino acid residues 
are shown by their single letter code. 
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 Carrier status Odds Ratio (CI 
95%) 
P 
 Yes No   
SI carrier     
CCP+ve 19 (23) 84 (49) 0.51 (0.27, 0.98) 0.044 
CCP -ve 63 (77) 89 (51)   
CEP1+ve 14 (18) 50 (26) 0.78 (0.38, 1.59) 0.494 
CEP1-ve 63 (82) 143 (74)   
     
S2 carrier     
CCP +ve 42 (56) 61 (34) 3.45 (1.77, 6.71) <0.001 
CCP -ve 33 (44) 119 (66)   
CEP1+ve 28 (36) 36 (19) 2.31 (1.20, 4.41) 0.012 
CEP1-ve 49 (64) 157 (81)   
     
S3P carrier     
CCP +ve 62 (55) 41 (29) 3.93 (2.10, 7.36) <0.001 
CCP -ve 51 (45) 101 (71)   
CEP1+ve 29 (24) 35 (23) 1.16 (0.62, 2.18) 0.639 
CEP1-ve 90 (76) 116 (77)   
     
S3D carrier     
CCP +ve 7 (33) 96 (41) 1.14 (0.40, 3.24) 0.809 
CCP -ve 14 (67) 138 (59)   
CEP1+ve 1 (5) 63 (25) 0.18 (0.02, 1.40) 0.102 
CEP1-ve 20 (95) 186 (75)   
 
Table 3.6. Relationship between du Montcel HLA-DRB1 genotype and anti-CCP 
and anti-CEP-1 antibody positivity. Genotype was determined according to the 
presence of alleles listed in Table 3.5. Odds ratios for being either anti-CCP or 
anti-CEP-1 antibody positive were calculated using Pearson Chi-squared test 
with 3 degrees of freedom. The number of subjects in each analysis, with the 
percentage in brackets, is listed in columns 2 and 3, with a single copy of the 
respective genotype being sufficient to be classed as a carrier. CI = confidence 
interval. 
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3.5 Relationship between anti-CEP-1 and smoking 
 
Previous studies have suggested an intriguing gene-environment interaction between 
smoking and the SE in the generation of anti-CCP antibodies. Smoking data defined 
as never or ever, was available on 195 of the 218 early RA patients in the NOAR 
cohort. The odds ratio for being anti-CEP-1 positive was 1.03 in the smoking group 
(Table 3.2). No statistical interaction with the HLA-DRB1 SE was demonstrable 
using multivariable analysis with an interactive term, with identical odds ratios in 
smokers and non-smokers for both 1 and 2 copies (Table 3.7). No smoking data was 
available for the NR cohort. 
These results are in contrast to those from the EIRA cohort, where a gene-
environment interaction between smoking and the SE was first demonstrated as a risk 
factor for anti-CCP positive RA
239
. The greater number of patients in this cohort 
allowed subdivision into the antibody subgroups and, using a case-control analysis 
with controls selected from the Swedish national population register and matched for 
age, gender and residential area, smoking was only significant as a risk factor for the 
anti-CCP+/anti-CEP-1+ subgroup (OR 2.1; Table 3.8). The effect of smoking 
combined with the SE resulted in a high odds ratio for the anti-CCP+/anti-CEP-1+ 
subgroup of 53, amongst smokers who carried 2 copies of the SE. This is considerably 
larger than the OR of 6 for being anti-CCP positive but anti-CEP-1 negative. The 
presence of a gene-environment biological interaction was supported by calculation of 
an attributable proportion due to interaction that reached 0.71 for smoking and 2 
copies of the shared epitope as risk factors for anti-CCP+/anti-CEP-1+ RA (Table 3.8). 
Attributable proportion refers to the proportion of disease which can be attributed to 
the interaction between 2 risk factors and values greater than 0 provide evidence for 
interaction on an additive scale. 
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Logistic regression of anti-CEP-1 antibody positivity.  
n=195 HLA-SE 0 copy HLA-SE 1 copy HLA-SE 2 copies 
Never smoke Referent 1.15 (0.35, 3.80) 2.68 (0.60, 12.05) 
Ever smoke 0.44 (0.12, 1.65) 1.21 (0.40, 3.68) 2.47 (0.72, 8.49) 
 
Table 3.7. Multivariate analysis of smoking and HLA-SE using an interactive 
term in predicting anti-CEP-1 antibody positivity in the NOAR cohort. Values 
are odds ratios (95% confidence interval). HLA-SE = HLA-DRB1 ‘shared 
epitope’. 
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Smoking 
CEP-1 / 
CCP 
risk factor case/control OR 95% CI 
- /- No smoke 64 / 347 1.0 ref. 
- /- smoke 114 /525 1.3 0.9 – 1.8 
- / + No smoke 87 / 347 1.0 ref. 
- / + smoke 148 / 525 1.2 0.9 – 1.6 
+ / + No smoke 101 / 347 1.0 ref. 
+ / + smoke 322 / 525 2.1 1.6 – 2.8 
Smoking – HLA-DRB1*SE 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
- / - No smoke 0 SE 28 / 154 1.0 ref. 
- / - No smoke 1 SE 27 / 150 1.0 0.6 – 1.8 
- / - No smoke 2 SE 9 / 43 1.2 0.5 – 2.7 
- / - smoke 0 SE 48 / 260 1.1 0.6 – 1.9 
- / - smoke 1 SE 52 / 223 1.4 0.8 – 2.3 
- / - smoke 2 SE 14 / 42 2.0 0.9 – 4.2 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
- / + No smoke 0 SE 27 / 154 1.0 ref. 
- / + No smoke 1 SE 38 / 150 1.5 0.9 – 2.7 
- / + No smoke 2 SE 22 / 43 2.9 1.5 – 5.7 
- / + smoke 0 SE 28 / 260 0.7 0.4 – 1.2 
- / + smoke 1 SE 81 / 223 2.2 1.3 – 3.6 
- / + smoke 2 SE 39 / 42 6.0 3.2 – 11.1 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
+ / + No smoke 0 SE 9 / 154 1.0 ref. 
+ / + No smoke 1 SE 59 / 150 6.9 3.3 – 14.6 
+ / + No smoke 2 SE 33 / 43 13.8 6.1 – 31.5 
+ / + smoke 0 SE 35 / 260 2.3 1.1 – 5.0 
+ / + smoke 1 SE 167 / 223 13.8 6.8 – 28.2 
+ / + smoke 2 SE 120 / 42 53.0 24.4 – 
115.0 
Interaction analysis smoking – HLA-DRB1*SE 
CEP-1 / 
CCP 
Interaction factor SE status AP 95% CI 
- / - smoke 1 SE 0.2 -0.36 – 0.76  
- / + smoke 1 SE 0.45 0.08 – 0.82 
+ / + smoke 1 SE 0.40 0.19 – 0.62 
- / - smoke 2 SE 0.37 -0.27 – 1.0 
- / + smoke 2 SE 0.57 0.23 – 0.91 
+ / + smoke 2 SE 0.71 0.55 – 0.88 
 
Table 3.8  
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Table 3.8. Association of smoking with anti-CEP-1 antibodies and the interaction 
between smoking and the HLA-DRB1 ‘shared epitope’ (SE) in the EIRA cohort. 
A case-control analysis was used with controls selected from the Swedish 
national population register and matched for age, gender and residential area. 
ELISAs were performed by Hiba Mahdi and statistical analysis by Dr Henrik 
Källberg, both of the Karolinska Institutet, Sweden. The early RA cohort is 
subdivided according to positivity for anti-CCP and anti-CEP-1 antibodies, 
detailed in the left-hand column. The risk factors being assessed in each analysis 
are recorded in the second column. OR = odds ratio; CI = confidence interval; 
AP = attributable proportion due to interaction. Ref. = reference group.
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3.6 Relationship with PTPN22.  
 
The tyrosine phosphatase PTPN22 R620W allele has been associated with RA and in 
particular the subsets positive for RF or anti-CCP
247 406
. PTPN22 data was available 
for 184 of the NR cohort; 125 with no copies of R620W, 57 with 1 copy and 2 with 2 
copies. No statistically significant association with anti-CEP-1 antibody levels was 
seen in this population (Table 3.9). 
Logistic regression in the EIRA cohort showed that PTPN22 only conferred an 
increased risk for the anti-CCP+/anti-CEP-1+ subgroup (OR 1.8; Table 3.10). Gene-
gene interaction between PTPN22 and the HLA-DRB1 SE was notably greater in the 
anti-CEP-1+/anti-CCP+ group (OR 17.8), compared to the anti-CEP-1-/anti-CCP+ 
group (OR 4.6) and calculation of the attributable proportion provided further 
evidence of departure from additivity and therefore biological interaction (AP 0.57 for 
the anti-CEP-1+/anti-CCP+ subgroup; Table 3.10). The interaction between the HLA-
DRB1 SE, the PTPN22 risk allele and smoking as risk factors for the different 
subgroups of RA in the EIRA cohort is expressed graphically in Figure 3.2. 
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A 
 
PTPN22 copy 
number 
Mean Anti-CEP-1 
Antibody Level 
SD Freq. 
0 copy 973 2059 124 
1 copy 2278 4851 57 
2 copy 526 575 2 
Total 1375 3238 183 
Kruskal-Wallis test: chi-squared = 0.224 with 2 degrees of freedom, p = 0.89. 
 
B 
 
Table 3.9. A, relationship between the copy number of the PTPN22 R620W allele 
and anti-CEP-1 antibody level. B, statistical comparison of differences in anti-
CEP-1 antibody level. P values were calculated using the Mann-Whitney test. SD 
= standard deviation. 
 1  PTPN22  copy 2  PTPN22  copy 
0  PTPN22   copy p=0.95 p=0.27 
1  PTPN22   copy  p=0.89 
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PTPN22 
CEP-1 / 
CCP 
risk factor case/control OR 95% CI 
- /- No PTPN22 129 / 614 1.0 ref. 
- /- PTPN22 48 / 179 1.3 0.9 – 1.9 
- / + No PTPN22 150 / 614 1.0 ref. 
- / + PTPN22 54 / 179 1.3 0.9 – 1.8 
+ / + No PTPN22 258 / 614 1.0 ref. 
+ / + PTPN22 131 / 179 1.8 1.4 – 2.4 
PTPN22 – HLA-DRB1*SE 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
- / - No PTPN22 0 SE 51 / 284 1.0 ref. 
- / - No PTPN22 1 or 2 SE 78 / 330 1.3 0.9 – 1.9 
- / - PTPN22 0 SE 24 / 95 1.3 0.7 – 2.2 
- / - PTPN22 1 or 2 SE 24 / 84 1.8 1.0 – 3.1 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
- / + No PTPN22 0 SE 34 / 284 1.0 ref. 
- / + No PTPN22 1 or 2 SE 116 / 330 3.0 2.0 – 4.6 
- / + PTPN22 0 SE 10 / 95 0.9 0.4 – 2.0 
- / + PTPN22 1 or 2 SE 44 / 84 4.6 2.7 – 7.8 
CEP-1 / 
CCP 
risk factor 
1 
risk factor 
2 
case/ control OR 95% CI 
+ / + No PTPN22 0 SE 28 / 284 1.0 ref. 
+ / + No PTPN22 1 or 2 SE 230 / 330 7.5 4.8 – 11.5 
+ / + PTPN22 0 SE 11 / 95 1.2 0.5 – 2.4 
+ / + PTPN22 1 or 2 SE 120 / 84 17.8 10.8 – 29.3 
Interaction analysis PTPN22 – HLA-DRB1*SE 
CEP-1 / 
CCP 
Interaction factor SE status AP 95% CI 
- / - PTPN22 1 or 2 SE 0.11 -0.48 – 0.71 
- / + PTPN22 1 or 2 SE 0.32 -0.01 – 0.65 
+ / + PTPN22 1 or 2 SE 0.57 0.41 – 0.73 
 
Table 3.10. Case-control analysis of the association with PTPN22, and the 
interaction between PTPN22 and HLA-DRB1*SE, of the three main anti-CCP 
and anti-CEP-1 antibody subgroups in the EIRA cohort. The number of cases 
and controls for each analysis is detailed in the third column. ELISAs were 
performed by Hiba Mahdi and statistical analysis by Dr Henrik Källberg, both 
of the Karolinska Institutet, Sweden.  OR = odds ratio. CI = confidence interval. 
ref. = reference group. PTPN22 = 620 W risk allele of PTPN22. SE = HLA-DRB1 
‘shared epitope’ copy number. AP = Attributable proportion due to interaction. 
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Figure 3.2. Odds ratios, derived by logistic regression, for the three main RA 
subsets in the EIRA cohort defined by anti-CCP and anti-CEP-1 antibodies: a) 
CEP-1-/CCP-, b) CEP-1-/CCP+ and c) CEP-1+/CCP+, in relation to the HLA-
DRB1 ‘shared epitope’, the 620W risk allele of PTPN22 and respectively 
cigarette smoking (ever / never). The combined effect of the three risk factors 
was strongest for the CEP-1+/CCP+ subset. OR = odds ratio. PTPN22 = 620 W 
risk allele of PTPN22. SE = HLA-DRB1 ‘shared epitope’ copy number. Figure 
generated by Dr Henrik Källberg, of the Karolinska Institutet, Sweden.   
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3.7 Identification of bromodomain containing 2 (BRD2) as an MHC 
gene independently associated with the anti-CEP-1 and anti-CCP 
antibody positive subgroup  
3.7.1 Method 
 
Dense single nucleotide polymorphisms (SNP) mapping of the MHC region has 
previously demonstrated genes, independent of HLA-DRB1, that are associated with 
anti-CCP antibody positive RA whereas none were found for the anti-CCP negative 
subset
46
. To investigate such associations with the anti-CEP-1/anti-CCP antibody 
subsets, available data from the EIRA cohort on a total of 2221 different SNPs 
locating to the MHC region between 6p22.2 and 6p21.31 was used. This data was 
derived using the Illumina Golden Gate assay and the Illumina Human Hap300 v1.0 
chip. Statistical analyses were undertaken by Dr Bo Ding. Unconditional logistic 
regression analysis was used to adjust for linkage disequilibrium with HLA-DRB1 by 
dividing the „shared epitope‟ alleles into 7 categories according to the strength of odds 
ratios for anti-CCP positive RA
46
.  
 
3.7.2 Results 
 
Data was available for 162 patients negative for both anti-CEP-1 and anti-CCP 
antibodies, 173 anti-CEP-1-/anti-CCP+ patients, 336 „double positives‟ and 631 
healthy controls. After adjusting for HLA-DRB1 alleles, 61 SNPs were found to be 
associated with the anti-CEP-1+/anti-CCP+ subset and no associations were found 
with the other 2 subsets. After Bonferroni correction, 3 SNPs remained significant 
(Table 3.11) and all were in the region of the Bromodomain-containing protein 2 
(BRD2) locus. 
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SNP Odds Ratio (95% CI) p-value 
rs6936967 0.51 (0.37-0.70) 3.74x10
-5
 
rs439852 0.51 (0.37-0.70) 3.76x10
-5
 
rs1049414 0.56 (0.42-0.75) 1.71x10
-4
 
 
Table 3.11. Single nucleotide polymorphisms (SNPs) in the MHC region 
associated with anti-CEP-1 positive/anti-CCP positive RA, statistically 
significant after Bonferroni correction and independent of the HLA-DRB1 
alleles. Data was derived using unconditional logistic regression by Dr Bo Ding. 
All SNPs are in the region of the Bromodomain-containing protein 2 (BRD2) 
locus. CI=confidence interval. 
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3.8 Discussion 
 
To help determine if antibodies to CEP-1 define a distinct subgroup of patients, we 
investigated whether they had any association with the major genetic and 
environmental risk factors, previously identified as associating with anti-CCP positive 
disease. Firstly, we found that antibodies to the immunodominant epitope of α-enolase, 
CEP-1, are associated with the SE. This would be consistent with citrullinated α-
enolase being a genuine autoantigen in RA. Interestingly, in both early and 
established RA, the relationship between anti-CCP2 antibodies and the SE appears 
stronger in the group which is also anti-CEP-1 antibody positive when compared with 
those that are anti-CEP-1 antibody negative. Similar to that reported with anti-CCP2, 
the effect is dominant and influences the magnitude of the response with higher titres 
in the SE-positive group
235
. Such a relationship has not been demonstrated for all 
antibodies to citrullinated peptides. Verpoort et al demonstrated an association with 
antibodies to a dominant citrullinated peptide from vimentin but not fibrinogen
200
.   
 
Patients who are anti-CCP2 antibody positive but lack the SE tend to have less erosive 
disease
404
. The suggested explanation for this finding is that these patients have lower 
levels of anti-CCP2 antibody. Amongst patients with undifferentiated arthritis, those 
with anti-CCP2 antibodies who smoke have a greater risk of progression to RA when 
compared with those who are anti-CCP2 positive but non-smokers. Again, the 
proposed explanation for the increased risk of progression in those who smoke is that 
these patients have higher levels of anti-CCP2 antibodies
245
. If some antibodies to 
citrullinated proteins/peptides have a stronger association with the shared epitope and 
with smoking, then it is possible that the explanation for all these findings may relate 
to antigen specificity rather than antibody levels detected by the anti-CCP2 ELISA.  
 
Secondly, we have shown that the relationship between anti-CEP-1 antibodies and the 
SE is due to HLA DR4 SE alleles and not DR1. Although the original SE hypothesis 
does not distinguish between DR4 and DR1, both *0101 and *0102 are associated 
with milder disease
29
. Furthermore, using the du Montcel classification of the SE, we 
have demonstrated that the relationship between predisposing and protective 
genotypes in the NOAR cohort differs between anti-CCP2 and anti-CEP-1 antibodies. 
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Both S2 and S3P are associated with anti-CCP2, but only the former (representing 
*0401 and *1303) with anti-CEP1. This genotype is especially associated with erosive 
progression
36 407
. This would be consistent with the anti-CCP2 assay detecting 
antibodies to more than one true autoantigen. An association with the S3P allele 
*0404 and anti-CEP-1 antibodies was demonstrated in the EIRA cohort, however in 
the du Montcel classification this is grouped together with a number of other alleles 
which may explain why no association is demonstrated. Interestingly, whilst S1 is 
protective against anti-CCP2 antibodies, no effect is demonstrated with anti-CEP-1. 
Conversely, for anti-CEP-1 there is a trend towards protection with S3D (DRRAA) 
when no effect is demonstrated in this cohort for anti-CCP2. Analysis of further 
samples would be required to determine if this is a real difference, although proving 
protection is difficult
37
. If it exists, the mechanism for such protection is unknown but 
could involve induction of anergy or regulatory T cells, negative selection of T cells, 
or T cell receptor antagonism
42
. It is important to note that the type of carrier analysis 
we used when analysing the du Montcel genotypes could introduce bias by 
overestimating or underestimating the effect of individual genotypes. The size of the 
S2 effect for example, would depend on the prevalence of S3D or S3P carriers in the 
control group
237
. An advantage of our study over that of Gourraud et al‟s237 is that we 
used Pearson Chi –squared test with 3 degrees of freedom, so reducing the problems 
implicit with multiple testing. Non-inherited maternal HLA-DRB1 alleles can also 
have predisposing
40
 or protective effects
41
 on RA and their influence on the results has 
not been considered in this study.  
   
The third finding regards the association with PTPN22. The R620W allele of the 
protein tyrosine phosphatase PTPN22 has been associated with anti-CCP antibody 
positive RA
247 408-410
. We were unable to replicate this finding in the NR cohort 
although this may be due to the high frequency of anti-CCP2 positivity in the cohort 
tested. This would not explain the lack of association with anti-CEP-1 however. 
Interestingly, in the EIRA data presented, a relationship with anti-CCP and anti-CEP-
1 antibodies was only demonstrated in the presence of the SE, suggesting a gene-gene 
interaction between the R620W allele of PTPN22 and the SE.  
 
Fourthly, we have presented divergent evidence on the effect of smoking. The 
remarkable interaction between smoking and the SE has been described in studies 
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from Northern Europe
239-241
 but not in a North American study
242
. The latter study 
considered greater air pollution as a possible confounding factor, explaining the lack 
of any observed interaction with smoking. Other explanations have been discussed 
above (see introduction section 1.2.4.4.3) and these could be factors in the lack of 
interaction seen in the NOAR cohort, but it is also important to note that due to 
limited sample size, no subdivision of the anti-CCP positive patients into anti-CEP-1 
antibody positive and negative was undertaken.  Furthermore, smoking data was 
limited and we were not able to stratify according to number of cigarettes smoked or 
pack-years. It is therefore possible that we might have missed an effect in heavy 
smokers. Confounding may also arise if the antigen specificities of antibodies 
detected by the anti-CCP2 assay vary between populations, due to differences in other 
genetic or environmental risk factors. In the larger EIRA dataset, a gene-environment 
interaction between smoking and the SE was demonstrated, and which was strongest 
in the subset of patients positive for both anti-CCP and anti-CEP-1 antibodies. This is 
of particular interest since this cohort provided the original evidence, and still the 
strongest, in support of an interaction between smoking and the SE in the generation 
of anti-CCP antibodies. 
 
Assessment of interaction has been a controversial topic in epidemiology. A 
distinction can be made between „statistical‟ interaction, which is defined as the 
requirement for a product term in a linear model
411, and „biological‟ interaction. The 
latter is defined as „the interdependent operation of two or more causes to produce 
disease‟412. Consequently, if there is no pathway to disease that involves both factors 
under consideration they would be considered independent
411
. Many epidemiologists 
believe that departure from additivity, rather than departure from multiplicativity, is 
the appropriate model for testing biological interaction
411
. Departure from additivity 
was the model used for assessing interaction in the EIRA cohort. A positive test for 
interaction on an additive but not on a multiplicative model can occur as departure 
from additivity is more sensitive. Alternatively, this situation may arise if biological 
interaction is taking place at the same step of an aetiological pathway rather than at 
different steps of a multistep process
412
. Although EIRA is a case-control study and 
outcomes are measured in odds ratios, the attributable proportion, which estimates the 
proportion of disease due to interaction between the risk factors under consideration, 
can still be used when the odds ratios approximate the relative risk ratio
413
. This is the 
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case in the EIRA cohort as the incidence of outcome, i.e. rheumatoid arthritis, in the 
source population is low. When odds ratios are substituted for relative risk ratios, the 
attributable proportion is more robust than other measures for departure from 
additivity
413
. 
 
The fifth finding was a novel gene association with the subgroup in the EIRA cohort 
positive for both anti-CEP-1 and anti-CCP antibodies. The gene encoding BRD2 has 
not previously been linked to RA, although an association with SNPs in the promoter 
region and juvenile myoclonic epilepsy has been reported
414
. A bromodomain is a 
conserved 110 amino acid sequence found in a group of proteins that regulate signal-
dependent transcription during cell proliferation, the over-expression of which has 
been linked to some cancers
415
. Brd2 contains 2 bromodomains, localises in the 
nucleus of proliferating cells, binds to hyperacetylated chromatin and facilitates 
transcription
416
. It also has protein kinase activity
417
. Brd2 remains bound to 
chromatin during mitosis and so may influence epigenetic inheritance
418
 
(transcriptional memory across cell divisions). Brd2 regulates cell cycle genes 
involved in G1 entry
416 419
 but may also have a role in apoptosis
415
. Brd2 is essential 
for embryo survival
420 421
. Given the complexity of the HLA-DRB1 locus, it is 
possible that confounding may still exist. This might be particularly so since these 
SNPs are associated with „protection‟, and the classification used for the 
unconditional logistic regression places the du Montcel S3D genotype, which may be 
associated with a lower risk of anti-CEP-1 antibodies, in several classes.  A solution 
to this would be to use conditional logistic regression on case-control pairs matched 
for identical HLA-DRB1 genotypes. However this would limit statistical power 
particularly in a sample of this size. Replication in a larger cohort is therefore required.  
 
In conclusion, we have demonstrated that anti-CEP-1 antibodies are associated with 
the DR4 SE, and that the association of anti-CCP antibodies with the shared epitope is 
strongest in the subgroup that is also positive for anti-CEP-1 antibodies. The gene-
gene and gene-environment interactions in the EIRA cohort are also most prominent 
in this subset suggesting that anti-CEP-1 antibodies may give some insight into 
aetiology. In healthy subjects, smoking upregulates PAD2 expression and 
citrullination within bronchoalveolar lavage cells
422
, although this is harder to detect 
in lung tissue due to background physiological citrullination
422 423
. If CEP-1 binds 
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preferentially to HLA-DRB1*04, then citrullination of enolase in the context of 
smoking would increase the opportunity for induction of immunity. Another 
hypothesis is that anti-CEP-1 antibodies arise through similarity in the peptide 
sequence between human and bacterial enolase leading to the breaking of tolerance. 
There is current interest in periodontitis, and in particular P. gingivalis, as a possible 
aetiological factor in RA
92
. Smoking is a known risk factor for periodontitis
424
 and 
sequence identity between P. gingivalis  and human enolase at peptide 1 is  82%, and 
100% when restricted to the 9 amino acids (amino acids 13-21) around the two 
arginine residues
399
. 
 
The gene-gene and gene-environment interactions we have presented are consistent 
with citrullinated α-enolase being a genuine autoantigen in RA although they are not 
evidence of pathogenicity, as conceivably anti-CEP-1 may segregate with other 
antibodies to citrullinated proteins and a bystander effect is not ruled out. However, 
longitudinal studies examining clinical measures and erosive change would be of 
interest. 
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CHAPTER 4: ANTI-CEP-1 ANTIBODIES IN RELATION TO 
CLINICAL OUTCOMES AND RESPONSE TO ANTI-TNF 
BIOLOGICS 
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4.1 Introduction 
 
Anti-CCP antibodies have established themselves as useful biomarkers in rheumatoid 
arthritis. They predict the development of rheumatoid arthritis in patients with early 
undifferentiated arthritis
162-164
. In established RA they predict a more severe disease 
course with greater disease activity
165 167
 and development of erosions
166 167 309 425 426
. 
They may also be associated with extra-articular manifestations
427 428
 although this is 
more controversial
165 429
. They may also be predictive of a poorer response to anti-
TNF
362
. Anti-CEP-1 antibodies define a subset of anti-CCP antibody positive patients 
preferentially associated with the most important genetic and environmental risk 
factors for RA described to date, namely the HLA-DRB1*04 alleles, the PTPN22 
R620W allele and smoking, although the latter 2 factors were only associated in the 
EIRA cohort. Analysis of the EIRA cohort also suggested a significant gene-
environment interaction associated with this subset. This implies that distinct 
pathogenic pathways may operate within this subset of patients and so we examine in 
this chapter whether anti-CEP-1 antibodies also define a clinical phenotype, by 
exploring relationships with disease activity, disability, erosions and responsiveness to 
anti-TNF. 
 
 
4.2 Clinical, functional and radiological outcomes 
4.2.1 Methods 
4.2.1.1 Patients 
 
Sera from 408 patients in the NOAR cohort (section 2.5.1.2), recruited between 
January 2000 and November 2004 and fulfilling ACR classification criteria for RA 
within 3 years of enrolment, were available for analysis. A second cohort consisting 
of 272 patients with early RA of less than 12 months duration and fulfilling the ACR 
classification criteria, were recruited at Karolinska University Hospital, Stockholm 
between January 1995 and October 2000 as previously described
430
. Evaluations 
included baseline joint counts, ESR, CRP, visual analogue scales for pain and global 
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assessment of disease activity (not in NOAR), the Health Assessment Questionnaire 
(HAQ)
306
 for measuring disability, and radiographs of the hands and feet. A 28 joint 
count was used for the Karolinska cohort and 28 and 51 joint counts in NOAR. 
Physician assessment on a 0-4 scale was also collected for the Karolinska cohort. 
Additional clinical measurements were made at 3 months and 1, 2, 3 and 5 years for 
the Karolinska cohort, with X-rays repeated at 1 and 2 years. More limited follow-up 
data collected in the NOAR cohort consisting of 51-joint counts and HAQ at 1, 2, 3 
and 5 years with repeat CRP at 5 years and repeat X-rays for a subset at 1 year. Both 
studies were approved by local research ethics committees. 
 
4.2.1.2 Anti-CCP and anti-CEP-1 antibodies, RF and HLA typing (NOAR) 
 
The presence of anti-CCP antibodies was determined using second-generation assays; 
Immunoscan RA (Eurodiagnostica, Malmo, Sweden) for the Karolinska cohort and 
DIASTAT (Axis-Shield, Dundee, UK) for NOAR. For measurement of anti-CEP-1 
antibodies, sera were tested using the quantitative anti-CEP-1 antibody ELISA 
described in section 2.5.1.1. A positive and negative control was included on each 
plate. The cut-off for positive samples was based on the 95
th
 percentile of 100 
Swedish healthy control sera for the Karolinska cohort and 136 healthy control sera 
for NOAR. Anti-CEP-1 antibody ELISAs for the Karolinska cohort were run by 
Monica Brode and Linda Björk. For the NOAR cohort, HLA typing was as described 
in section 3.2.1 and an immunoturbidimetric assay (RF-PAIA, Orion Diagnostica, 
Espoo, Finland) was used to detect IgM RF. These assays were undertaken in the arc 
Epidemiology Unit laboratory at Manchester University. 
 
4.2.1.3 Radiographs 
 
For NOAR, radiographs of the hands and feet were scored using the Larsen score as 
previously described
431
. The total possible score was 190. For the Karolinska cohort, a 
modified Larsen score which excluded grade 1 and had a maximum score of 160 was 
used as previously described
430
. 
 
Chapter 4              Anti-CEP-1 and clinical outcomes 
143 
 
4.2.1.4 Statistics 
 
Comparisons between groups were analysed with the Mann-Whitney test or, if 
normally distributed, a two-sample T test for normally distributed data. For 
differences in proportions, the chi-square or Fisher‟s exact tests were used. Logistic 
regression was employed for predictions of HAQ scores greater than 1 and erosions in 
the NOAR cohort. Other statistical methodology is described as it arises in the text. P 
values less than 0.05 were considered significant. Statistical analyses for the NOAR 
cohort were undertaken by Dr Darren Plant, Manchester University.  Those for the 
Karolinska cohort were undertaken by Dr Johan Rönnelid 
 
4.2.2 Results 
4.2.2.1 Baseline characteristics 
 
In the Karolinska University Hospital cohort, 57.4% were anti-CCP antibody positive 
and 27.2% had anti-CEP-1 antibodies. This compared with 50% and 24% respectively 
in the NOAR cohort. Most patients with anti-CEP-1 antibodies were also anti-CCP 
positive (92% in Karolinska, 85% in NOAR). Baseline demographics of patients with 
anti-CEP-1 antibodies were similar to those without, with the exception that, in the 
Karolinska cohort, patients with anti-CEP-1 antibodies had a younger median age and 
longer disease duration at baseline (Table 4.1).  Both anti-CCP2 and RF occurred 
more commonly in the anti-CEP-1 positive population, and in the NOAR cohort, CRP 
and DAS28(CRP) scores were significantly higher (Table 4.1). Overall, DAS-28 
scores were lower in NOAR which reflects this being an early, primary care-based 
cohort. However the calculation was not entirely comparable, with the NOAR cohort 
utilising CRP and a 3 variable formula, instead of the more usual 4 variable formula 
incorporating ESR. At baseline in the Karolinska cohort, 45% of anti-CEP-1 antibody 
positive patients were treated with sulfasalazine, 21%  methotrexate, 12% another 
DMARD and 22% no DMARD, compared to 45%, 25%, 16% and 13% (p=0.09) 
respectively for those without anti-CEP-1 antibodies. Six patients in the Karolinska 
cohort were found to have higher OD values with the arginine-containing control 
peptide when compared with the citrulline-containing CEP-1 peptide and were 
excluded from further analysis.
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 Karolinska NOAR 
 anti-CEP-
1 negative 
n=199 
anti-
CEP-1 
positive 
n=73 
p-value anti-CEP-
1 negative 
n=310 
anti-CEP-
1 positive 
n=98 
p-value 
Age 
(years) 
58 
(48,72) 
53 
(44,60) 
0.0034 58  
(49,68) 
58  
(49,66) 
0.66 
Female: 
number 
(%) 
140  
(70%) 
52  
(71%) 
†NS 215 
(69.4%) 
70 
(71.4%) 
†0.80 
Disease 
duration 
(months) 
5.0 
(3.0, 7.0) 
6.0 
(4.0, 8.7) 
0.0094 - - - 
CRP 14.0 
(7.0,30.0) 
16.0 
(7.0, 
32.5) 
NS 9.9 
(3.6,20.0) 
15  
(8,26.2) 
0.0016 
ESR 20 
(10,40) 
23 
(15, 39) 
NS 37  
(17,52) 
29 
(18,49.5) 
0.67 
Swollen 8 
(5,13) 
10 
(6, 15) 
NS 5  
(2,9) 
5  
(2,13) 
0.38 
Tender 7 
(4,13) 
7 
(4,11) 
NS 6  
(2,16) 
6.5  
(2,18) 
0.59 
DAS-28: 
mean 
(SD)§ 
5.03 
(1.18) 
 
5.08 
(1.00) 
‡NS 3.88  
(1.22) 
4.17  
(1.29) 
‡0.03 
Global 
VAS 
44 
(19,68) 
47 
(26,60) 
NS - - - 
VAS pain 45 
(25,66) 
47 
(25,62) 
NS 47  
(24,60) 
49  
(20,61) 
0.82 
Physician‟s 
assessment 
2 
(2,3) 
2 
(2,3) 
NS - - - 
HAQ 0.88 
(0.63, 
1.38) 
1.00 
(0.50, 
1.38) 
 
NS 1.0 
(0.50,1.88) 
1.25 
(0.63,1.88) 
0.36 
RF+ 104/197 
(52.8%) 
66/73 
(90.4%) 
†<0.0001 124/309 
(40.1%) 
72/97 
(74.2%) 
†<0.0001 
CCP2+ 88/199 
(44.2%) 
68/73 
(93.2%) 
†<0.0001 88/296 
(29.7%) 
82/97 
(84.5%) 
†<0.0001 
 
 
 
 
Table 4.1 
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Table 4.1. Baseline characteristics for the 272 patients with RA in the Karolinska 
cohort and the 408 NOAR subjects who fulfilled ACR classification criteria for 
RA by 3 years, divided according to anti-CEP-1 antibody status. All results are 
median (IQR) except where specified. Statistical analysis was with the Mann-
Whitney or *Fishers exact/Chi square or **Two-sample t tests. § DAS28(CRP) 
used for NOAR. Age refers to age at symptom onset for the NOAR cohort and 
age at enrolment for the Karolinska cohort. NS=statistically non-significant 
(p>0.05) 
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4.2.2.2 Clinical characteristics over time 
 
Clinical outcomes according to anti-CEP-1 antibody status were initially similar in the 
Karolinska cohort but with a late divergence leading to significantly higher average 
scores at 3 and 5 years for physician‟s assessment (p=0.02 and 0.03) and swollen joint 
count (p=0.007 and 0.001), and a trend for tender joint count (p=0.02 and 0.06), in 
patients with anti-CEP-1 antibodies (Figure 4.1). Much more significant differences 
were noted in these measures, as well as in DAS-28 scores, when comparing subjects 
with anti-CEP-1 antibodies to those negative for both anti-CEP-1 and anti-CCP 
antibodies (Figure 4.2). This is unsurprising since anti-CCP antibodies are associated 
with poorer outcome and almost all patients with anti-CEP-1 antibodies also have 
anti-CCP antibodies. The higher CRP seen with anti-CEP-1 antibodies at baseline in 
the NOAR cohort was also seen at 5 years, and borderline significant lower tender 
joint counts were seen at 1 and 3 years (Table 4.2).  
 
Given the strong gene-environment interaction associated with the subset of RA 
patients positive for both anti-CEP-1 and anti-CCP antibodies, the cohorts were 
divided into three subpopulations: anti-CEP-1-/anti-CCP-, anti-CEP-1-/anti-CCP+ 
and anti-CEP-1+/anti-CCP+. A fourth fraction, anti-CEP-1+/anti-CCP-, was too small 
for statistical analysis and was not considered further. No statistically significant 
difference was demonstrated between the anti-CEP-1 positive and negative subsets of 
the anti-CCP positive group in the Karolinska cohort (Figure 4.3). Similarly there was 
no difference between these subsets in the NOAR cohort (Table 4.3 for baseline 
characteristics and Table 4.4 for follow-up data) although there was a trend towards 
higher CRP, DAS28(CRP) and RF positivity in the anti-CEP-1+/anti-CCP+ subset.  
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Figure 4.1. Comparison of mean clinical indices over time between patients with 
anti-CEP-1 antibodies (anti-CEP-1+) and those without (anti-CEP-1-) in the 
whole Karolinska early rheumatoid arthritis cohort (n=267; 68 anti-CEP-1 
antibody positive, 199 anti-CEP-1 antibody negative). *p<0.05; **p<0.01; 
***p<0.001. CRP=C-reactive protein. ESR=Erythrocyte sedimentation rate. 
VAS=visual analogue scale (0-100). Global VAS is a patient measure of their 
disease activity. HAQ=Health Assessment Questionnaire. Physician’s assessment 
measured on a 0-4 scale. DAS28=Disease Activity Score-28. mo=months; 
yrs=years. 
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Figure 4.2. Comparison of mean clinical indices over time between patients with 
anti-CEP-1 antibodies (anti-CEP-1+) and those without both anti-CCP 
antibodies and anti-CEP-1 antibodies i.e. ‘double negatives’ (CEP-1-/CCP-) in 
the Karolinska early rheumatoid arthritis cohort (n=179; 68 anti-CEP-1 
antibody positive, 111 ‘double negative’). *p<0.05; **p<0.01; ***p<0.001. 
CRP=C-reactive protein. ESR=Erythrocyte sedimentation rate. VAS=visual 
analogue scale (0-100). Global VAS is a patient measure of their disease activity. 
HAQ=Health Assessment Questionnaire. Physician’s assessment measured on a 
0-4 scale. DAS28=Disease Activity Score-28. mo=months; yrs=years.  
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Figure 4.3. Comparison of mean clinical indices over time between the three 
fractions of RA defined by anti-CEP-1 and anti-CCP2 antibodies in the 
Karolinska early rheumatoid arthritis cohort (n=111 CEP-1-/CCP2-, n=88 CEP-
1-/CCP2+ and n=62 CEP-1+/CCP2+). A fourth fraction, CEP-1+/CCP2-, was too 
small for analysis and is not shown. Statistical comparisons were performed at 
each time point using the Mann Whitney test. Asterisks denote statistically 
significance differences between the anti-CEP-1-/anti-CCP2- and the anti-CEP-
1+/anti-CCP2+ subsets.  No significant differences were found between the anti-
CEP-1-/anti-CCP2+ and the anti-CEP-1+/anti-CCP2+ subsets. *p<0.05; 
**p<0.01; ***p<0.001. CRP=C-reactive protein. ESR=Erythrocyte 
sedimentation rate. VAS=visual analogue scale (0-100). Global VAS is a patient 
measure of their disease activity. HAQ=Health Assessment Questionnaire. 
Physician’s assessment measured on a 0-4 scale. DAS28=Disease Activity Score-
28. mo=months; yrs=years. 
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Swollen 
Joint 
Count 
Baseline Year 1 Year 2 Year 3 Year 5 
CEP-1- 5 (2,9) 3 (0,8) 3 (0,6) 2 (0,6) 2 (0,5) 
CEP-1+ 5 (2,13) 
p=0.38 
3 (1,6) 
p=0.93 
2 (1,5) 
p=0.23 
1.5 (0,4.5) 
p=0.12 
2 (0,6) 
p=0.88 
Tender 
Joint 
Count 
     
CEP-1- 6 (2,16) 5 (1,16) 5 (1,18) 6 (1,22) 5 (1,16) 
CEP-1+ 6.5 (2,18) 
p=0.59 
3 (1,9) 
p=0.04 
4 (0,12) 
p=0.10 
3 (0.5,12.5) 
p=0.03 
3 (1,13) 
p=0.51 
HAQ      
CEP-1- 1.00  
(0.50,1.88) 
1.00 
(0.38,1.75) 
1.13 
(0.38,1.88) 
1.25 
(0.50,1.88) 
1.25 
(0.50,2.13) 
CEP-1+ 1.25 
(0.63,1.88) 
p=0.36 
1.06 
(0.50,1.63) 
p=0.96 
0.13 
(0.38,1.69) 
p=0.87 
1.13 
(0.38,1.81) 
p=0.73 
1.44 
(0.19,1.75) 
p=0.44 
CRP      
CEP-1- 9.9 (3.6,20) - - - 10.8 
(4.9,17.7) 
CEP-1+ 15.0 
(8.0,26.2) 
p=0.0016 
- - - 16 
(8.9,28.2) 
p=0.002 
 
Table 4.2. Comparison between anti-CEP-1 antibody positive (CEP-1+) and 
negative (CEP-1-) patients in the NOAR cohort. Longitudinal data was only 
available for 51 joint counts, HAQ scores and CRP (measured at baseline and 5 
years only). Data are medians (IQR) compared with the Mann Whitney test. 
N=408. Ref. = referent. 
Chapter 4              Anti-CEP-1 and clinical outcomes 
151 
 
 
 CEP-1-/CCP- CEP-1-/CCP+ CEP-
1+/CCP+ 
Difference 
between 
CCP+ subsets 
Age 56 (47, 69) 
ref. 
61 (53, 68) 
p=0.053 
58 (49, 66) 
p=0.66 
p=0.13 
Female 143/208 
ref. 
60/88 
p=1.0 
60/82 
p=0.48 
*p=0.50 
CRP 9.1 (3,18) 
ref. 
11.5 (4.8,24.4) 
p=0.055 
16.5 (8.3,27) 
p=0.0001 
p=0.11 
ESR 34 (16,51) 
ref. 
39 (23,58) 
p=0.08 
29 (19,49.5) 
p=0.66 
p=0.14 
Swollen 5 (2,9) 
ref. 
5 (2,9.5) 
p=0.97 
5 (2,13) 
p=0.77 
p=0.86 
Tender 7 (2,19) 
ref. 
5 (1,10) 
p=0.02 
6 (2,14) 
p=0.42 
p=0.21 
DAS28 
mean (sd) 
3.92 (1.23) 
ref. 
3.82 (1.22) 
**p=0.73 
4.10 (1.24) 
**p=0.15 
**p=0.08 
VAS pain 50 (30,65) 
ref. 
40 (15,52) 
p=0.02 
40 (20,60) 
p=0.10 
p=0.61 
HAQ 1.13 (0.63, 
1.75) 
ref. 
1.0 (0.25,1.86) 
p=0.23 
1.25 
(0.75,1.75) 
p=0.58 
p=0.17 
RF (%) 59/208 
(28.4%) 
ref. 
59/87  
(67.8%) 
p<0.0001 
66/81  
(81.5%) 
p<0.0001 
*p=0.052 
 
Table 4.3. Baseline characteristics for the 408 NOAR subjects who fulfilled ACR 
classification criteria for RA by 3 years, divided according to anti-CEP-1 and 
anti-CCP antibody status. All results are median (IQR) except where specified. 
Statistical analysis was with the Mann-Whitney or *Fishers exact/Chi square or 
**Two-sample t tests. Age refers to age at symptom onset. P values in columns 3 
and 4 refer to comparisons with the CEP-1-/CCP- subset, whereas those in 
column 5 compare the two CCP+ subsets divided according to anti-CEP-1 
antibody status. 
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Swollen 
Joint 
Count 
Baseline Year 1 Year 2 Year 3 Year 5 
-/- 5 (2,9) 
ref. 
3 (0,8) 
ref. 
3 (0,7) 
ref. 
2 (0,6) 
ref. 
2 (0,5) 
ref. 
-/+ 5 (2,9.5) 2 (0,7) 
p=0.76 
2 (1,5) 
p=0.82 
2 (0,5) 
p=0.68 
2 (0,4) 
p=0.48 
+/+ 5 (2,13) 3 (1,6) 
p=0.69 
2 (0,4) 
p=0.20 
2 (0,5) 
p=0.33 
2.5 (0,6) 
p=0.93 
Tender 
Joint 
Count 
     
-/- 7 (2,19) 
ref. 
6 (1,19) 
ref. 
6.5 (1,23) 
ref. 
8 (1,29) 
ref. 
5 (2,20) 
ref. 
-/+ 5 (1,10) 
p=0.02 
4 (0,12) 
p=0.01 
3 (0,8.5) 
p=0.01 
6 (0,13) 
p=0.04 
2 (0,10) 
p=0.005 
+/+ 6 (2,14) 
p=0.42 
3 (0,9) 
p=0.01 
4.0 (0,12) 
p=0.02 
3 (0,12) 
p=0.008 
3 (0.5,12) 
p=0.09 
HAQ      
-/- 1.13  
(0.63,1.75) 
ref. 
1.13 
(0.38,1.88) 
ref. 
1.25 
(0.50,1.88) 
ref. 
1.25 
(0.50,2.0) 
ref. 
1.38 
(0.63,2.13) 
ref. 
-/+ 1.0 
(0.25,1.86) 
p=0.23 
0.75 
(0.38,1.63) 
p=0.12 
0.88 
(0.38,1.63) 
p=0.22 
1.13 
(0.38,1.75) 
p=0.33 
1.06 
(0.50,1.75) 
p=0.29 
+/+ 1.25 
(0.75,1.75) 
p=0.58 
1.0 
(0.50,1.63) 
p=0.49 
1.13 
(0.31,1.63) 
p=0.42 
1.0 
(0.38,1.88) 
p=0.54 
1.25 
(0.13,1.63) 
p=0.18 
CRP      
-/- 9.1  
(3,18) 
ref. 
- - - 9.3 
(4.4,16.6) 
ref. 
-/+ 11.5 
(4.8,24.4) 
p=0.055 
- - - 13.4 
(8.9,23.1) 
p=0.03 
+/+ 16.5 
(8.3,27) 
p=0.0001 
- - - 16.6 
(9.9,28.4) 
p=0.0008 
 
 
 
 
 
 
Table 4.4 
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Table 4.4. Comparison of the three RA fractions, divided according to anti-CEP-
1 and anti-CCP antibody status, in the NOAR cohort. Anti-CEP-1+/anti-CCP- 
patients are excluded due to insufficient data. Longitudinal data was only 
available for 51 joint counts, HAQ scores and CRP (measured at baseline and 5 
years only). Data are medians (IQR) compared with the Mann Whitney test. -/-  
anti-CEP-1 and anti-CCP negative; -/+ anti-CEP-1 negative but anti-CCP 
positive; +/+ anti-CEP-1 and anti-CCP positive. Ref. = referent. 
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4.2.2.3 Radiographic outcomes 
 
In the Karolinska cohort, anti-CEP-1 antibodies were not predictive of erosions at 
baseline or 1 year but did predict a greater increase in Larsen score between 1 and 2 
years (Table 4.4). A similar but non-significant trend towards prediction of erosions at 
1 year was seen in the NOAR cohort with logistic regression, adjusted for age at 
symptom-onset, gender and baseline erosions giving an odds ratio of 7.76 (95% CI 
0.82 ,73.73; n=61) for erosions at 1 year compared to 0.73 (0.31 ,1.76; n=132) for 
baseline erosions. However the predictive value in both cohorts was weaker than that 
seen with anti-CCP antibodies. Given the findings presented in the preceding chapter, 
it would be of interest to know if there was a discernable difference in the anti-CCP 
predictive effect between the subsets positive and negative for anti-CEP-1 antibodies. 
No statistically significant difference was seen between these subsets in the 
Karolinska cohort (Table 4.5) or the NOAR cohort. Analysis for the latter cohort used 
relative risk ratios derived from multinomial logistic regression for erosions at 
baseline, but there was insufficient data to repeat this analysis for erosions at 1 year. 
  
In order to determine if higher titres of anti-CEP-1 antibodies were associated with a 
greater number of erosions, a linear regression analysis for the NOAR data was 
performed. Anti-CEP-1 antibodies were not predictive of baseline Larsen scores 
(p=0.67) or change in Larsen scores between baseline and 1 year (p=0.53). Again the 
number of subjects available for study was limited but if a strong effect existed this 
might still have been detected. 
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 Whole cohort Anti-CCP+ subjects 
 
 
Anti-CCP 
Positive vs. negative 
Anti-CEP-1 
Positive vs. negative 
Anti-CEP-1 
Positive vs. negative 
Larsen score 
baseline 
4.000 vs. 5.000 
p=NS (0.08) 
3.500 vs. 4.500 
p=NS 
3.500 vs. 4.000 
p=NS 
Larsen score 1 
year 
10.500 vs. 11.250 
p=NS 
11.250 vs. 10.500 
p=NS 
11.250 vs. 10.000 
p=NS 
Larsen score 2 
years 
14.000 vs. 13.000 
p=NS 
14.250 vs. 13.250 
p=NS 
14.500 vs. 13.500 
p=NS 
Larsen score 
1yr – baseline 
4.500 vs. 4.250 
p=NS 
4.000 vs. 4.250 
p=NS 
5.000 vs. 4.000 
p=NS 
Larsen score 
2yrs – baseline 
7.125 vs. 6.000 
p=0.0126 
6.750 vs. 6.250 
p=NS 
8.125 vs. 7.000 
p=NS 
Larsen score 
2yrs – 1yr  
2.750 vs. 1.000 
p<0.0001 
2.625 vs. 2.000 
p=0.0455 
2,750 vs. 2.500 
p=NS 
 
 
Table 4.5. Modified Larsen scores derived from X-rays of hands and feet. In the 
left-hand column, data for anti-CCP antibody positive patients (n=143) is 
compared with anti-CCP antibody negative (n=110) in the whole cohort (n=253). 
In the middle column, the cohort is divided into anti-CEP-1 positive (n=63) and 
negative (n=190). In the right-hand column, the analysis is restricted only to 
those patients with anti-CCP antibodies (n=143), divided into those with (n=57) 
and without (n=86) anti-CEP-1 antibodies. Statistically significant results are 
shown in bold. NS=non-significant. Vs.=versus. Larsen score=change in Larsen 
score. 
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4.2.2.4 Comparison with other potential predictors of disability 
 
Using the NOAR cohort, we explored whether the presence of anti-CEP-1 antibodies 
at baseline could predict a HAQ score of >1, representing moderate disability, 
occurring within 3 years of enrolment, after adjusting for baseline HAQ score, gender 
and age at symptom onset. This was compared with other potential predictors 
including swollen and tender 28 joint counts (tertiles), DAS28, smoking, the HLA-
DRB1 shared epitope, baseline erosions and CRP as well as anti-CCP antibodies and 
RF. The results showed that the only statistically significant predictors were tender 28 
joint counts (OR 2.09; CI 1.09, 4.00 for second tertile and 4.08; CI 1.55, 6.10 for the 
third tertile). No significant association was seen with anti-CEP-1 antibodies (OR 0.75; 
CI 0.41, 1.34) but neither was there one with anti-CCP or RF. It was not possible to 
take treatment history into account which might be an important confounding factor. 
If patients with anti-CCP and anti-CEP-1 antibodies had more severe disease, it is 
probable they would be treated earlier and more aggressively which might prevent 
them developing further disability. Correcting for baseline HAQ might also have 
underestimated the autoantibody effect if some had had significant disability at 
baseline, although this effect would probably have been small given the enrolment of 
patients early after symptom onset. 
 
4.2.2.5 Comparison with other potential predictors of erosions 
 
A similar analysis was done for baseline erosions, adjusted for gender and age at 
symptom onset, and only the second tertile of tender and swollen 28 joint counts 
combined (OR 2.42; CI 0.92, 6.36) showed a trend. For erosions at one year, adjusted 
also for baseline erosions, past smoking (OR 8.91; CI 1.23, 64.58), anti-CCP 
antibodies (OR 12.3; 2.03, 74.6) and RF (OR 9.57; CI 1.49, 61.64) were predictive. 
This compared to the trend for anti-CEP-1 antibodies of 7.76 (95% CI 0.82,73.73; 
n=61) for erosions at 1 year.   
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4.2.2.6 Do higher levels of anti-CEP-1 antibodies associate with more clinical 
disease activity? 
 
Again using the NOAR early arthritis cohort, we examined whether anti-CEP-1 
antibody level associated with increased disease activity, determined clinically using 
tender and swollen joint counts. Firstly, mean titres of anti-CEP-1 for each joint count 
tertile were analysed using the Kruskal-Wallis test (tables 4.5 and 4.6) and secondly, 
we did a quantile (including median) regression of joint counts at baseline by anti-
CEP-1 titre, adjusting for gender and age at symptom onset. Data shown are for the 
whole cohort tested for anti-CEP-1 levels as these did not differ significantly from the 
group which fulfilled ACR classification criteria by 3 years. Using both these methods, 
no association between anti-CEP-1 antibody level and swollen or tender joint counts 
was demonstrated. 
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Tertiles Swollen Tender Both swollen and tender 
 Mean  SD Obs Mean  SD Obs Mean  SD Obs 
1
st
 576 1229 203 643 1587 194 649 1480 267 
2
nd
  603 1104 174 737 1524 192 719 1681 141 
3
rd
  923 2089 182 714 1503 173 763 1505 151 
Total 697 1538 559 697 1538 559 697 1538 559 
Probability p=0.32 p=0.84 p=0.18 
Table 4.5. Mean anti-CEP-1 titre for each tertile of tender or swollen 28-joint count at baseline. Results are analysed using the Kruskal-
Wallis test. Results shown are from all subjects assayed for anti-CEP-1 antibodies, where data is available. 
 
Tertiles Swollen Tender Both swollen and tender 
 Mean  SD Obs Mean  SD Obs Mean  SD Obs 
1
st
  517 979 127 496 917 110 569 1066 173 
2
nd
  593 1064 80 683 1243 110 630 1024 42 
3
rd
  876 2045 116 826 2062 103 831 2066 108 
Total 665 1474 323 665 1474 323 665 1474 323 
Probability p=0.93 p=0.23 p=0.80 
Table 4.6. Mean anti-CEP-1 antibody titre for each tertile of tender or swollen 28-joint count at year 3. Results are analysed using the 
Kruskal-Wallis test. Results shown are from all subjects assayed for anti-CEP-1 antibodies, where data is available
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4.4 Do anti-CEP-1 antibodies predict response to anti-TNF agents? 
4.4.1 Methods 
 
Serum samples were made available from the Biologics in Rheumatoid Arthritis 
Genetics and Genomics Study Syndicate (BRAGGSS), described in section 2.5.1.2. 
BRAGGSS samples were provided by Dr Anne Barton. Statistical analysis was 
undertaken by Dr Laura Gibbons. 
 
4.4.2 Results 
 
1485 patients from the 20 collaborating centres fulfilled the study criteria. Of these, 
1292 (87%) responded to the invitation letter and 1195 (80%) agreed to take part. 
Serum samples were obtained from 521 (35%) of these patients of which 450 (30%) 
had a full set of data suitable for analysis. Baseline demographics are detailed in 
Table 4.7. These are comparable to previously published measures for the BSRBR as 
a whole
362
. 
Change in DAS28 by 6 months and EULAR response criteria did not differ from the 
BSRBR as a whole. No significant difference was seen between drugs (Table 4.8); 
Chi square for EULAR response was 5.96, p=0.2. 
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Baseline 
Characteristics 
Etanercept Infliximab Adalimumab Combined 
Number (%) 189 (42.0) 223 (49.6) 38 (8.4) 450 (100) 
Female (%) 142 (75.1) 156 (70.0) 33 (86.8) 331 (73.6) 
Age (sd) 56.0 (11.5) 57.4 (10.9) 59.8 (11.0) 57.0 (11.2) 
Disease 
duration (sd) 
12.6 (9.3) 15.1 (10.0) 13.9 (11.0) 13.9 (9.9) 
HAQ (sd) 2.0 (0.5) 2.2 (0.5) 2.2 (0.5) 2.1 (0.5) 
DAS28 (sd) 6.6 (0.95) 6.5 (0.93) 6.5 (0.91) 6.6 (0.94) 
Current 
smokers (%) 
37 (19.6) 44 (19.7) 2 (5.3) 83 (18.4) 
Ex-smokers 
(%) 
75 (39.7) 83 (37.2) 19 (50) 177 (39.3) 
Concurrent 
DMARDs (%) 
113 (59.8) 211 (94.6) 28 (73.7) 352 (78.2) 
Concurrent 
steroids (%) 
67 (35.5) 91 (40.8) 12 (31.6) 170 (37.8) 
Previous 
biologic (%) 
22 (11.6) 12 (5.4) 1 (2.6) 35 (7.8) 
 
Table 4.7. Baseline demographics of Biologics in Rheumatoid Arthritis Genetics 
and Genomics Study Syndicate (BRAGGSS) cohort; n=450. The final column 
represents the pooled results of patients receiving the three different anti-TNF 
inhibitors. sd=standard deviation. HAQ=Health Assessment Questionnaire. 
DAS28=Disease Activity Score-28. DMARDs=disease-modifying anti-rheumatic 
drugs. 
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 Etanercept Infliximab Adalimumab Combined 
Baseline 
DAS28 (sd) 
6.63 (0.95) 6.52 (0.93) 6.51 (0.91) 6.56 (0.94) 
DAS28 at 6 
months (sd) 
4.14 (1.52) 4.16 (1.54) 3.57 (1.09) 4.10 (1.51) 
Change in 
DAS28 (sd) 
-2.49 (1.53) -2.36 (1.57) -2.93 (1.36) -2.46 (1.54) 
No response 
(%) 
36 (19.1) 56 (25.1) 4 (4.2) 96 (21.3) 
Moderate 
response (%) 
98 (51.9) 111 (49.8) 20 (52.6) 229 (50.9) 
Good response 
(%) 
55 (29.1) 56 (25.1) 14 (36.8) 125 (27.8) 
 
Table 4.8. Baseline and follow-up DAS28 scores, and EULAR response criteria 
for each of the 3 different anti-TNF inhibitors used by patients enrolled in this 
cohort. DAS28 scores are absolute values with standard deviation in brackets. 
EULAR response criteria are numbers of patients with percentage in brackets. 
The final column represents the pooled results of patients receiving the three 
different anti-TNF inhibitors. sd=standard deviation. 
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Anti-CEP-1 antibodies were positive in 174 (38.7%) patients; 75 (39.7%), 84 (37.7%) 
and 15 (39.5%) in the etanercept, infliximab and adalimumab groups respectively. 
When patients who were anti-CEP-1 antibody positive were compared with those who 
were negative, no significant differences were discernible between baseline DAS28, 
mean reduction after 6 months of treatment and EULAR response group (Table 4.9).   
Linear regression analysis was also performed to control for other variables that might 
influence response and act as suppressor factors. An initial analysis of clinical 
variables (Table 4.10) showed that a greater fall in DAS28 at 6 months was associated 
with higher baseline DAS28, lower HAQ and never smoking. Notably the adjusted R-
squared for this model was 0.13 indicating that it explains only 13% of the variability 
in change of DAS28 at 6 months.  
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 Anti-CEP1 
status 
Etanercept Infliximab Adalimumab Combined 
Number - 114 139 23 276 
+ 75 84 15 174 
Baseline 
DAS28 
- 6.66 (0.96) 6.49 (0.93) 6.60 (0.92) 6.57 (0.94) 
+ 6.60 (0.94) 6.57 (0.92) 6.37 (0.92) 6.56 (0.93) 
Change in 
DAS28 
- -2.44 (1.56) -2.46 (1.54) -2.98 (1.11) -2.50 (1.52) 
+ -2.56 (1.48) -2.20 (1.62) -2.86 (1.72) -2.41 (1.58) 
No 
response 
- 22 (19.3) 33 (23.7) 2 (8.7) 57 (20.7) 
+ 14 (18.7) 23 (27.4) 2 (13.3) 39 (22.4) 
Moderate 
Response 
- 60 (52.6) 67 (48.2) 13 (56.5) 140 (50.7) 
+ 38 (50.7) 44 (52.4) 7 (46.7) 89 (51.2) 
Good 
response 
- 32 (28.1) 39 (28.1) 8 (34.8) 79 (28.6) 
+ 23 (30.7) 17 (20.2) 6 (40.0) 46 (26.4) 
 
Table 4.9.  DAS28 scores and EULAR response criteria for anti-CEP-1 positive 
and negative patients in each treatment group and for all anti-TNF drugs 
combined; n=450. DAS28 scores are absolute values with standard deviation in 
brackets. EULAR response criteria are numbers of patients with percentage in 
brackets. The final column represents the pooled results of patients receiving the 
three different anti-TNF inhibitors. sd=standard deviation. 
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Predictor Linear regression 
coefficient (95% CI) 
p 
Baseline DAS28 -0.62 (-0.78, -0.46) 1.00E-13 
Concomitant DMARD -0.28 (-0.61, 0.05) 0.095 
Gender (female) 0.3 (-0.01, 0.62) 0.060 
HAQ 0.44 (0.16, 0.72) 0.002 
Age at baseline 0.01 (-0.01, 0.02) 0.429 
Duration of RA 0 (-0.01, 0.02) 0.604 
Ex-smoker -0.36 (-0.75, 0.04) 0.076 
Never smoker -0.53 (-0.91, -0.14) 0.008 
Concomitant steroids -0.03 (-0.32, 0.25) 0.811 
 
Table 4.10. Results of linear regression analysis for baseline clinical variables, 
using change in DAS28 at 6 months as outcome; n=421. A negative coefficient 
indicates improvement. Statistically significant results are in bold. 
DAS28=Disease Activity Score 28. HAQ=Health Assessment Questionnaire. 
CI=confidence interval. 
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Linear regression for anti-CEP-1 antibodies, adjusting for baseline DAS28, 
concomitant DMARDS, gender and HAQ and smoking, gave a coefficient of 0.04 
(p=0.77) when antibody positive. No improvement in the adjusted R-squared (0.13) 
was achieved. Additional adjustment for disease duration at baseline, the particular 
anti-TNF drug (infliximab, etanercept or adalimumab), or exclusion of those 
previously exposed to biologic drugs, made no difference to the analysis of anti-CEP-
1 antibodies and response. Combining anti-CEP-1, anti-CCP and RF in the same 
model and with the same adjustments gave coefficients of 0.007 (p=0.96), 0.21 
(p=0.36) and 0.48 (p=0.05) respectively, confirming that anti-CEP-1 antibodies have 
no independent predictive value. In this model there was a trend towards RF positivity 
being associated with a poorer outcome as determined by change in DAS28. Anti-
CCP was not independently associated with response, although this likely reflects 
collinearity with RF. Overall the adjusted R-squared was only marginally increased to 
0.15. The possibility that being positive for both anti-CEP-1 and anti-CCP antibodies 
might have a greater influence on outcome was also examined. However, no 
difference between the anti-CEP-1- / anti-CCP+ and the anti-CEP-1+ / anti-CCP+ 
subgroups was shown (Table 4.11). The R
2
 for this model was 0.16 which was 
identical to that for a comparable model that did not subdivide the anti-CCP positive 
population. 
Ordinal logistic regression using the EULAR outcome criteria as the dependent 
variable was also performed. In this analysis only baseline HAQ was predictive. 
Additionally adjusting for disease duration at baseline, anti-TNF type, or exclusion of 
those previously exposed to biologic drugs, made no difference to the analysis of anti-
CEP-1 antibodies.  
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Predictor Linear regression 
coefficient (95% CI) 
p-value 
Anti-CEP-1- / anti-CCP+ 0.37 (-0.04, 0.78) 0.08 
Anti-CEP-1+ / anti-CCP+ 0.41 (-0.02, 0.84) 0.06 
DAS28 -0.61 (-0.77, -0.45) <0.001 
Concurrent DMARDs -0.28(-0.61, 0.05) 0.09 
Female 0.31 (-0.01, 0.63) 0.05 
HAQ 0.48 (0.20, 0.76) 0.001 
Ex-smoker -0.34 (-0.73, 0.05) 0.09 
Never smoker -0.53 (-0.92, -0.14) 0.007 
 
Table 4.11. Linear regression analysis of the major anti-CEP-1 / anti-CCP 
antibody subsets (anti-CEP-1- / anti-CCP- patients as referent), adjusted for the 
listed baseline characteristics. DAS28=Disease Activity Score 28. HAQ=Health 
Assessment Questionnaire. CI=confidence interval. 
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4.5 Effect of rituxumab on anti-CEP-1 antibody levels in RA 
4.5.1 Methods 
 
Longitudinal samples were available from an observational cohort of 51 patients with 
RA treated with rituximab at University College Hospital, University College London. 
Samples were collected with informed consent and ethical approval and were kindly 
provided by Dr Jo Cambridge. For measurement of anti-CEP-1 antibodies, sera were 
tested using the quantitative anti-CEP-1 antibody ELISA described in section 2.5.1.1. 
Anti-CCP2 (Bindazyme, The Binding Site, UK) and anti-MCV antibodies (Orgentec, 
Germany) were determined by commercial ELISAs used according to the 
manufacturers‟ instructions. IgA and IgM RF were determined using an RF detection 
kit (TheraTest Laboratories, Chicago, US) based on the binding of RF to rabbit IgG. 
Normal levels for IgM RF and IgA RF are <25 and <35 IU/ml. Serum levels of BLyS 
were measured by ELISA according to a previously published method
432
. RF and 
BLyS data was kindly provided by Dr G. Cambridge. 
 
4.5.2 Results 
 
Baseline samples were screened for anti-CEP-1 antibodies and 15 (29%) were found 
to be positive of which 14 had longitudinal samples and clinical data suitable for 
analysis. All subjects were also positive for anti-MCV, anti-CCP, IgM RF and IgA 
RF. As a number of these subjects did not have a complete set of samples, it was not 
possible to analyse the nadir levels or time to nadir. Instead, analysis was done on 
samples pre-treatment and at approximately 6 months. Results for the autoantibody 
analysis show a slightly greater decline in anti-CEP-1 antibody levels in comparison 
with anti-MCV and anti-CCP, but less marked than that seen with IgM RF (Table 
4.12). Seven out of the 14 patients became negative for anti-CEP-1 antibodies 
following treatment with rituximab. All of these subjects had relatively low positive 
antibody levels at baseline. No subjects became negative for anti-CCP or anti-MCV, 
however all subjects started out as being strongly positive. A close relationship 
existed between changes in level of different anti-citrullinated protein/peptide 
antibodies as demonstrated in the sample chart of longitudinal values in a single 
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patient (Figure 4.4). This also demonstrates the elevation in BLyS that is seen after 
rituximab therapy. The median time to relapse in this group of patients was 11 months 
(range 6 to 45). A rise in anti-CEP-1 level was seen in 10 of the 14 patients (71%) at 
or before the time of relapse. An elevation in one or more isotypes of RF was seen in 
all subjects with available data (n=12), at or before relapse.  
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Parameter n Baseline 6 months Reduction 
(%) 
p 
Anti-CEP-1 14 2143 
(1006, 4566) 
1111 
(516, 2392) 
48 0.0001 
Anti-MCV 13 492 
(267, 907) 
 288  
(157, 529) 
41 0.01 
Anti-CCP 14 1372 
(878, 2145) 
884 
(523, 1495) 
36 0.04 
IgM RF 12 199 
(98, 403) 
78 
(40, 153) 
61 0.0005 
IgA RF 12 117 
(72, 191) 
68 
(37, 125) 
42 0.05 
 
Table 4.12 Effect of rituximab on the levels of anti-CEP-1, anti-CCP and anti-
MCV antibodies and RF. All values are arbitrary units except RF (IU/ml). 
Levels pre-treatment (baseline) and at around 6 months are expressed as 
geometric means (95% CI). Statistical analysis was the Wilcoxon signed rank 
test. Data for RF kindly provided by Dr G. Cambridge. MCV, mutated 
citrullinated vimentin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4              Anti-CEP-1 and clinical outcomes 
170 
 
 
 
 
 
 
Figure 4.4. Relationship between anti-CEP-1 and anti-MCV antibodies, BLyS 
and relapse in a representative patient treated with rituximab. Arbitrary units of 
anti-CEP-1 and anti-MCV antibodies are marked on the left-hand y-axis. 
Arbitrary units of BLyS are marked on the right-hand y-axis. BCDT, B cell 
depletion therapy with rituximab. MCV, mutated citrullinated vimentin. BLyS, 
B lymphocyte stimulator. Clinical and BLyS data kindly provided by Dr G. 
Cambridge. 
Retreat
1st 
BCDT
B DEPLETED B DEPLETED
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4.6 Conclusion 
 
It is now well established that anti-CCP antibodies are associated with a more severe 
disease course, however the epitopes they recognise in vivo are less clear. We have 
proposed CEP-1 as a candidate and the experiments in this chapter have examined 
whether anti-CEP-1 antibodies have prognostic value using two independent cohorts 
of patients with early rheumatoid arthritis. 
 
We demonstrated that anti-CEP-1 antibodies were associated with higher CRP and 
DAS28(CRP) scores in the NOAR cohort. Significantly higher physician‟s 
assessments and swollen joint counts, with a trend for CRP and tender joint counts, 
were seen at later time points in the Karolinska cohort. An increase in late 
development of erosions was observed in both cohorts. However these associations 
were weaker than those seen with anti-CCP antibodies
430
 and reflect the fact that most 
patients with anti-CEP-1 antibodies are also anti-CCP positive. Furthermore, when 
restricting the analysis to anti-CCP positive patients, no statistically significant 
differences were associated with anti-CEP-1 antibodies, although there was a non-
significant trend towards higher CRP and DAS28(CRP) in the NOAR cohort. There 
was no predictive value for the progression of functional disability or response to anti-
TNF agents. 
 
There are a number of points worthy of note. Firstly, it is difficult to exclude a 
confounding effect from treatment. Whilst choice of DMARD did not differ according 
to anti-CEP-1 antibody status at enrolment in the Karolinska cohort, we have not 
analysed changes in therapy, cumulative dosage over time or the use of concomitant 
steroids in either cohort. The potential impact of therapy is illustrated by the NOAR 
cohort where neither RF, anti-CEP-1 nor anti-CCP antibodies were predictive of a 
HAQ score greater than 1 at any point in the first 3 years after enrolment. This is at 
variance with the findings from an earlier NOAR study, where being RF positive at 
baseline predicted a HAQ score ≥1 at 3 and 5 years433 434. In the earlier study, the 1 
year HAQ score was a better predictor of subsequent outcome than the baseline score, 
suggesting potential for early interventions to modify later disability
435
. The 
contemporary practice of treating newly diagnosed seropositive RA earlier and more 
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aggressively, particularly when accompanied by high levels of disease activity or 
disability, makes differentiation according to higher HAQ scores a difficult target to 
obtain. Secondly, the sensitivity for predicting disability might be increased by using 
statistical methods that do not dichotomise the data (complicated by the skewed 
distribution of scores), or by using a modified HAQ incorporating more complex 
activities of daily living, since the original HAQ was developed in the 1970s and so 
predates the current therapeutic era where expectations are higher
307
. Thirdly, the 
analysis of erosions in NOAR was limited by subject numbers and it is likely that a 
statistically significant positive association might exist in a larger cohort, and this is 
corroborated by the Swedish data. With the data available however, no difference was 
discernible between anti-CCP positive patients who were either positive or negative 
for anti-CEP-1 antibodies. Fourthly, whilst there is a statistically significant effect of 
anti-CCP antibodies in predicting poorer response to anti-TNF agents in the large and 
well-characterised BRAGGSS cohort, overall this effect is small. Samples were not 
collected prior to treatment with TNF inhibitors and, as a result of this, levels of anti-
CEP-1 antibody in relation to response were not analysed. It is therefore not possible 
to exclude an effect at higher antibody levels. Data available for anti-CCP suggest that 
there may be a modest change in titres following treatment with anti-TNF but a 
change in status from positive to negative is unusual
436 437
.  Similarly, we have shown 
that, whilst treatment with infliximab results in a reduction in anti-CEP-1 antibody 
levels that is statistically significant at 18 and 52 weeks, this effect is small (data not 
shown). Therefore it might be of interest in future to compare tertiles of antibody 
level; however one would predict this to be negative given the complete absence of 
effect seen in the analyses performed to date. Fifthly, whilst there is collinearity 
because most patients carry both anti-CCP antibodies and RF, the effect of anti-CCP 
antibodies themselves in the current study appear less than that of RF when combined 
in the same model. A greater influence of RF compared with anti-CCP antibodies 
might be consistent with RF being a more dynamic marker of disease activity
368
. 
Sixthly, we have only measured common outcomes and it is possible that anti-CEP-1 
antibodies may yet define a subgroup with characteristic clinical features, especially 
since some of phenotypic variations in RA such as differences in temporal pattern, 
response to specific treatments, synovial histology and extra-articular manifestations, 
are not always recorded in cohort studies. Overall however, the data we have 
available suggests that the anti-CEP-1 test is unlikely to provide clinically useful 
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prognostic information additional to that given by the anti-CCP2 assay for the 
outcomes assessed. 
 
This conclusion does not exclude a real pathogenic effect of anti-CEP-1 antibodies in 
RA for several reasons. Firstly, measured concentrations are total IgG and other 
antibody classes, or differences in antibody affinity and avidity, may contribute. 
Secondly, and more importantly, it has been suggested that antibodies to citrullinated 
autoantigens might share a common pathway
182
. Anti-CEP-1 antibodies may arise in a 
particular environmental and genetic context, but if antibodies to other citrullinated 
proteins utilise the same final common pathway then the downstream clinical effects 
are not only likely to be similar, but an assay that is capable of detecting many such 
antibodies is likely to have greater value in predicting outcomes than an assay 
detecting only one (Figure 4.5). Epitope spreading to other citrullinated autoantigens 
is also likely to be pertinent and has been demonstrated in an animal model
190
. The 
pathway may also be modified by time since pathogenic mechanisms may progress 
within the same patient such that triggering factors may not be the same as those that 
promote chronicity. The final part of such a pathway for this and numerous other 
pathological processes would involve TNF-mediated pathology and it is possible that 
the best predictors of response to anti-TNF agents may be more closely related to 
these downstream events. Thus anti-CEP-1 antibodies may provide useful aetiological 
insights whilst not predicting clinical outcomes. In a similar fashion, the HLA-DRB1 
shared epitope and PTPN22 are not predictive of response to anti-TNF
362
. In contrast, 
and in support of this concept, TNF bioassays
370
 and possibly TNF gene variants
438
 
show promise. 
 
We have also presented preliminary longitudinal data on the effect of rituximab on 
anti-CEP-1 antibody levels. The significant reduction in anti-CEP-1 antibody levels 
demonstrate a feature shared by other more well known autoantibodies, of selective 
decline following B cell depletion that is greater than that of total immunoglobulins. 
Such selective decline may indicate the constant generation of short-lived plasma 
cells from CD20-positive precursors, or that their location outside of secondary 
lymphoid organs renders them more susceptible to depletion. Alternatively, there may 
be a proportion of autoreactive antibody-secreting cells that are not fully 
differentiated to the CD20 negative plasma cell stage. This small study raises the 
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possibility that anti-CEP-1 antibodies may respond more dynamically than anti-CCP2 
or anti-MCV to treatment with rituximab.  
 
The evidence presented suggests two possible uses for the anti-CEP-1 ELISA that 
require further investigation. Firstly, it might be a useful tool to further study 
immunogenetic associations in the aetiology of RA. Additionally, the strong genetic 
associations might indicate those with family members at greater risk of developing 
the disease. Secondly, it might be useful longitudinally as a marker of response to 
rituximab and predictor of relapse.  
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Figure 4.5. Hypothetical ‘pathway of citrulline immunity.’ The interaction of 
environmental and genetic factors in the generation of immunity to citrullinated 
enolase is an ‘upstream’ event that may be followed by epitope spreading to 
other citrullinated autoantigens. There may be a hierarchy of autoantigens since 
some studies have shown a less significant association of fibrinogen peptides with 
the HLA-DRB1 ‘shared epitope’ (section 2.4.4.2). There are further levels 
beyond this, including the interaction of RF, other autoantibodies and 
macrophages as well as many other factors before the more downstream TNF 
component of the pathway is reached which will ultimately result in clinical 
outcomes. Many of the downstream components are influenced by positive and 
negative feedback pathways, genetic influences and the variable failure of 
inflammation resolution. Consequently, antibodies to CEP-1 are likely to be less 
predictive of clinical outcomes than an assay that detects antibodies to many 
different citrullinated proteins. This is particularly likely to be true for 
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predicting response to anti-TNF agents, where anti-CCP antibodies have only 
limited value. Sampling biomarkers more closely linked to the TNF component 
of the pathway may be of greater value. ACPA=antibodies to citrullinated 
protein antigens. RF=rheumatoid factor. AAb=autoantibodies. 
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5.1 Discussion 
 
In this thesis I have demonstrated that antibodies to an immunodominant epitope of 
citrullinated α-enolase, CEP-1, are diagnostically specific for RA. They also define a 
subset for the analysis of aetiology and pathogenesis of the disease. The original 
description of autoantibodies to citrullinated α-enolase protein in RA found that 
positive results were obtained in 15% of healthy controls, sera from which also 
reacted with uncitrullinated α-enolase216. It was therefore hypothesised that the 
binding of control sera to citrullinated α-enolase was due to recognition of 
uncitrullinated epitopes. Indeed, antibodies to native enolase are common following 
infection and in a variety of other disorders
208
. It was proposed that identification of 
an immunodominant peptide would improve the specificity of the assay. By 
examining several differing cohorts of patients with both early and established RA, 
we have shown that antibodies to CEP-1 are a real feature of the immune 
abnormalities seen in this disorder. This receives additional support from the findings 
of Snir et al, who reported higher concentrations of anti-CEP-1 antibodies in synovial 
fluid when compared with serum, suggesting local production within the joint
182
. 
Furthermore, anti-CEP-1 antibodies only have limited cross-reactivity with CCP 
peptides and with other known citrullinated autoantigens
182 399
.  
 
Anti-CEP-1 antibodies are found in about half of anti-CCP positive sera, which 
approximates to 40% of RA patients in most cohorts tested. Modifications to the assay, 
as discussed in chapter 2, might increase its sensitivity. In particular, although 
cysteine residues were added to the ends of the peptide to allow a cyclic peptide 
conformation through formation of cystine, this step relied on auto-oxidation. When 
Schellekens et al made CCP1 they forced cyclisation with an iodine/methanol 
oxidation step
159
. However, it is also becoming evident that there is no single 
citrullinated autoantigen in RA and that the multiple peptides in the CCP2 assay may 
detect different specificities. There are now at least four well-documented 
citrullinated antigens: fibrin, vimentin, collagen type II and, most recently α-enolase 
(reviewed by Wegner et al.
175
).  The antigen specifity is supported by limited cross-
reactivity between antigens demonstrated by absorption studies
182
. Further supportive 
evidence that there may be several citrullinated autoantigens is provided by the 
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immunogenetic association studies reported here. The associations with the HLA-
DRB1 „shared epitope‟, and the gene-gene and gene-environment interactions with 
the R620W allele of PTPN22 and smoking, were uniquely strong in the subset of anti-
CCP antibody positive patients that also had anti-CEP-1 antibodies. The 
distinctiveness of this subset was further suggested by the novel gene association with 
BRD2. 
 
The strength of the gene-environment interaction led us to investigate whether the 
combination of anti-CCP and anti-CEP-1 antibodies predicted clinical and 
radiological outcomes. This seemed particularly relevant given a previous study 
which found that anti-CCP antibodies occurring in the absence of the shared epitope 
were associated with less radiographic progression
404
. Somewhat surprisingly then, in 
two early arthritis cohorts there was no difference in clinical or radiological outcomes 
between the anti-CEP-1+/anti-CCP+ and anti-CEP-1-/anti-CCP+ subsets. The 
exceptions were that, in the NOAR cohort, there was a trend towards higher CRP and 
DAS28(CRP) levels, and more RF positive patients, in the subgroup positive for anti-
CEP-1 antibodies. In the BRAGGSS cohort, anti-CEP-1 antibodies did not predict 
response. These findings might be explained by confounding, since physicians 
escalate treatment until patients reach a low disease activity target. Such a target 
includes the outcome measures assessed here. Another explanation might be that RA 
arises as a final common pathway of anti-citrullinated protein immunity, regardless of 
the context in which it has arisen. Were this to be the case, one might have to look 
outside the joint to find clinical associations for anti-CEP-1 antibodies. However, 
based on the preliminary longitudinal data that we have provided, the anti-CEP-1 
ELISA may have value in assessing response to the anti-B cell therapy rituximab.   
 
The association between the HLA-DRB1 „shared epitope‟ and antibodies to 
citrullinated proteins could arise if these alleles preferentially present citrullinated 
peptides in their binding groove. Activation of CD4
+
 T cells would then provide 
„help‟ for B cells specific for citrullinated proteins. The P4 pocket of the DRB1 
peptide binding site is positively charged in those alleles bearing the „shared 
epitope‟28, and therefore has low affinity for positively charged amino acids such as 
arginine. Conversion of an arginine residue to citrulline might therefore increase 
binding affinity. Support for this hypothesis was provided by Hill et al.
195
 who 
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selected a peptide from vimentin that was predicted to bind to HLA-DRB1*0401 and 
had an arginine at the P4 pocket. Mice transgenic for HLA-DRB1*0401 were 
immunised either with this peptide, or the identical peptide in which the arginine was 
replaced by citrulline. Only the citrulline-containing peptide stimulated strong T cell 
proliferation and IFNγ production. Peptide competition assays showed that the 
citrulline-containing peptide bound with much greater affinity to HLA-DRB1 alleles 
containing the „shared epitope‟ but not to those which did not. Furthermore, 
immunisation with citrullinated but not uncitrullinated fibrinogen induced arthritis in 
mice transgenic for human HLA-DRB1*0401
190
. 
 These findings may also explain the relationship between the HLA-DRB1 „shared 
epitope‟ and anti-CEP-1 antibodies. Using the method of Hammer et al.439, we have 
shown that a peptide from enolase containing the second arginine residue (FDS-R15-
GNPTV) was not predicted to bind to *0401. However, when the arginine was 
replaced by glutamine (FDS-Q15-GNPTV), a positive peptide binding score was given 
(2.2 versus -0.4 for the arginine-containing peptide). Glutamine was used as a 
surrogate for citrulline, which is not recognised in this model, as it contains the same 
terminal side chain group
1
. As PAD is absent from the thymus it is likely that T-cells 
specific for citrullinated proteins may occur in the normal repertoire
51 189
. However T 
cell activation could be prevented by the low ratio of citrullinated to uncitrullinated 
peptides in vivo. This might be overcome by MHC class II antigens with high affinity 
for a citrullinated peptide, but not the corresponding arginine-containing peptide. 
 
The high specificity of antibodies to citrullinated proteins for RA suggests a 
contribution to pathology. Van Venrooij has proposed a cycle which could start with 
any episode of joint inflammation provided it is accompanied by necrosis of 
inflammatory cells (Figure 5A)
441
. The latter might result either from massive 
apoptosis, following a toxin or infection for example, or from a defect in immune 
clearance. Consequent to this would be the release of citrullinated intracellular 
proteins as well as PAD enzymes, which would allow further citrullination to occur in 
                                                 
1
 Using another algorithm, NetMHCIIpan (www.cbs.dtu.dk/services/NetMHCIIpan), the maximum 
predicted binding affinities were 1334nM and 14280nM for the „citrulline‟ and arginine-containing 
nonamer cores respectively. It is acknowledged that, given the limited plasticity in T cell recognition of 
modified residues in MHC class II bound peptides440. de Haan EC, Wagenaar-Hilbers JP, Liskamp 
RM, Moret EE, Wauben MH. Limited plasticity in T cell recognition of modified T cell receptor 
contact residues in MHC class II bound peptides. Mol Immunol 2005;42(3):355-64., substitution of 
glutamine may not allow for accurate predictions. 
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the extracellular environment.  The presence of certain HLA molecules would 
facilitate presentation of citrullinated peptides to T cells. Subsequent activation of B 
cells would result in anti-citrullinated protein antibodies. The formation of immune 
complexes would fix complement, perpetuate inflammation and increase its severity. 
As a result there would be further immune cell recruitment, necrosis and release of 
PAD enzymes
441
. The model as stated appears too general however. For example, 
whilst there is a relationship between the „shared epitope‟ and anti-citrullinated 
protein antibodies
239 241 242 247
, RA and anti-CCP antibodies do not develop in patients 
with other inflammatory arthritides. This is despite a similar extent of citrullination 
both in the synovium
183
 and in the synovial fluid
176, and the presence of the „shared 
epitope‟ in a substantial proportion of patients442. Furthermore, clearing of immune 
complexes and phagocytosis of apoptotic cells is often inadequate in patients with 
SLE, who frequently have arthritis in the absence of anti-CCP antibodies. Other 
factors, which might include the generation of specific citrullinated target antigens, 
must be important. Furthermore, it need not be assumed that necrosis is always 
required before citrullinated antigens can be presented to the immune system. A 
recent publication identified the chaperone protein Grp78 as being present in a 
citrullinated form on the surface of monocytes. This was a target for anti-citrullinated 
protein antibodies which, when bound, induced TNF expression
443
. 
 
A two-step model has also been proposed (Figure 5B)
239
. In the first step, smoking 
increases lung citrullination leading to loss of tolerance to a citrullinated autoantigen 
and generation of anti-citrullinated protein antibodies, particularly in the context of 
the „shared epitope‟. The second step is an independent episode of undifferentiated 
arthritis associated with synovial citrullination. The interaction of synovial 
citrullinated autoantigens with the pre-existing antibodies leads to perpetuation of 
synovitis. In the case of anti-CEP-1 antibodies, an alternative first step could be an 
infectious agent given that antibodies to microbial α-enolases occur commonly, and α-
enolase is highly conserved between species. One attractive candidate for a microbial 
trigger is Porphyromonas gingivalis. This expresses its own PAD enzyme, so 
potentially facilitating citrullination of bacterial and human antigens in an 
environment where there is activation of innate and adaptive immunity (see section 
1.5.4.1.2). There is a high sequence similarity between human and P. gingivalis CEP-
1, and Karin Lundberg has shown that antibodies raised against human CEP-1 cross-
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react with P. gingivalis CEP-1
399
. Other hypothetical candidates include Candida 
albicans and Group A streptococcus. Candida albicans α-enolase is a cell wall 
antigen known to induce anti-enolase antibodies in local and systemic infection
444
. 
There is high homology with enolase peptide 1 (82%) and candida infection is more 
common with female sex, smoking
445
 and obesity; all thought to be risk factors for 
RA. Antibodies to human α-enolase also occur after group A streptococcal infection 
and in higher titres in those with acute rheumatic fever
220
. Some questions arise with 
such a 2 step hypothesis. Firstly, not only anti-CCP antibodies but also CRP
446 447
, 
peripheral blood cytokines
448
 and RF are elevated prior to the onset of joint symptoms. 
This is indicative either of sustained infection or subclinical inflammation prior to the 
onset of clinically manifested joint disease. That levels of anti-CCP antibodies, 
cytokines and CRP rise as the onset of joint symptoms gets closer, is suggestive of 
one and the same disease process before and after the diagnosis of RA. Secondly, no 
single „second hit‟ explains the joint distribution of RA. Inflammation following an 
injury could explain those cases where RA presents as a mono- or oligoarthritis but 
not how this develops into a symmetrical oligoarthritis. Some cases present as a 
symmetrical polyarthritis but symptoms suggestive of a preceding viral infection are 
uncommon. Furthermore, osteoarthritis is associated with synovial citrullination
183
 but 
has a characteristically different joint distribution to RA. Rather than RA arising after 
a „second hit‟ has led to synovial citrullination, the onset of clinical disease could be 
associated with epitope spreading to a new antigen. In the model of arthritis induced 
by immunising HLA-DRB1*0401 transgenic mice with citrullinated human 
fibrinogen, there were few differences in the repertoire of anti-citrullinated fibrinogen 
antibodies compared with non-transgenic control mice. In contrast, significant 
differences were seen in antibodies to citrullinated vimentin peptides
190 196
. 
 
Conceivably there is a „one-hit‟ hypothesis whereby antibodies to a systemic 
autoantigen arise spontaneously, maybe as a result of immune senescence (Figure 5C). 
Inflammation secondary to immune complexes localises to the joint, possibly due to 
insufficient complement regulators on cartilage as in the K/BxN mouse
137 449
. Against 
this is that production of antibodies to citrullinated proteins has been demonstrated to 
occur in the joint, although this might be a secondary event especially if the 
autoantigens themselves are found to bind to cartilage. Similarly, we speculate that 
antibodies to α-enolase arise following microbial infection at a mucosal surface 
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(explaining the higher sensitivity of IgA RF when compared with IgM RF in the pre-
clinical phase; Figure 5D). The presence of the HLA-DRB1 „shared epitope‟ allows 
the preferential presentation of CEP-1 peptide despite the relative excess of the 
uncitrullinated peptide. A persistent low grade inflammation occurs, maybe confined 
to the lymphoid tissue or bone marrow
450
. However a critical, and maybe inevitable, 
second step is required. This consists of epitope spreading to an accessible 
citrullinated synovial or cartilage bound antigen which is followed by the syndrome of 
RA. 
 
 
5.2 Future directions 
 
A number of approaches could be taken to address the role of anti-citrullinated α-
enolase antibodies in RA. Starting with mouse models, preliminary work by Andrew 
Kinloch has demonstrated a high incidence of arthritis in HLA-DRB1*0401 
transgenic mice following immunisation with citrullinated but also native α-enolase. T 
cell and antibody responses need further clarification (Andrew Kinloch personal 
communication) but the results suggest that loss of tolerance to native enolase may be 
a requirement. Further work should establish if the mice develop extra-articular 
pathology and if the distribution of joint disease reflects the degree of enolase binding 
to cartilage, as might be the case with GPI in the K/BxN mouse. The involvement of 
the innate immune system could also be investigated. If α-enolase binds to TLRs, this 
might be a means of breaking tolerance, particularly in the context of RF
114
. To 
further explore a possible relationship with P. gingivalis, a model of infection in the 
HLA-DRB1*0401 transgenic mice is being developed. A comparison of the 
arthritogenic potential between affinity purified anti-CCP and anti-CEP-1 antibodies 
in FcγRIIB deficient mice might also be of interest.  
 
In order to determine whether there is a hierarchy of citrullinated autoantigens, with 
one or more breaking tolerance followed by epitope spreading to other autoantigens 
coinciding with the onset of clinical disease, studies of antibody reactivity in pre-RA 
sera would be of value, using candidate antigens before and after citrullination. The 
time point at which anti-CEP-1 antibodies typically occurred, in relation to other 
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autoantibodies and the onset of clinical disease, might give some insight into their role 
in initiating disease. The relationship between the „fine specificity‟ of the anti-
citrullinated protein antibody response and clinical outcomes could be further tested 
using peptides from other candidate antigens and by further refining the anti-
citrullinated α-enolase peptide ELISA.  
 
Finally, there are several approaches to clinical intervention based upon these avenues 
of investigation. If ongoing synovial citrullination contributes to pathogenesis, 
inhibitors of PAD2 or PAD4 might ameliorate disease. Asymptomatic anti-
citrullinated protein antibody positive patients could be collected by screening high 
risk groups such as smoking relatives of RA patients. They could be studied to 
determine whether intervention would reduce the risk of developing clinical RA, and 
for understanding the natural history of anti-citrullinated protein antibodies and 
preclinical RA. A suitable low-risk intervention might be a long acting intramuscular 
steroid preparation. Alternatively, if P. gingivalis is considered to be an aetiological 
factor, then periodontal treatment such as scaling and root planing might prevent the 
onset of clinical disease. Utilising the anti-CEP-1 ELISA in a clinical setting will 
eventually establish, over time, whether there is a particular characteristic or 
phenotype that can be labelled „anti-CEP-1 RA‟.  
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Figure 5A 
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Figure 5. Hypothetical models for the role of anti-citrullinated protein antibodies 
in the pathogenesis of RA. Figure 5A depicts an entirely joint-based process with 
a self-perpetuating positive feedback cycle originating after an episode of joint 
inflammation. Figure 5B shows a two-step model with the first step occurring 
outside the joint but leading to the formation of anti-citrullinated protein 
antibodies These only become pathogenic following a subsequent, unrelated 
episode of joint inflammation. Figure 5C shows a one-step model with anti-
citrullinated protein antibodies arising systemically but giving rise, via immune 
complexes, to a primarily joint-based disease. Finally, Figure 5D depicts anti-
citrullinated protein antibodies arising during mucosal inflammation and 
leading to subclinical arthritis. Following epitope spreading, this becomes 
manifest clinically as the syndrome of RA. 
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